



Singapore 2007


27th INTERNATIONAL



EPILEPSY
CONGRESS

8th - 12th July 2007

Final Programme



DATES FOR YOUR DIARY

UPCOMING EPILEPSY CONGRESSES WORLDWIDE



7TH AOEC
XIAMEN, CHINA 2008

7th Asian & Oceanian Epilepsy Congress (ILAE & IBE)

Xiamen, China
15th - 18th May, 2008



Under the auspices of
the Germanland Israeli ILAE Chapters
Berlin, September 21-25, 2008


8th European Congress on Epileptology (ILAE)

Berlin, Germany
21st - 25th September, 2008



11th European Conference on Epilepsy & Society (IBE)

Marseille, France
15th - 17th October, 2008



5th Congreso Latinoamericano de Epilepsia (ILAE & IBE)

Montevideo, Uruguay
5th - 8th November, 2008



28th International Epilepsy Congress (ILAE & IBE)

Budapest, Hungary
28th June - 2nd July, 2009

For further details on all upcoming meetings please contact:

The ILAE/IBE Congress Secretariat,
7 Priory Hall, Stillorgan, Dublin 18, Ireland

Phone: + 353 1 2056720 Fax: + 353 1 2056156

Email: info@epilepsycongress.org Website: www.epilepsycongress.org

Contents



1	Welcome Message and Committees:	2
2	General Congress Information:	6
3	Congress Centre Plans:	12
4	General Scientific Information:	16
5	Full Week Timetable:	20
6	Scientific Programme:	
	Saturday 7th July	22
	Sunday 8th July	24
	Monday 9th July	28
	Tuesday 10th July	38
	Wednesday 11th July	48
	Thursday 12th July	58
7	Platform Sessions:	
	Monday 9th July	62
	Tuesday 10th July	64
	Wednesday 11th July	67
	Thursday 12th July	69
8	Poster Sessions:	
	Monday 9th July - Wednesday 11th July	70
9	Speakers List:	88
10	Exhibitors List and Exhibition Floor Plan:	98

Welcome Messages and Committees



A MESSAGE FROM THE CHAIRS OF THE 27TH INTERNATIONAL EPILEPSY CONGRESS

Dear Friends and Colleagues,

It gives us great pleasure to welcome all delegates of the 27th International Epilepsy Congress to the magnificent city of Singapore, gateway to the west, and portal to the east, for a congress which promises to offer outstanding scientific value.

We are proud to present an interesting and varied scientific programme for your benefit, with the main topics selected to be of potential interest to both physicians and investigators, without neglecting social issues and the overall global care of our patients.

The 27th International Epilepsy Congress has several new innovations, including the announcement of two new EUREPA distance learning courses.

We would like to take this opportunity to thank all those who actively participated in the organisation of this congress and made it possible. We are confident their work will be rewarded through the critical evaluation of all delegates

We hope that you will enjoy the ambience of the Orient in this wonderful city of Singapore and that you will join us on Wednesday 11th July in the 6-star Ritz Carlton Hotel, for the Gala Dinner.

We look forward to meeting you over the coming days.

Yours sincerely,



SHIH-HUI LIM (SINGAPORE)

Co Chair
International Organising Committee &
Scientific Advisory Committee



MIKE GLYNN (IRELAND)

Co Chair
International Organising Committee



PETER WOLF (DENMARK)

Co Chair
Scientific Advisory Committee

Welcome Messages and Committees



A MESSAGE FROM THE PRESIDENTS OF ILAE AND IBE

Dear Friends,

It gives us great pleasure to welcome you to the wonderful city of Singapore for the 27th International Epilepsy Congress.

This congress promises to offer outstanding scientific value by presenting an interesting and varied scientific programme for your benefit, with leading epileptologists and opinion leaders from around the world participating in the 27th International Epilepsy Congress.

Continuing on from programmes introduced at the International Epilepsy Congress in Lisbon, and then in Paris, a comprehensive system of support has been implemented again for this congress. A Bursary Fund of €50,000 was established by ILAE to assist delegates from all areas to attend the congress. This fund was divided between the Travel Bursaries and the Young Investigators Award and assisted 36 delegates.

While in Singapore, we hope that you will take some time to enjoy this vibrant cosmopolitan city with a unique blend of cultures, cuisine, arts and architecture. With something for everyone, this truly unique place will stay with you for many years to come.

On behalf of the International League Against Epilepsy and the International Bureau for Epilepsy, we wish you a productive and enjoyable experience at the 27th International Epilepsy Congress.

Yours,



Susanne Lund
President
International Bureau For Epilepsy



Peter Wolf
President
International League Against Epilepsy

Welcome Messages and Committees



HONORARY CONGRESS PRESIDENT



KATHIRAVELU PUVANENDRAN
(SINGAPORE)

INTERNATIONAL ORGANISING COMMITTEE



MIKE GLYNN
(IRELAND)
Co Chair



SHIH HUI LIM
(SINGAPORE)
Co Chair



KATHIRAVELU PUVANENDRAN
(SINGAPORE)
Honorary President



ALEXIS ARZIMANOGLOU
(FRANCE)



MARTIN BRODIE
(UK)



SUSANNE LUND
(SWEDEN)



ANDREW PAN
(SINGAPORE)



GRACE TAN
(SINGAPORE)



PETER WOLF
(DENMARK)

Welcome Messages and Committees



SCIENTIFIC ADVISORY COMMITTEE



SHIH-HUI LIM
(SINGAPORE)
Co-Chair



PETER WOLF
(DENMARK)
Co-Chair



CARLOS ACEVEDO
(CHILE)



MICHEL BAULAC
(FRANCE)



NADIR BHARUCHA
(INDIA)



JOHAN FALK PEDERSEN
(NORWAY)



W. ALLEN HAUSER
(USA)




MICHAEL SALING
(AUSTRALIA)



ANNA MARIA VEZZANI
(ITALY)



General Congress Information



REGISTRATION

The Registration Area is located on Level 1 of Suntec. Congress bags should be collected on-site in this area. Please note that name badges must be worn at all times.

SPEAKERS' ROOM

The Speakers' Room is located in Room 207, Level 2. Opening times for this area are listed on the Facilities Timetable Overview. Facilities to review and amend presentations will be available to all speakers and technical assistance will also be provided in this room.

Please note that all presentations should be in PowerPoint and will be projected exclusively via a centralized server.

POSTERS

Posters are on display in the Exhibition Area situated on Level 6. Please refer to the floor plans on pages 12, 13 & 14 for further details.

To allow sufficient time for delegates to visit and discuss poster presentations, each poster will be displayed for three days, Monday and Tuesday, between 09.00 and 17.00 and Wednesday, between 09.00 and 16.00.

Poster presenters are required to set up their posters between 08.00 and 09.00 on Monday 9th July. Posters must be removed between 16.00 and 17.00 on Wednesday 11th July.

Please note that presenting authors are required to be present each day between 13.15 and 14.15.

EXHIBITION

The Exhibition Area is situated on Level 6. Exhibition opening times are listed on the Facilities Timetable Overview. Exhibitor badges (pre-registered exhibitors only) will be available for collection at the exhibition desk situated in the Registration Area.

LUNCHES AND COFFEE BREAKS

Lunches will be served from Monday to Wednesday in the Exhibition Area, Level 6. Coffee Breaks will be served from Monday to Thursday, break times are listed on the Facilities Timetable Overview.

General Congress Information



FACILITIES TIMETABLE OVERVIEW

	Sunday	Monday	Tuesday	Wednesday	Thursday
Registration	08:00 - 19:30	07.00 - 18.00	07.00 - 18.00	07.00 - 17.30	07.00 - 14.00
Speakers' Room	08:00 - 19.30	07.00 - 18.00	07.00 - 18.00	07.00 - 18.00	07.00 - 11.00
Posters		09.00 - 17.00	09.00 - 17.00	09.00 - 16.00	
Exhibition		09.00 - 17.00	09.00 - 17.00	09.00 - 17.00	09.00 - 12.00
Coffee Breaks		09.30 - 10.00 15.15 - 15.45	09.30 - 10.00 15.15 - 15.45	09.30 - 10.00 15.15 - 15.45	09.45 - 10.15
Lunch		13.15 - 14.15	13.15 - 14.15	13.15 - 14.15	

LANGUAGE

The official language of the 27th International Epilepsy Congress is English.

REPLACEMENT BADGES

Please note that a fee of €50 will be charged for a replacement badge. Delegates should ensure that badges are worn at all times.

CERTIFICATES OF ATTENDANCE

Certificates of Attendance may be collected in the Registration Area.

SOCIAL EVENTS


OPENING CEREMONY

The Opening Ceremony will take place on Sunday 8th July at 19:30 in Hall 603, Level 6. The Ceremony will open with welcome addresses from representatives from IBE and ILAE. This will be followed by the Awards Ceremony, which this year will consist of the Ambassador for Epilepsy Award, the Award for Social Accomplishment, the Michael Prize and the Morris-Coole Prize. Further details on these awards can be found on Page 17 and in the Awards Booklet which will be distributed at the Opening Ceremony.

WELCOME RECEPTION

The Opening Ceremony will be followed by a Welcome Reception in the Concourse situated on Level 3. All delegates will have the opportunity to stroll around typical Singapore Market Stalls called "Hawker's Stalls" and enjoy a selection of Indian, Singaporean, Malaysian and international culinary delights.

General Congress Information



GALA DINNER

The Gala Dinner is being held on Wednesday 11th July in the sumptuous setting of the beautiful 6-star Ritz Carlton Hotel.

Participants will enjoy the ambience of the Orient, to the strains of relaxing classical music, while sampling the culinary delights of the Gala Dinner and reception.

Tickets may be purchased at the Social Events Desk in the Registration Area.

TOURS

A large choice of tours is on offer, including coach, private and Beyond Singapore tours. From "Breakfast at the Zoo" to the "Night Adventure with Merlion Cruise" there is something for everyone in this unique vibrant city. Bookings may be made at the Accommodation and Tours Desk situated in the main Registration Area.

Available Tours

Night Adventure with Merlion Cruise
Sentosa with Dolphin Lagoon
Night Safari
Jurong Birdpark
Peranakan Experience
Singapore Tropica Cruise
The City Experience
Breakfast at the Zoo



SINGAPORE TOURISM BOARD

For further information on what to do in Singapore, please go to the Singapore Tourism Board "Uniquely Singapore" stand situated in the Exhibition Area. Please note that this stand will only be open on Monday and Tuesday. You may also check www.visitsingapore.com for the latest tourist information.




CONGRESS SECRETARIAT

Members of the Congress Secretariat may be contacted at anytime at the Registration Area. For queries arising after the congress, please contact:

27th International Epilepsy Congress
ILAE/IBE Congress Secretariat
7 Priory Hall
Stillorgan
Dublin 18
Ireland
Tel +353 1 205 6720
Fax +353 1 205 6156
E-mail info@epilepsycongress.org

General Congress Information



CONGRESS CENTRE

Suntec Singapore
International Convention and Exhibition Centre
1 Raffles Boulevard,
Suntec City,
Singapore 039593
www.suntecsingapore.com

ON-SITE INFORMATION


Smoking Policy	Suntec is a no smoking area.
Wheelchair Access	All session rooms in Suntec are wheelchair-accessible.
Message Board	Situated in the Registration Area. Delegates are advised to check it regularly.
Speakers' Room	Situated in Room 207, Level 2
Internet Centre	Situated in the Exhibition Area, Hall 602, Level 6.

INSURANCE

The congress organisers will not accept liability for personal injury or loss/damage to property/belongings of participants or accompanying persons, either before, during or following the congress, tours or their stay in Singapore. It is therefore recommended that participants arrange their own personal health, accident and travel insurance.



General Congress Information



SINGAPORE - PRACTICAL INFORMATION

BANKING

Banking hours in Singapore are Monday - Friday 10.00 - 15.00, Saturday 09.30 - 13.00 and in some cases, Sunday 09.30 - 15.00.

Most banks handle travellers' cheques and change foreign currencies. However some banks do not have foreign exchange dealings on a Saturday.

Passports are required when cashing travellers' cheques. A nominal commission may be charged.

CURRENCY

The national currency of Singapore is Singapore Dollars and Cents. Other than the Singapore Dollar, US and Australian Dollars, Yen, Euro and British Pounds are also accepted in most major shopping centres and big department stores.

CREDIT CARDS

International credit cards (Visa, American Express, Euro card, Diners Club and MasterCard) are widely accepted in hotels, restaurants and retail shops. There are over 1,000 ATMs located throughout Singapore. Currency can be exchanged at all bank branches and at "bureaux de change".

ELECTRICITY

The power supply is 220V - 240V AC, 50 Hz with three pin square plugs. Appliances designed to operate on 110/120V require a voltage converter and a plug adapter.

TAXIS

Taxis may be found at taxi stands, may be hailed in the street or may be booked through the taxi company's hotline or website. Taxis carry a maximum of four passengers and some may stop only at taxi stands along major roads.

With the deregulation of the taxi industry, different operators charge different fares and surcharges for their taxi services. Surcharges include Electronic Road Pricing surcharge, peak hour surcharge, public holiday surcharge, etc. A surcharge may also be imposed by taxis for picking up passengers from certain places like the Changi International Airport and Singapore Expo Centre. As such, it is best to check the fares and surcharges with the taxi driver before boarding a taxi.

PUBLIC TRANSPORT

Suntec is conveniently accessible by MRT and buses. The nearest MRT station is City Hall.

TIME DIFFERENCE

In July, Singapore is 7 hours ahead of GMT.



The 7th Asian & Oceanian Epilepsy Congress

Xiamen, China | 15th - 18th May 2008



www.epilepsyxiamen2008.org




INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY **ILAE**
ESTABLISHED 1990

Congress Centre Floor Plans



SUNTEC SINGAPORE INTERNATIONAL CONVENTION & EXHIBITION CENTRE

LEVEL 1




	SESSION ROOM		TOILET		CATERING AREA
	BUSINESS MEETING ROOM		LIFT		INTERNET CENTRE
	SPEAKERS' ROOM		ESCALATOR		CAFE
	EXHIBITION AREA		POSTER AREA		

Congress Centre Floor Plans




SUNTEC SINGAPORE INTERNATIONAL CONVENTION & EXHIBITION CENTRE

LEVEL 2



LEVEL 3




Congress Centre Floor Plans



SUNTEC SINGAPORE INTERNATIONAL CONVENTION & EXHIBITION CENTRE

LEVEL 6



 SESSION ROOM	TOILET	CATERING AREA
 BUSINESS MEETING ROOM	LIFT	INTERNET CENTRE
 SPEAKERS' ROOM	ESCALATOR	CAFE
 EXHIBITION AREA	POSTER AREA	

Where the early detection of cancer helps you enjoy a longer life and Asia's first Keystone Symposia brought breakthroughs in stem cell research to the world.



SINGAPORE


WHERE GREAT THINGS HAPPEN

Asia's first Keystone Symposia convened scientists to exchange findings on stem cell research and served to accelerate applications that benefit medical science. Singapore is home to the global manufacturing facilities of eight leading pharmaceutical companies. Drug discovery and development laboratories of numerous biomedical sciences companies are also present here. A city that brings together global scientific leaders, Singapore is known for its world-class research infrastructure while its vibrant cityscape and unique culture provide enriching experiences for visitors. Choose Singapore for your corporate meetings, conferences, exhibitions and incentive travel. visitsingapore.com/businessesevents



UNIQUELY
Singapore
visitsingapore.com

General Scientific Information



SCIENTIFIC INFORMATION

PRESIDENTIAL SYMPOSIUM

The Presidential Symposium will take place on Sunday 8th July from 17.00 to 19.00 in Hall 603, Level 6.

Generic Antiepileptic Drugs

Generic drugs have over the last years developed into an issue of high relevance for the praxis of epilepsy care. Because of their lower price, generics can improve the availability of pharmacotherapy to patients and reduce the financial burden of epilepsy. They may thus help to close the existing treatment gaps. But they must also be used with consideration since there are possible risks, especially connected with preparation shifts and continuity of supply. The case of epilepsy is unique because of the pivotal importance of complete seizure control for patients' quality of life and the existence of therapeutic and toxic thresholds which sometimes leave only a narrow therapeutic window. In the Symposium, IBE President Susanne Lund will introduce the subject from the patient's perspective, Emilio Perucca will present the pharmacological issues related to generics, including bioequivalence, likenesses and differences of preparations, and Barry Gidal will consider the various aspects of preparation shift.

Tarun Dua will present the WHO's perspective on the potential of generic AEDs for reducing the treatment gap, and ILAE President Peter Wolf will finish with a report on a political campaign in Denmark to deal with legislation resulting in frequent preparation shifts. It is our hope that the Symposium will provide the audience with a comprehensive and well-balanced picture of all aspects of this up-to-date topic.

CHAIRS' SYMPOSIUM - 27TH INTERNATIONAL EPILEPSY CONGRESS HIGHLIGHTS

The symposium will be held on Thursday 12th July between 12.00 and 13.30.

Delegates will be offered a unique opportunity to attend a concluding session with the participation of all Chairs of the seven main topics debated during the 27th International Epilepsy Congress.

Organised by the Co-Chairs of the Scientific Advisory Committee, this special session will include a commented selection of original data presented during the Congress.

EUREPA DISTANCE LEARNING PROGRAMME: VIREPA - THE VIRTUAL EPILEPSY ACADEMY

Two new EUREPA distance learning courses ("Clinical Pharmacology and Pharmacotherapy" and "Neuroimaging") are being launched during the 27th International Epilepsy Congress. The onsite seminars of these blended learning courses were held as a pre-congress activity.

Further details regarding the EUREPA distance learning programme are available on the EUREPA website: www.epilepsy-academy.org and at the ILAE booth during the Congress

EUREPA SEMINARS

Three series of teaching seminars will be held during the 27th International Epilepsy Congress.

The first series is dedicated to "Difficult cases in adult epilepsies", the second series to "Difficult cases in childhood epilepsies", whilst the third series will focus on "Seizure related automatisms". For further details on the programme, please refer to the daily schedules.


ILAE CHAPTER CONVENTION

The ILAE Chapter Convention will take place on Sunday 8th July between 08:30 and 13:00 in room 208/209, Level 2.

EAC MEETING

The European Advisory Council (EAC) will hold a European Chapter Convention on Sunday 8th July between 14.00 and 16.30 in Room 208/209, Level 2.

General Scientific Information



AWARDS

TRAVEL BURSARIES

This bursary scheme was designed to assist delegates who could not have otherwise considered attending the International Epilepsy Congress. Once again, a particular emphasis was given to those coming from developing regions who are locally very active in the field of epilepsy. 28 delegates were granted assistance through this special fund.

YOUNG INVESTIGATORS' AWARDS

This award was reserved for delegates under the age of 45 years who submitted an abstract. It was open to basic scientists, neurologists, neurophysiologists, physicians, biologists, nurses, sociologists and psychologists working in universities, hospitals or specialised epilepsy services.

All papers were reviewed by the Scientific Advisory Committee and 8 abstracts, which were considered to be of excellent quality, were selected. The Young Investigators will be acknowledged at the Opening Ceremony.

AMBASSADORS FOR EPILEPSY

The Ambassador for Epilepsy Awards of ILAE and IBE will be presented in recognition of outstanding international contributions to the cause of epilepsy, for activities which have either been performed at an international level or have had international impact.

The recipients will be honoured at the Opening Ceremony. They will be presented with an 'Ambassador for Epilepsy' pin which reflects peer recognition of their individual contributions to the international cause of epilepsy.

AWARD FOR SOCIAL ACCOMPLISHMENT

Every two years, one person who has accomplished outstanding activities aimed at the social benefit of people with epilepsy, is recognized by the International Bureau for Epilepsy and the International League Against Epilepsy. The recipient of this award will be honoured during the Opening Ceremony.

THE MICHAEL PRIZE


Presented bi-annually, this prize was originally set up to stimulate epilepsy research among young scientists in Germany. It has now developed into an international award for the best scientific and clinical research, promoting further development in epileptology. The presentation of this award will take place during the Opening Ceremony on Sunday evening. The winning researchers will also present their papers during the Awards Symposium to be held on Tuesday 10th July between 17.30 and 18.30.

THE MORRIS-COOLE PRIZE

The ILAE is proud to announce the establishment of a new prize, the Morris-Coole prize, of €10,000. The prize is awarded annually for the paper published in "Epilepsia" during the previous calendar year, which has, in the judges' opinion, made the most significant advance in knowledge in the field of epilepsy.

The Judging panel comprises of President of ILAE and the two Editors-in-Chief of "Epilepsia". The panel considered a short-list of papers prepared by the Associate Editors of "Epilepsia". The prize will be awarded during the Opening Ceremony. The winning researcher will also present his/her paper during the Awards Symposium to be held on Tuesday 10th July between 17.30 and 18.30.

General Scientific Information



CME ACCREDITATION

The 27th International Epilepsy Congress is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 27th International Epilepsy Congress is designated for a maximum of 27 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

SYMPOSIUM FOR PEOPLE WITH EPILEPSY AND THEIR CARERS

This special pre-Congress session jointly organised by the IBE Singapore Chapter and the IBE Singapore Association, was held on July 7th. Topics such as Family and Marital Relationships, Women in Epilepsy, Employment, Epilepsy and the Law / Driving, Education and Learning Issues, and Children with Epilepsy were addressed. The session was chaired by a panel of distinguished speakers comprising of doctors, social workers and professionals.

IBE MEMBERS' POSTER DISPLAY

To highlight the wealth, diversity, achievements and aspirations of its world wide membership and to encourage other epilepsy associations to consider IBE membership, a special display of posters has been mounted for the duration of the congress and can be viewed in the Ballrooms Foyer on Level 2. Prepared by individual Members of the IBE, the posters aim to facilitate the international exchange of information about how Members operate, the issues they address and the services they provide.





You've only just arrived and already we're thinking of your next trip.

As the official airline network for **The 27th International Epilepsy Congress**, we'd like to thank you for choosing the Star Alliance™ network and hope that all goes really well for you here today.

Whilst you concentrate on the day's events, we hope you'll consider us the next time you need to attend a conference.

With over 16,000 flights a day to 855 airports across 155 countries, our 17 member airlines will extend a wide choice of flights to any future conference you're planning to attend. And no matter which of those airline's frequent flyer programmes you belong to, you can earn and redeem across all of them.

So the next time you want to concentrate all your energies on your conference, we hope you'll decide to leave the travel arrangements to us.

AIR CANADA

AIR NEW ZEALAND

ANA

ASIANA AIRLINES

Austrian

bmi

LOT POLISH AIRLINES

Lufthansa

Scandinavian Airlines

SINGAPORE AIRLINES

SOUTH AFRICAN AIRWAYS

Spanair

swiss

TP TAP PORTUGAL

THAI

UNITED

U.S. AIRWAYS

www.staralliance.com

Information correct as at 01/2007.

STAR ALLIANCE
THE AIRLINE NETWORK FOR EARTH.




Full Week Timetable



	Saturday 7 th July	Sunday 8 th July	Monday 9 th July
07.30-07.45	ASEPA Teaching Course	Symposium for People with Epilepsy and their Carers	EUREPA Seminars 07.30-08.30
07.45-08.00			
08.00-08.15			Issues in developing countries 08.30-09.30
08.15-08.30			
08.30-08.45			Coffee Break
08.45-09.00			
09.00-09.15			Issues in developing countries 10.00-11.30
09.15-09.30			
09.30-09.45			Parallel Sessions 10.00-11.30
09.45-10.00			
10.00-10.15			Platform Sessions 10.00-11.30
10.15-10.30			
10.30-10.45			UCB Pharma SA Satellite Symposium 12.00-13.30
10.45-11.00			
11.00-11.15	Symposium for People with Epilepsy and their Carers	ASEPA Teaching Course	Lunch 13.15-14.15
11.15-11.30			
11.30-11.45			Prognosis in people with epilepsy 14.15-15.15
11.45-12.00			
12.00-12.15			Break
12.15-12.30			
12.30-12.45			Prognosis in people with epilepsy 15.45-17.15
12.45-13.00			
13.00-13.15			Parallel Sessions 15.45-17.15
13.15-13.30			
13.30-13.45			Platform Sessions 15.45-17.15
13.45-14.00			
14.00-14.15			Pfizer Inc. Satellite Symposium 17.30-19.00
14.15-14.30			
14.30-14.45	ASEPA Teaching Course	Symposium for People with Epilepsy and their Carers	Opening Ceremony 19.30-20.30
14.45-15.00			
15.00-15.15			Welcome Reception 20.30-21.30
15.15-15.30			
15.30-15.45			
15.45-16.00			
16.00-16.15			
16.15-16.30			
16.30-16.45			
16.45-17.00			
17.00-17.15			
17.15-17.30			
17.30-17.45			
17.45-18.00			
18.00-18.15			
18.15-18.30			
18.30-18.45			
18.45-19.00			
19.00-19.15			
19.15-19.30			
19.30-19.45			
19.45-20.00			
20.00-20.15			
20.15-20.30			
20.30-20.45			
20.45-21.00			
21.00-21.15			
21.15-21.30			

Full Week Timetable



Tuesday 10 th July			Wednesday 11 th July			Thursday 12 th July				
EUREPA Seminars 07.30-08.30			EUREPA Seminars 07.30-08.30			Video Session 07.30-08.30			07.30-07.45 07.45-08.00 08.00-08.15 08.15-08.30	
Posters	Men and women with epilepsy throughout life 08.30-09.30		Stigma and epilepsy - A comprehensive view 08.30-09.30			Difficult to treat situations in epilepsy 08.45-09.45			08.30-08.45 08.45-09.00 09.00-09.15 09.15-09.30 09.30-09.45	
	Coffee Break		Coffee Break			Coffee Break			09.45-10.00 10.00-10.15	
	Men and women with epilepsy throughout life 10.00-11.30	Parallel Sessions 10.00-11.30	Platform Sessions 10.00-11.30	Stigma and epilepsy 10.00-11.30	Parallel Sessions 10.00-11.30	Platform Sessions 10.00-11.30	Difficult to treat situations in epilepsy 10.15-11.45	Parallel Sessions 10.15-11.45	Platform Sessions 10.15-11.45	10.15-10.30 10.30-10.45 10.45-11.00 11.00-11.15 11.15-11.30 11.30-11.45
									11.45-12.00	
	Schwarz Pharma Satellite Symposium 12.00-13.30		Valeant Pharmaceuticals International Satellite Symposium 12.00-13.30			Highlights Session 12.00-13.30			12.00-12.15 12.15-12.30 12.30-12.45 12.45-13.00 13.00-13.15	
									13.15-13.30	
	Lunch 13.15-14.15		Lunch 13.15-14.15						13.30-13.45 13.45-14.00 14.00-14.15	
	Epileptogenesis 14.15-15.15		Nueropsychological and psychosocial aspects of epilepsy 14.15-15.15						14.15-14.30 14.30-14.45 14.45-15.00 15.00-15.15	
	Break		Break						15.15-15.30 15.30-15.45	
	Epileptogenesis 15.45-17.15	Parallel Sessions 15.45-17.15	Platform Sessions 15.45-17.15	Nueropsychological and psychosocial aspects of epilepsy 15.45-17.15	Parallel Sessions 15.45-17.15	Platform Sessions 15.45-17.15				15.45-16.00 16.00-16.15 16.15-16.30 16.30-16.45 16.45-17.00
								17.00-17.15 17.15-17.30		
Awards Symposium 17.30-18.30								17.30-17.45 17.45-18.00 18.00-18.15 18.15-18.30		
								18.30-18.45 18.45-19.00 19.00-19.15 19.15-19.30 19.30-19.45 19.45-20.00 20.00-20.15 20.15-20.30 20.30-20.45 20.45-21.00 21.00-21.15		
		Gala Dinner 20.00-late						21.15-21.30		

Scientific Programme

SATURDAY, 7TH JULY 2007

	Room 209	Room 203	
07.30-07.45			07.30-07.45
07.45-08.00			07.45-08.00
08.00-08.15			08.00-08.15
08.15-08.30			08.15-08.30
08.30-08.45			08.30-08.45
08.45-09.00			08.45-09.00
09.00-09.15			09.00-09.15
09.15-09.30			09.15-09.30
09.30-09.45			09.30-09.45
09.45-10.00			09.45-10.00
10.00-10.15		ASEPA Course	10.00-10.15
10.15-10.30		ASEPA Course	10.15-10.30
10.30-10.45		ASEPA Course	10.30-10.45
10.45-11.00		ASEPA Course	10.45-11.00
11.00-11.15		ASEPA Course	11.00-11.15
11.15-11.30		ASEPA Course	11.15-11.30
11.30-11.45		ASEPA Course	11.30-11.45
11.45-12.00		Brunch	11.45-12.00
12.00-12.15		Brunch	12.00-12.15
12.15-12.30		ASEPA Course	12.15-12.30
12.30-12.45		ASEPA Course	12.30-12.45
12.45-13.00		ASEPA Course	12.45-13.00
13.00-13.15		ASEPA Course	13.00-13.15
13.15-13.30		ASEPA Course	13.15-13.30
13.30-13.45		ASEPA Course	13.30-13.45
13.45-14.00		ASEPA Course	13.45-14.00
14.00-14.15		ASEPA Course	14.00-14.15
14.15-14.30		ASEPA Course	14.15-14.30
14.30-14.45			14.30-14.45
14.45-15.00			14.45-15.00
15.00-15.15			15.00-15.15
15.15-15.30			15.15-15.30
15.30-15.45			15.30-15.45
15.45-16.00			15.45-16.00
16.00-16.15			16.00-16.15
16.15-16.30			16.15-16.30
16.30-16.45			16.30-16.45
16.45-17.00			16.45-17.00
17.00-17.15			17.00-17.15
17.15-17.30			17.15-17.30
17.30-17.45			17.30-17.45
17.45-18.00			17.45-18.00
18.00-18.15			18.00-18.15
18.15-18.30			18.15-18.30
18.30-18.45			18.30-18.45
18.45-19.00			18.45-19.00
19.00-19.15			19.00-19.15
19.15-19.30			19.15-19.30
19.30-19.45			19.30-19.45
19.45-20.00			19.45-20.00
20.00-20.15			20.00-20.15
20.15-20.30			20.15-20.30
20.30-20.45			20.30-20.45
20.45-21.00			20.45-21.00
21.00-21.15			21.00-21.15
21.15-21.30			21.15-21.30

Symposium for People with Epilepsy and their Carers

Scientific Programme



SATURDAY, 7TH JULY 2007

08.30 – 11.30

ASEPA Teaching Course

Room 203

Refer to Abstract
Book Page 3

Basic Neurobiology Of Epilepsy: What Do Clinicians Need to Know

What we need to model and what is now available
Moshe, S.L. (USA)

What is the contribution of whole animal models of temporal lobe epilepsy?
O'Brien, T (Australia)

In vitro models: how to understand their contribution to the pathophysiology of the focus?
Petrou, S (Australia)

Genetic Study: How to go about it and what are potential clinical applications?
Yamakawa, K (Japan)

EEG Gamma and other rhythms and astrocyte swelling: pathway to seizures
Willoughby, J (Australia)

12.00 – 14.30

ASEPA Teaching Course

Room 203

Refer to Abstract
Book Page 4

Basic Neurobiology Of Epilepsy: What Do Clinicians Need to Know


Brain Imaging: Can we predict the evolution of the syndrome?
Jackson, G (Australia)

Does pathology explain the physiology? Lessons from surgical series
Mathern, G.W. (USA)

Pursuing the development of new treatments
Galanopoulou, A (USA)

Refractory Epilepsy - What are the mechanisms of pharmacoresistance and what therapeutic strategies can we use?
Bertram, E.H. (USA)

Scientific Programme

SUNDAY, 8TH JULY 2007

	Hall 603	Room 203	
07.30-07.45			07.30-07.45
07.45-08.00			07.45-08.00
08.00-08.15			08.00-08.15
08.15-08.30			08.15-08.30
08.30-08.45			08.30-08.45
08.45-09.00			08.45-09.00
09.00-09.15			09.00-09.15
09.15-09.30		Imaging serotonergic neurotransmission in epilepsy 09.00-10.30	09.15-09.30
09.30-09.45			09.30-09.45
09.45-10.00			09.45-10.00
10.00-10.15			10.00-10.15
10.15-10.30			10.15-10.30
10.30-10.45			10.30-10.45
10.45-11.00		Invasive basic research in an epilepsy surgery setting 10.45-12.15	10.45-11.00
11.00-11.15			11.00-11.15
11.15-11.30			11.15-11.30
11.30-11.45			11.30-11.45
11.45-12.00			11.45-12.00
12.00-12.15			12.00-12.15
12.15-12.30			12.15-12.30
12.30-12.45		Ion channel mutations in epilepsy 12.45-14.15	12.30-12.45
12.45-13.00			12.45-13.00
13.00-13.15			13.00-13.15
13.15-13.30			13.15-13.30
13.30-13.45			13.30-13.45
13.45-14.00			13.45-14.00
14.00-14.15			14.00-14.15
14.15-14.30			14.15-14.30
14.30-14.45	Merritt-Putnam Symposium 14.30-16.30		14.30-14.45
14.45-15.00			14.45-15.00
15.00-15.15			15.00-15.15
15.15-15.30			15.15-15.30
15.30-15.45			15.30-15.45
15.45-16.00			15.45-16.00
16.00-16.15			16.00-16.15
16.15-16.30			16.15-16.30
16.30-16.45			16.30-16.45
16.45-17.00			16.45-17.00
17.00-17.15	Presidential Symposium <i>Generic AEDs</i> 17.00-19.00		17.00-17.15
17.15-17.30			17.15-17.30
17.30-17.45			17.30-17.45
17.45-18.00			17.45-18.00
18.00-18.15			18.00-18.15
18.15-18.30			18.15-18.30
18.30-18.45			18.30-18.45
18.45-19.00			18.45-19.00
19.00-19.15			19.00-19.15
19.15-19.30			19.15-19.30
19.30-19.45			19.30-19.45
19.45-20.00	Opening Ceremony 19.30-20.30		19.45-20.00
20.00-20.15			20.00-20.15
20.15-20.30			20.15-20.30
20.30-20.45	Welcome Reception 20.30-21.30		20.30-20.45
20.45-21.00			20.45-21.00
21.00-21.15			21.00-21.15
21.15-21.30			21.15-21.30

Scientific Programme



SUNDAY, 8TH JULY 2007

09:00 - 10:30

Scientific Session

Room 203

Refer to Abstract
Book Page 5

Imaging Serotonergic Neurotransmission In Epilepsy

Theodore, W (USA), Chair

18F-MPPF PET and epileptogenicity
Ryvlin, P (France)

18F-FCWAY 5HT1A receptor imaging, depression and epilepsy
Theodore, W (USA)

Imaging serotonin precursor uptake and epileptogenesis
Chugani, D (USA)

10:45 - 12:15

Scientific Session

Room 203

Refer to Abstract
Book Page 6

Invasive Basic Research In An Epilepsy Surgery Setting

Staba, R (USA), Chair

Chronic microelectrode recordings and microdialysis in limbic system to understand mechanisms of epilepsy
Staba, R (USA)

Chronic microelectrode recordings in neocortex to identify areas of abnormal excitability
Alarcon, G (UK)

Chronic standard depth electrode recordings in limbic system and neocortex to understand basic mechanisms of epilepsy
Gotman, J (Canada)

12:45 - 14:15

Scientific Session

Room 203

Refer to Abstract
Book Page 7

Ion Channel Mutations In Epilepsy: The Case Of KCNQ Channels

Beck, H (Germany), Chair

Clinical and genetic aspects: Review of the clinical features of BFNC and the underlying mutations
Taglialetela, M (Italy)

Molecular aspects: How do mutations alter KCNQ channel function in human epilepsy
Lerche, H (Germany)

Functional aspects: Control of neuronal excitability by KCNQ channels
Yaari, Y (Israel)

Please replace with sticker saying
"Refer to Abstract Book Page 6"

Scientific Programme

SUNDAY, 8TH JULY 2007

14:30 - 16:30

Satellite Symposium

Hall 603

Refer to Abstract
Book Page 155

Merritt-Putnam Symposium - 'Seizures in Patients with Brain Tumours- From Mechanisms to Management'

Lim, S.H. (Singapore), Chair

The epidemiology of seizures in patients with brain tumours

Hauser, A (USA)

How can brain tumours and their treatment modify neuronal excitability?

Köhling, R (Germany)

The role of chemotherapy in seizure control and its interactions with AEDs

Vecht, C.J. (Netherlands)

Prophylactic and therapeutic role of AEDs in brain tumour patients

Ryvlin, P (France)

Please replace with sticker
saying "Refer to Abstract Book
Page 166 "

17:00 - 19:00

Presidential Symposium

Hall 603

Refer to Abstract
Book Page 7

Generic Antiepileptic Drugs

Lund, S (Sweden) & Wolf, P (Denmark), Co-Chairs

Introduction, Patient's perspective

Lund, S (Sweden)

General Overview

Perucca, E (Italy)

Generic substitution

Gidal, B.E. (USA)

Essential antiepileptic drugs: reduction in treatment gap

Dua, T (Switzerland)

Political campaign in Denmark

Wolf, P (Denmark)

19:30 - 20:30

Opening Ceremony

Hall 603


20:30 - 21:30

Welcome Reception

Concourse



Scientific Programme



MONDAY, 9TH JULY 2007

	Poster Area	Hall 603	Ballroom 2	Ballroom 1	Ballroom 3
07.30-07.45				EUREPA Seminar "Difficult cases in childhood epilepsies"	
07.45-08.00					
08.00-08.15	Posters set up				
08.15-08.30					
08.30-08.45					
08.45-09.00		Issues in developing countries 08.30-09.30			
09.00-09.15					
09.15-09.30					
09.30-09.45	Posters	Coffee Break 09.30-10.00			
09.45-10.00					
10.00-10.15		Closing the three gaps - knowledge, research and treatment 10.00-11.30	Multi-level EEG recordings in epilepsy surgery 10.00-11.30	Evidence-based imaging in refractory paediatric epilepsy 10.00-11.30	Non-conventional targets for novel antiepileptic strategies 10.00-11.30
10.15-10.30					
10.30-10.45					
10.45-11.00					
11.00-11.15					
11.15-11.30					
11.30-11.45					
11.45-12.00					
12.00-12.15		UCB Pharma SA Satellite Symposium 12.00-13.30			
12.15-12.30					
12.30-12.45					
12.45-13.00					
13.00-13.15					
13.15-13.30	Authors of Posters present 13.15-14.15	Lunch 13.15-14.15			
13.30-13.45					
13.45-14.00					
14.00-14.15					
14.15-14.30	Posters		Prognosis in people with epilepsy 14.15-15.15		
14.30-14.45					
14.45-15.00					
15.00-15.15					
15.15-15.30					
15.30-15.45					
15.45-16.00			Acute symptomatic seizures: what is the frequency, the prognosis and the relation to epilepsy 15.45-17.15	Mood Disorders, A Co-Morbidity In Children With Epilepsy 15.45-17.15	Addressing Epilepsy Knowledge And Research Gaps In Developing Countries 15.45-17.15
16.00-16.15					
16.15-16.30					
16.30-16.45					
16.45-17.00					
17.00-17.15					
17.15-17.30					
17.30-17.45					
17.45-18.00		Pfizer Inc. Satellite Symposium 17.30-19.00			
18.00-18.15					
18.15-18.30					
18.30-18.45					
18.45-19.00					

Scientific Programme



Theatre	Room 209	Room 203	
EUREPA Seminar "Difficult cases in adult epilepsies"	EUREPA Seminar "Seizure related automatisms"		07.30-07.45
			07.45-08.00
			08.00-08.15
			08.15-08.30
			08.30-08.45
			08.45-09.00
		09.00-09.15	
		09.15-09.30	
Coffee Break 09.30-10.00			09.30-09.45
Epilepsy genetics in the 21st century Part 1 10.00-11.30	Platform Session 1 Social issues 10.00-11.30	Platform Session 2 AEDs and trial issues 10.00-11.30	09.45-10.00
			10.00-10.15
			10.15-10.30
			10.30-10.45
			10.45-11.00
			11.00-11.15
			11.15-11.30
			11.30-11.45
			11.45-12.00
			12.00-12.15
			12.15-12.30
			12.30-12.45
			12.45-13.00
			13.00-13.15
			13.15-13.30
			13.30-13.45
			13.45-14.00
			14.00-14.15
			14.15-14.30
			14.30-14.45
			14.45-15.00
			15.00-15.15
			15.15-15.30
Epilepsy genetics in the 21st century Part 1 15.45-17.15	Human herpes virus 6 and epilepsy 15.45-17.15	Platform Session 3 Neurophysiology and imaging 15.45-17.15	15.30-15.45
			15.45-16.00
			16.00-16.15
			16.15-16.30
			16.30-16.45
			16.45-17.00
			17.00-17.15
			17.15-17.30
			17.30-17.45
			17.45-18.00
			18.00-18.15
			18.15-18.30
			18.30-18.45
			18.45-19.00

Scientific Programme



MONDAY, 9TH JULY 2007

07:30 - 08:30

EUREPA Seminar

Ballroom 1

Refer to Abstract
Book Page 8

EUREPA Seminar Series 1 - Discussion on Difficult Cases in Childhood Epilepsies

Seizures in Infancy

Discussants:

Plouin, P (France)

Capovilla, G (Italy)

Covanis, A (Greece)

Koutroumanidis, M (UK)

07:30 - 08:30

EUREPA Seminar

Theatre

Refer to Abstract
Book Page 8

EUREPA Seminar Series 2 - Discussion on Difficult Cases in Adult Epilepsies

Surgery

Van Emde Boas, W (Netherlands), Discussant

Najm, I (USA)

Velis, D (Netherlands)

Ozkara, C (Turkey)

07:30 - 08:30

EUREPA Seminar

Room 209

Refer to Abstract
Book Page 8

EUREPA Seminar Series 3 - Discussion on Seizure Related Automatisms

Seizure related automatisms

Tassinari, C.A. (Italy) & Luders, H.O. (USA), Discussants

Oro-alimentary automatisms

Canevini, M.P. (Italy)

Gestural automatisms

Baumgartner, C (Austria)

Scientific Programme

MONDAY, 9TH JULY 2007

08:30 - 09:30

Main Session

Hall 603

(in collaboration with the Global Campaign Against Epilepsy)

Refer to Abstract
Book Page 8

Issues In Developing Countries - The Three Gaps: Knowledge, Research and Treatment*Bharucha, N.E. (India) & Lee, P (UK), Co-Chairs*

Addressing the knowledge gap in the age of the Internet

Lim, S.H. (Singapore)

Addressing the treatment gap - lessons learnt from organization and delivery of neurological services in the developing world

Silberberg, D (USA)

Epilepsy research gap - an exploration

Avanzini, G (Italy)

Please replace with sticker
saying "Refer to Abstract
Book Page 9 "

10:00 - 11:30

Post Main Session

Hall 603

(in collaboration with the Global Campaign Against Epilepsy)

Refer to Abstract
Book Page 9

Closing The Three Gaps: Knowledge, Research And Treatment*Gedlie Damtie, Z (Ethiopia) & Andermann, F (Canada), Co-Chairs*

The role of Phenobarbiton

Kwan, P (Hong Kong)

Stigma - A wedge in the gaps

Birbeck, G (USA)

Role of patient care organisations in epilepsy treatment

Ali, A (Jamaica)

The contribution of epidemiological research to closing the treatment gap

Dumas, M (France)

Scientific Programme



MONDAY, 9TH JULY 2007

10:00 - 11:30

Parallel Session

Ballroom 2

Refer to Abstract
Book Page 10

Multi-Level EEG Recordings In Epilepsy Surgery

Locharernkul, C (Thailand) & Luders, H.O. (USA), Co-Chairs

Defining epileptogenic zone - role of scalp interictal spikes and electrographic seizures

Elger, C (Germany)

Subdural EEG recordings - strategies, power and limitations

Najm, I (USA)

Intracerebral EEG recordings -state of the art

Kahane, P (France)

Foramen ovale electrodes and intraoperative ECoG in presurgical evaluation

Sakamoto, A (Brazil)

10:00 - 11:30

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 10

Evidence-Based Imaging In Refractory Paediatric Epilepsy

Gaillard, W.D. (USA), Chair

Evidence for MRI in the evaluation and outcome of chronic paediatric epilepsy

Harvey, S (Australia)

Evidence for SPECT in the evaluation and outcome of chronic paediatric epilepsy

Chiron, C (France)

Evidence for PET in the evaluation and outcome of chronic paediatric epilepsy

Juhasz, C (USA)

Scientific Programme

MONDAY, 9TH JULY 2007

10:00 - 11:30

Parallel Session

Ballroom 3

Refer to Abstract
Book Page 10

Non-Conventional Targets For Novel Antiepileptic Strategies

Rogawski, M.A. (USA), Chair

Neurosteroids as therapeutic agents: seizure protection and antiepileptogenesis

Rogawski, M.A. (USA)

Targeting cytokine signaling for seizure inhibition

Ravizza, T (Italy)

Blood-brain barrier as a target for therapeutic intervention

Friedman, A (Israel)

Inactivation of Multidrug Transport Proteins for improving AED efficacy in drug-resistant epilepsies

Potschka, H (Germany)

Please replace with
sticker saying "Refer to
Abstract Book Page 11
"

10:00 - 11:30

Parallel Session

Theatre

Refer to Abstract
Book Page 11

**Epilepsy Genetics In The 21st Century (Part 1):
Building Bridges From The Laboratory To Patient Care**

Bernard, C (France) & Jain, S (India), Co-Chairs

Genetic variations in human epilepsies: terminology and biological significance

Scheffer, I (Australia)

Human mutations in mice: what can we learn?

Escayg, A (USA)

Genetics in time: why certain mutations express themselves at particular ages

Polack, O (France)

Please replace with sticker
saying "Refer to Abstract
Book Page 12 "

10:00 - 11:30

Platform Session 1

Room 209

Refer to Abstract
Book Page 28

Social Issues

Mehndiratta, M.M. (India), Chair

Please replace with sticker saying "Refer to Abstract Book
Page 41 "

10:00 - 11:30

Platform Session 2

Room 203

Refer to Abstract
Book Page 29

AEDs and Trial Issues

Perucca, E (Italy), Chair

Please replace with sticker saying
"Refer to Abstract Book Page 42 "

Scientific Programme

MONDAY, 9TH JULY 2007

12:00 - 13:30

Satellite Symposium

Hall 603

Refer to Abstract
Book Page 156

Satellite Symposium UCB Pharma S.A. - 'The Balancing Act of Epilepsy Management: Meeting the Needs of People with Epilepsy'

Berkovic, S.F. (Australia), Chair

A patient perspective - 'I may have epilepsy but epilepsy does not have me'

Clignet, M (France)

Efficacy of AEDs : what is the current evidence?

Ryvlin, P (France)

Effectiveness of AEDs : a risk-benefit assessment

Kwan, P (Hong Kong)

Tailoring treatment to your patients' needs

Benbadis, S (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 168 "

14:15 - 15:15

Main Session

Ballroom 2

Refer to Abstract
Book Page 11

Prognosis In People With Epilepsy: Seizure Control, Remission And Intractability

Hauser, A (USA), Chair

Seizure control and outcomes in the newly-diagnosed patient with epilepsy

Brodie, M.J. (UK)

What is intractability and are there predictors?

Berg, A (USA)

What is the longterm outcome in intractable cases. Are there vistas beyond surgery?

French, J (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 13"

15:45 - 17:15

Post Main Session

Ballroom 2

Refer to Abstract
Book Page 12

Acute Symptomatic Seizures: What Is The Frequency, The Prognosis And The Relation To Epilepsy

Hauser, A (USA) & Ali, R.A. (Malaysia), Co-Chairs

Early seizures with acute neurologic illness and incidence of acute symptomatic seizures

Hauser, A (USA)

Seizures in association with metabolic and toxic exposures

Beghi, E (Italy)

Acute symptomatic seizures in developing countries

Carpio, A (Ecuador)

Please replace with sticker
saying "Refer to Abstract
Book Page 13"

Scientific Programme

MONDAY, 9TH JULY 2007

15:45 - 17:15

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 12

Mood Disorders, A Co-Morbidity In Children With Epilepsy*Hermann, B. (USA), Chair*

Psychiatric co-morbidities in children
Heyman, I (UK)

Epidemiology and mood disorders in children with epilepsy
Hesdorffer, D.C. (USA)

Depression and anxiety in children with epilepsy
Caplan, R (USA)

Treatment of mood disorders in children with epilepsy
Dunn, D (USA)

Please replace with sticker
saying "Refer to Abstract Book
Page 14"

15:45 - 17:15

Parallel Session

Ballroom 3

(in collaboration with the Global Campaign Against Epilepsy)

Refer to Abstract
Book Page 13

Addressing Epilepsy Knowledge And Research Gaps In Developing Countries*Avanzini, G (Italy) & Gedlie Damtie, Z (Ethiopia), Co-Chairs*

Free on-line journals - Is this the solution for developing countries?
Tan, C.T. (Malaysia)

Narrowing the Research Gap - Is this mission impossible?
Mehndiratta, M.M. (India)

Closing the 3 Gaps - The Next Lap
Cavalheiro, E (Brazil)

Please replace with sticker
saying "Refer to Abstract Book
Page 15"

15:45 - 17:15

Parallel Session

Theatre

Refer to Abstract
Book Page 13

Epilepsy Genetics In The 21st Century (Part 2): Building Bridges From The Laboratory To Patient Care*Bernard, C (France) & Jain, S (India), Co-Chairs*

Potential clinical applications of gene discoveries: the present and the future
Serratosa, J (Spain)

Genetic testing in the epilepsies: guidelines and principles
Ottman, R (USA)

Meta-analysis of allelic association studies - strength in numbers?
Tan, N (Singapore)

Please replace with sticker
saying "Refer to Abstract Book
Page 15"

Scientific Programme



MONDAY, 9TH JULY 2007

15:45 - 17:15

Parallel Session

Room 209

Refer to Abstract
Book Page 13

Human Herpes Virus 6 And Epilepsy

Theodore, W (USA), Chair

HHV-6: an emerging neuropathogen
Jacobson, S (USA)

Epidemiology of febrile seizures and HHV-6
Shinnar, S (USA)

HHV-6 in mesial temporal sclerosis
Gaillard, W.D. (USA)

Is Rasmussen's encephalitis a viral disease?
Bien, C.G. (Germany)

Please replace with sticker
saying "Refer to Abstract
Book Page 16"

15:45 - 17:15

Platform Session 3

Room 203

Refer to Abstract
Book Page 31

Neurophysiology and Imaging

Lee, B.I. (Korea), Chair

Please replace with sticker saying
"Refer to Abstract Book Page 44"

17:30 - 19:00

Satellite Symposium

Hall 603

Refer to Abstract
Book Page 156

Satellite Symposium Pfizer Inc. - 'The Joy of Sleep - a Close Look at the Interaction Between Sleep and Epilepsy'

Bazil, C.W. (USA), Chair

Sleep disturbance and anxiety in epilepsy
Kwan, P (Hong Kong)


The importance of sleep in epilepsy
Noachtar, S (Germany)

Achieving better nights for better days in epilepsy
Bazil, C.W. (USA)

Please replace with sticker
saying "Refer to Abstract Book
Page 168"



Scientific Programme



TUESDAY, 10TH JULY 2007

	Poster Area	Hall 603	Ballroom 2	Ballroom 1	Ballroom 3
07.30-07.45	Posters			EUREPA Seminar "Difficult cases in childhood epilepsies"	
07.45-08.00					
08.00-08.15					
08.15-08.30					
08.30-08.45		Men and women with epilepsy throughout life 08.30-09.30			
08.45-09.00					
09.00-09.15					
09.15-09.30					
09.30-09.45		Coffee Break 09.30-10.00			
09.45-10.00					
10.00-10.15	Posters	Men and women with epilepsy throughout professional life 10.00-11.30	Uncommon seizures and unusual seizure manifestations 10.00-11.30	Anxiety and depression - impact on epilepsy and quality of life 10.00-11.30	Adeno-associated virus vectors in gene therapy for epilepsy 10.00-11.30
10.15-10.30					
10.30-10.45					
10.45-11.00					
11.00-11.15					
11.15-11.30					
11.30-11.45					
11.45-12.00					
12.00-12.15		Schwarz Pharma Satellite Symposium 12.00-13.30			
12.15-12.30					
12.30-12.45					
12.45-13.00					
13.00-13.15	Authors of Posters present 13.15-14.15				
13.15-13.30					
13.30-13.45					
13.45-14.00					
14.00-14.15	Posters				
14.15-14.30			Epileptogenesis in relation to genetic predisposition 14.15-15.15		
14.30-14.45					
14.45-15.00					
15.00-15.15					
15.15-15.30					
15.30-15.45					
15.45-16.00					
16.00-16.15			Epileptogenesis in relation to genetic predisposition 15.45-17.15	European and Asian action to improve quality of life 15.45-17.15	Complementary and alternative therapy for epilepsy 15.45-17.15
16.15-16.30					
16.30-16.45					
16.45-17.00					
17.00-17.15					
17.15-17.30					
17.30-17.45					
17.45-18.00					
18.00-18.15					
18.15-18.30					
18.30-18.45					
18.45-19.00					

Scientific Programme



Theatre	Room 209	Room 203	
EUREPA Seminar "Difficult cases in adult epilepsies"	EUREPA Seminar "Seizure related Automatisms"		07.30-07.45
			07.45-08.00
			08.00-08.15
			08.15-08.30
			08.30-08.45
			08.45-09.00
			09.00-09.15
			09.15-09.30
Coffee Break 09.30-10.00			09.30-09.45
			09.45-10.00
Seizure and Epilepsy Mortality 10.00-11.30	Platform Session 4 Paediatric epileptology 10.00-11.30	Platform Session 5 Basic science 10.00-11.30	10.00-10.15
			10.15-10.30
			10.30-10.45
			10.45-11.00
			11.00-11.15
			11.15-11.30
			11.30-11.45
			11.45-12.00
			12.00-12.15
			12.15-12.30
			12.30-12.45
			12.45-13.00
			13.00-13.15
			13.15-13.30
Lunch 13.15-14.15			13.30-13.45
			13.45-14.00
			14.00-14.15
			14.15-14.30
			14.30-14.45
			14.45-15.00
			15.00-15.15
Coffee Break 15.15-15.45			15.15-15.30
			15.30-15.45
Seizure and epilepsy classification - consensus and controversies 15.45-17.15	Platform Session 6 Social Issues 15.45-17.15	Platform Session 7 Treatment Issues 15.45-17.15	15.45-16.00
			16.00-16.15
			16.15-16.30
			16.30-16.45
			16.45-17.00
			17.00-17.15
			17.15-17.30
Awards Symposium 17.30-18.30			17.30-17.45
			17.45-18.00
			18.00-18.15
			18.15-18.30
			18.30-18.45
			18.45-19.00

Scientific Programme



TUESDAY, 10TH JULY 2007

07:30 - 08:30

EUREPA Seminar

Ballroom 1

Refer to Abstract
Book Page 13

EUREPA Seminar Series 1

- Discussion On Difficult Cases In Childhood Epilepsies

Seizures in Childhood

Discussants:

Plouin, P (France)
Capovilla, G (Italy)
Covanis, A (Greece)
Koutroumanidis, M (UK)

Please replace with sticker
saying "Refer to Abstract
Book Page 17"

07:30 - 08:30

EUREPA Seminar

Theatre

Refer to Abstract
Book Page 14

EUREPA Seminar Series 2

- Discussion On Difficult Cases In Adult Epilepsies

Classification

Avanzini, G (Italy), Discussant

Van Emde Boas, W (Netherlands)
Najm, I (USA)
Stefan, H (Germany)

Please replace with sticker
saying "Refer to Abstract
Book Page 17"

07:30 - 08:30

EUREPA Seminar

Room 209

Refer to Abstract
Book Page 14

EUREPA Seminar Series 3

- Discussion On Seizure Related Automatisms

Seizure related automatisms

Lüders, H.O. (USA), Discussant

Automatisms with motor behaviors: semiology and SEEG
Gardella, E (Italy)
Francione, S (Italy)

Ictal automatisms and emotion
Kahane, P (France)

Please replace with sticker
saying "Refer to Abstract
Book Page 17"

Scientific Programme

TUESDAY, 10TH JULY 2007

08:30 - 09:30

Main Session

Hall 603

Refer to Abstract
Book Page 14

Men And Women With Epilepsy Throughout Life

Falk Pedersen, J.K. (Norway) & Hung, A (Hong Kong), Co-Chairs

Gender-specific causes and phenomenology of epilepsy
Yacubian, E.M. (Brazil)

Gender-specific side effects of antiepileptic drugs throughout life
Tauboll, E (Norway)

Gender-specific issues in the eyes of the patient
Hills, M (New Zealand)

Please replace with
sticker saying "Refer to
Abstract Book Page
17"

10:00 - 11:30

Post Main Session

Hall 603

Refer to Abstract
Book Page 15

**Men And Women With Epilepsy Throughout Professional Life:
Experiences And Challenges Of Forging A Professional Career And Living
With Epilepsy**

Hargis, E (USA) & Yeo, S (Singapore), Co-Chairs

The young professionals
Yeo, S (Singapore)

The not-so-young professionals
Morris-Coole, C (UK)

Epilepsy in sports and beyond
Clignet, M (France)

Sparks of creativity - the influence of epilepsy on art
Chambliss, J (Australia)

Please replace with
sticker saying "Refer to
Abstract Book Page 18"

10:00 - 11:30

Video Session

Ballroom 2

Refer to Abstract
Book Page 16

Uncommon Seizures And Unusual Seizure Manifestations

Kotagal, P (USA) & Ikeda, A (Japan), Co-Chairs

Case Presentation 1
Ikeda, A (Japan)

Case Presentation 2
Bleasel, A (Australia)

Case Presentation 3
Ebner, A (Germany)

Case Presentation 4
Kotagal, P (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 19"

Scientific Programme

TUESDAY, 10TH JULY 2007

10:00 - 11:30

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 16

Anxiety And Depression - Impact On Epilepsy And Quality Of Life*Cramer, J (USA) & Kazuichi, Y (Japan), Co-Chairs*

Stress, genes and neuroanatomy contribute to depression in epilepsy
Cramer, J (USA)

Etiology and pathogenesis of anxiety and depression in epilepsy
D'Alessio, L (Argentina)

Effects of anxiety and depression on health-related quality of life
Lee, S.A. (South Korea)

Diagnosis and treatment of anxiety and depression in epilepsy
Salzberg, M (Australia)

Please replace with sticker
saying "Refer to Abstract Book
Page 19"

10:00 - 11:30

Parallel Session

Ballroom 3

Refer to Abstract
Book Page 17

Adeno-Associated Virus Vectors In Gene Therapy For Epilepsy: Reality Or Science Fiction?*Kokaia, M (Sweden), Chair*

Viral vectors for gene therapy in neurological diseases
During, M.J. (USA)


Controlling epileptic seizures by GABAA receptor gene therapy
Brooks-Kayal, A (USA)

NPY gene therapy in epileptic rats: inhibition of spontaneous seizures and disease-modifying effects
Noe, F (Italy)

Functional reorganization of synaptic circuitry by NPY gene transfer in hippocampus
Kokaia, M (Sweden)

Please replace with
sticker saying "Refer to
Abstract Book Page 20"

Scientific Programme



TUESDAY, 10TH JULY 2007

10:00 - 11:30 Parallel Session Theatre

Refer to Abstract
Book Page 17

Seizure And Epilepsy Mortality

Hauser, A (USA) & Tsai, J.J. (Taiwan), Co-Chairs

Mortality of Epilepsy in Taiwan

Tsai, J.J. (Taiwan)

Premature mortality in people with epilepsy in rural China

Ding, D (China)

Prognosis of acute symptomatic seizures: mortality, morbidity, and risk for subsequent epilepsy

Hesdorffer, D (USA)

SUDEP, from prediction to prevention

Tomson, T (Sweden)

Please replace with sticker
saying "Refer to Abstract
Book Page 21"

10:00 - 11:30 Platform Session 4 Room 209

Refer to Abstract
Book Page 33

Paediatric Epileptology

Arzimanoglou, A (France), Chair

Please replace with sticker saying
"Refer to Abstract Book Page 46"

10:00 - 11:30 Platform Session 5 Room 203

Refer to Abstract
Book Page 34

Basic Science

Yamakawa K (Japan) & Jackson G (Australia), Co-Chairs

Please replace with sticker saying
"Refer to Abstract Book Page 47"

12:00 - 13:30 Satellite Symposium Hall 603

Refer to Abstract
Book Page 158

Satellite Symposium Schwarz Pharma - 'A Novel AED on the Way to New Horizons'

Somerville, E (Australia), Chair

Recent advances in antiepileptic drug mechanisms: new molecular targets
Rogawski, M.A. (USA)

Lacosamide -pharmacokinetic and safety profile of oral and intravenous formulations
Krauss, G.L. (USA)

Lacosamide - efficacy and safety results in adults with partial-onset seizures

Ben Menachem, E (Sweden)

Please replace with sticker
saying "Refer to Abstract Book
Page 169"



Scientific Programme

TUESDAY, 10TH JULY 2007

14:15 - 15:15

Main Session

Ballroom 2

Refer to Abstract
Book Page 17

Epileptogenesis In Relation To Genetic Predisposition In Abnormal Brain

Vezzani, A (Italy) & Berkovic, S.F. (Australia), Co-Chairs

Human epilepsies - interaction of genetic and acquired factors

Berkovic, S.F. (Australia)

Biological pathways to idiopathic epileptogenesis in animal models and relevance to human epilepsies

Noebels, J.L. (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 22"

15:45 - 17:15

Post Main Session

Ballroom 2

Refer to Abstract
Book Page 18

Epileptogenesis In Relation To Genetic Predisposition In Abnormal Brain

Berkovic, S.F. (Australia), Chair

Effect of genetic background on epileptogenesis in animal models of symptomatic epilepsies-current knowledge and translation to human epilepsy

Pitkanen, A (Finland)

Neuronal migration disorders and epileptogenesis in man and rodents

Battaglia, G (Italy)

Febrile seizures in the predisposed brain: new models of TLE

Carmant, L (Canada)

Please replace with sticker
saying "Refer to Abstract
Book Page 22"

15:45 - 17:15

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 18

European And Asian Action To Improve Quality Of Life

Covanis, A (Greece) & Kubova, H (Czech Republic), Co-Chairs

Political action at eu and european parliaments

Dahlqvist, P (Sweden)

Canvassing governmental support to improve quality of life

Sethi, P (India)

Driving licenses in Europe

Glynn, M (Ireland)

Driving licenses in Asia

Pan, A (Singapore)

Please replace with sticker
saying "Refer to Abstract
Book Page 22"

Scientific Programme

TUESDAY, 10TH JULY 2007

15:45 - 17:15

Parallel Session

Ballroom 3

Refer to Abstract
Book Page 18

Complementary And Alternative Therapy For Epilepsy

Nunez, L (Mexico) & Medina, M.T. (Honduras), Co-Chairs

Overview on the complementary and alternative therapy for epilepsy
Chavez Sell, F.C. (Costa Rica)

Anthropological and cultural issues on alternative therapy in Latin America
Medina, M.T. (Honduras)

Alternative therapies since prehispanic days to present time
Nunez, L (Mexico)

The use of alternative therapy for epilepsy in Uruguay: the European influence
Bogacz, A (Uruguay)

Please replace with
sticker saying "Refer to
Abstract Book Page 23"

15:45 - 17:15

Parallel Session

Theatre

Refer to Abstract
Book Page 19

Seizure And Epilepsy Classification - Consensus And Controversies

Ebner, A (Germany) & Plouin, P (France), Co-Chairs

History of seizure and epilepsy classification
Wolf, P (Denmark)

Use of testable hypotheses in construction of classification
Berg, A (USA)

The semiological concept of seizure and epilepsy classification
Luders, H.O. (USA)

The paediatric perspective of seizure and epilepsy classification
Akiyama, T (Japan)

Please replace with sticker
saying "Refer to Abstract
Book Page 25"



Scientific Programme

TUESDAY, 10TH JULY 2007

15:45 - 17:15

Platform Session 6

Room 209

Refer to Abstract
Book Page 36

Social Issues

Hargis, E (USA), Chair

Please replace with sticker saying "Refer to Abstract Book Page 49"

15:45 - 17:15

Platform Session 7

Room 203

Refer to Abstract
Book Page 38

Treatment Issues

Kwan, P (Hong Kong), Chair

Please replace with sticker saying "Refer to Abstract Book Page 51"

17:30 - 18:30

Awards Symposium

Theatre

Refer to Abstract
Book Page 19

Michael Prize and Morris-Coole Prize

The Michael Prize:

The Neurovascular Unit in Epileptogenesis: From Bed-Side to Bench and Back

Friedman, A (Israel)

Epilepsy: a question of reorganization
Bernard, C (France)

The Morris-Coole Prize:

The functional significance of gap junction channels in the epileptogenicity and seizure susceptibility of juvenile rats
Gajda, Z (Hungary)

Please replace with sticker saying "Refer to Abstract Book Page 26"



Scientific Programme



WEDNESDAY, 11TH JULY 2007

	Poster Area	Hall 603	Ballroom 2	Ballroom 1	Ballroom 3
07.30-07.45				EUREPA Seminar "Evolution of focal nonidiopathic epilepsies in children"	
07.45-08.00					
08.00-08.15					
08.15-08.30					
08.30-08.45		Stigma and epilepsy, a comprehensive view 08.30-09.30			
08.45-09.00					
09.00-09.15	Posters				
09.15-09.30					
09.30-09.45		Coffee Break 09.30-10.00			
09.45-10.00					
10.00-10.15		Quality of life 10.00-11.30	From evidence-based analysis to practical recommendations 10.00-11.30	Paediatric epilepsy syndromes and their treatment Part 1 10.00-11.30	Sexuality and epilepsy throughout life 10.00-11.30
10.15-10.30					
10.30-10.45					
10.45-11.00					
11.00-11.15					
11.15-11.30					
11.30-11.45					
11.45-12.00		Valeant Pharmaceuticals International Satellite Symposium 12.00-13.30			
12.00-12.15					
12.15-12.30					
12.30-12.45					
12.45-13.00					
13.00-13.15	Authors of Poster present 13.15-14.15				
13.15-13.30		Lunch 13.15-14.15			
13.30-13.45					
13.45-14.00					
14.00-14.15					
14.15-14.30	Posters		Neuropsychological and psychological aspects 14.15-15.15		
14.30-14.45					
14.45-15.00					
15.00-15.15					
15.15-15.30		Coffee Break 15.15-15.45			
15.30-15.45			Neuropsychological and psychological aspects 15.45-17.15	Paediatric epilepsy syndromes and their treatment Part 2 15.45-17.15	Neuroinfections and epilepsy 15.45-17.15
15.45-16.00					
16.00-16.15					
16.15-16.30					
16.30-16.45					
16.45-17.00					
17.00-17.15					
:					
:					
:					
:					
:					
20.00-20.15	Gala Dinner 20.00-late				
20.15-20.30					

Scientific Programme



Theatre	Room 209	Room 203		
EUREPA Seminar "Difficult cases in adult epilepsies"	EUREPA Seminar "Seizure related automatisms"		07.30-07.45	
			07.45-08.00	
	08.00-08.15			
	08.15-08.30			
	08.30-08.45			
	08.45-09.00			
	09.00-09.15			
	09.15-09.30			
Coffee Break 09.30-10.00			09.30-09.45	
			09.45-10.00	
Epileptogenesis and the developing brain 10.00-11.30	Platform Session 8 Adult Epileptology 10.00-11.30	Platform Session 9 Neuropsychology and Psychiatry 10.00-11.30	10.00-10.15	
			10.15-10.30	
			10.30-10.45	
			10.45-11.00	
			11.00-11.15	
			11.15-11.30	
			11.30-11.45	
			11.45-12.00	
			12.00-12.15	
			12.15-12.30	
			12.30-12.45	
			12.45-13.00	
			13.00-13.15	
Lunch 13.15-14.15			13.15-13.30	
			13.30-13.45	
			13.45-14.00	
			14.00-14.15	
			14.15-14.30	
			14.30-14.45	
			14.45-15.00	
			15.00-15.15	
Coffee Break 15.15 - 15.45			15.15-15.30	
			15.30-15.45	
AES session <i>Curing epilepsy in 2007</i> 15.45-17.15	The role of neuropeptides in epilepsy 15.45-17.15	Platform Session 10 Basic Science 15.45-17.30	15.45-16.00	
			16.00-16.15	
			16.15-16.30	
			16.30-16.45	
			16.45-17.00	
			17.00-17.15	
			17.00-17.30	
			:	
			:	
			:	
			:	
Gala Dinner 20.00-late			20.00-20.15	
			20.15-20.30	



Scientific Programme

WEDNESDAY, 11TH JULY 2007

07:30 - 08:30

EUREPA Seminar

Ballroom 1

Refer to Abstract
Book Page 20

Eurepa Seminar Series 1

- Evolution Of Focal Non-Idiopathic Epilepsies In Children And Treatment Strategies

Evolution of focal non-idiopathic epilepsies in children and treatment strategies

Discussants:

Cross, H (UK)

French, J (USA)

Arzimanoglou, A (France)

Please replace with sticker
saying "Refer to Abstract Book
Page 27"

07:30 - 08:30

EUREPA Seminar

Theatre

Refer to Abstract
Book Page 20

EUREPA Seminar Series 2

- Discussion On Difficult Cases In Adult Epilepsies

Comorbidity

Ozkara, C (Turkey), Discussant

Tomson, T (Sweden)

Guekht, A (Russia)

Kanner, A.M. (USA)

Please replace with
sticker saying "Refer to
Abstract Book Page 27"

07:30 - 08:30

EUREPA Seminar

Room 209

Refer to Abstract
Book Page 20

EUREPA Seminar Series 3

- Discussion On Seizure Related Automatisms

Seizure related automatisms

Kahane, P (France), Discussant

Automatisms as fixed action patterns in an ethological perspective:

the role of central pattern generators

Tassinari, C.A. (Italy)

Please replace with
sticker saying "Refer to
Abstract Book Page 27"



Scientific Programme

WEDNESDAY, 11TH JULY 2007

08:30 - 09:30
Main Session
Hall 603

Refer to Abstract
Book Page 20

Stigma And Epilepsy, A Comprehensive View
Acevedo, C (Chile) & Li, S (China), Co-Chairs

The impact of stigma on quality of life
Jacoby, A (UK)

Stigma and epilepsy - The China perspective
Li, S (China)

Stigma in developing countries - the Latin American perspective
Fernandez, P.T. (Brazil)

Please replace with
sticker saying "Refer to
Abstract Book Page 27"

10:00 - 11:30
Post Main Session
Hall 603

Refer to Abstract
Book Page 21

Quality Of Life
Acevedo, C (Chile) & Lai, C.W. (Taiwan), Co-Chairs

Quality of life - significance and importance
Acevedo, C (Chile)

Comparison of health-related quality of life in adults with and without
epilepsy
Liou, H.H. (Taiwan)

Patient's quality of life: should doctors assess it and use it?
D'Souza, C (India)

Epilepsy and quality of life: how to interpret the results of the
measurements
Wiebe, S (Canada)

Please replace with
sticker saying "Refer to
Abstract Book Page 28"

10:00 - 11:30
Parallel Session
Ballroom 2

Refer to Abstract
Book Page 22

From Evidence-Based Analysis To Practical Recommendations And Beyond
French, J (USA), Chair

Guidelines and practice in the treatment of newly-diagnosed and refractory
epilepsy
Ben Menachem, E (Sweden)

Applicability of guidelines to the economically-challenged nations
Yardi, N (India)

Looking to the future: guidelines and practice in epilepsy surgery
Mathern, G (USA)

Please replace with
sticker saying "Refer to
Abstract Book Page 29"

Please replace with
sticker saying "Refer to
Abstract Book Page 30"



Scientific Programme

WEDNESDAY, 11TH JULY 2007

10:00 - 11:30	Parallel Session	Ballroom 1
---------------	------------------	------------

Refer to Abstract
Book Page 22

Paediatric Epilepsy Syndromes And Their Treatment (Part 1)

Chugani, H.T. (USA) & Moshe, S.L. (USA), Co-Chairs

Epileptic spasms
Chugani, H.T. (USA)

Epilepsies associated with aphasia / dysphasia
Mikati, M (Lebanon)

Lennox-Gastaut and Doose syndromes
Dulac, O (France)

The Occipital Lobe Epilepsies
Koutroumanidis, M (UK)

Please replace with
sticker saying "Refer to
Abstract Book Page 30"

10:00 - 11:30	Parallel Session	Ballroom 3
---------------	------------------	------------

Refer to Abstract
Book Page 22

Sexuality And Epilepsy Throughout Life

Ozkara, C (Turkey) & Cabral Lim, L (Philippines), Co-Chairs

Sexuality in men with epilepsy
Harden, C.L. (USA)

Sexuality in women with epilepsy
Sabers, A (Denmark)

Epilepsy surgery and sexuality
Reutens, D (Australia)

Sexuality and quality of life
Cabral Lim, L (Philippines)

Please replace with
sticker saying "Refer to
Abstract Book Page 31"

10:00 - 11:30	Parallel Session	Theatre
---------------	------------------	---------

Refer to Abstract
Book Page 23

Epileptogenesis And The Developing Brain

Nehlig, A (France), Chair

Neuropathological and behavioral consequences of early status epilepticus
Kubova, H (Czech Republic)

Inflammation-related events induced by seizures during post-natal development: implications for epileptogenesis
Vezzani, A (Italy)

Epileptogenesis and the developing brain: an imaging approach
Nehlig, A (France)

Epilepsy and the immature brain: insights from basic and clinical research
Brooks-Kayal, A (USA)

Please replace with
sticker saying "Refer to
Abstract Book Page 31"

Scientific Programme



WEDNESDAY, 11TH JULY 2007

10:00 - 11:30

Platform Session 8

Room 209

Refer to Abstract
Book Page 39

Adult Epileptology

Hauser, A (USA), Chair

Please replace with sticker saying
"Refer to Abstract Book Page 52"

10:00 - 11:30

Platform Session 9

Room 203

Refer to Abstract
Book Page 41

Neuropsychology and Psychiatry

Saling, M (Australia), Chair

Please replace with sticker saying
"Refer to Abstract Book Page 54"

12:00 - 13:30

Satellite Symposium

Hall 603

Refer to Abstract
Book Page 158

Satellite Symposium Valeant Pharmaceuticals International 'Neuron-Specific M-Current Potassium Channels: A New Target in Managing Epilepsy'

Perucca, E (Italy), Chair

Epidemiology of refractory epilepsy
French, J (USA)

Anatomy and physiology of neuron-specific potassium channels
Rogawski, M.A. (USA)

Pharmacology of neuron-specific M-current potassium channel activation
White, H.S. (USA)

Clinical evidence for M-current potassium channels as a therapeutic target
in epilepsy
French, J (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 170"

14:15 - 15:15

Main Session

Ballroom 2

Refer to Abstract
Book Page 23

Neuropsychological and Psychosocial Aspects Of Epilepsy: Neurobiological And Psychopathological Context

Saling, M (Australia) & Inoue, Y (Japan), Co-Chairs

Epilepsy and depression: a bi-directional relationship
Kanner, A.M. (USA)

Neurobiological and psychosocial indicators of patient adjustment to
epilepsy
Wilson, S.J. (Australia)

Biological and social risk factors for depression in epilepsy
Hopwood, M. (Australia)

Please replace with
sticker saying "Refer
to Abstract Book
Page 32"

Scientific Programme

WEDNESDAY, 11TH JULY 2007

15:45 -17:15

Post Main Session

Ballroom 2

Refer to Abstract
Book Page 24

Neuropsychological and Psychosocial Aspects Of Epilepsy: New Directions In Pre-And Post-Surgical Evaluation And Management

Hermann, B (USA) & Wilson, S.J. (Australia), Co-Chairs

New directions in presurgical evaluation: plasticity in language and memory

Suzuki, K (Japan)

The Future of the WADA Test

Baxendale, S (UK)

Memory and language difficulties after surgery: psychosocial and management issues

Baker, G (UK)

Neuropsychological and psychosocial aspects of post-surgical management

O'Shea, M (Australia)

Please replace with sticker
saying "Refer to Abstract
Book Page 33"

15:45 - 17:15

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 24

Paediatric Epilepsy Syndromes And Their Treatment (Part 2)

Chugani, H.T. (USA) & Moshe, S.L. (USA), Co-Chairs

Animal models for catastrophic epilepsies

Moshe, S.L. (USA)

Seizures in infancy and childhood associated with non-CNS infections

Lee, W.L. (Singapore)

Benign epileptic syndromes of infancy

Capovilla, G (Italy)

Benign epileptic syndromes of childhood

Fejerman, N (Argentina)

Please replace with
sticker saying "Refer
to Abstract Book Page
34"

Scientific Programme

WEDNESDAY, 11TH JULY 2007

15:45 - 17:15

Parallel Session

Ballroom 3

Refer to Abstract
Book Page 25

Neuroinfections And Epilepsy

Gueye, L (Senegal) & Gunawan, D (Indonesia), Co-Chairs

Plasmodium falciparum - Its epileptogenic potential
Newton, C (Kenya)

Subacute sclerosing panencephalitis and epilepsy - a disappearing entity?
Gurses, C (Turkey)

Neurocysticercosis - are clinicians doing enough to understand its
epidemiology?
Singhi, P (India)

Neuroinfection and epilepsy in Latin America - are we different from the rest
of the world?
Garcia, H.H. (Peru)

Please replace with sticker
saying "Refer to Abstract Book
Page 35"

15:45 - 17:15

Parallel Session

Theatre

Refer to Abstract
Book Page 25

AES Session - Curing Epilepsy In 2007

Swann, J.W. (USA) & Spencer, D (USA), Co-Chairs

Translating discoveries of epilepsy genes into cures
Scheffer, I (Australia)

Translating discoveries of epileptogenic mechanisms into cures
Swann, J.W. (USA)

Beyond seizures: cognitive and psychological issues in epilepsy
Brooks-Kayal, A (USA)

Emerging technologies of diagnostic materials and cellular and molecular
therapeutics
Spencer, D (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 36"

Scientific Programme

WEDNESDAY, 11TH JULY 2007

15:45 - 17:15

Parallel Session

Room 209

Refer to Abstract
Book Page 25

The Role Of Neuropeptides In Epilepsy

Sperk, G (Austria), Chair

Neuropeptide Y in Epilepsy: plasticity and possible treatment strategies

Sperk, G (Austria)

Evidence for an endogenous anticonvulsant role of dynorphin in an animal model of seizures induced by herpes simplex virus infection

Solbrig, M (USA)

Neuropeptides and seizure-induced neurogenesis

Gray, W (UK)

Corticotropin-releasing hormone in frontal lobe epilepsy

Combi, R (Italy)

Please replace with sticker
saying "Refer to Abstract Book
Page 36"

15:45 - 17:30

Platform Session 10

Room 203

Refer to Abstract
Book Page 42

Basic Science

Kubova H (Czech Republic) & Galanopoulou A (USA), Co-Chairs

Please replace with sticker saying
"Refer to Abstract Book Page 55"


20:00 - Late

Gala Dinner

Ritz Carlton Hotel



Scientific Programme



THURSDAY 12TH JULY 2007

	Ballroom 2	Ballroom 1	Ballroom 3	Room 203	
07.30-07.45		Video Session Seizure mimickers 07.30-08.30			07.30-07.45
07.45-08.00					07.45-08.00
08.00-08.15					08.00-08.15
08.15-08.30					08.15-08.30
08.30-08.45					08.30-08.45
08.45-09.00	Difficult to treat situations in epilepsy 08.45-09.45				08.45-09.00
09.00-09.15					09.00-09.15
09.15-09.30					09.15-09.30
09.30-09.45					09.30-09.45
09.45-10.00					09.45-10.00
10.00-10.15	Coffee Break 09.45-10.15				10.00-10.15
10.15-10.30	Improving medical evidence and therapeutic strategies in difficult-to-treat situations 10.15-11.45	Sleep, epilepsy and nocturnal attacks 10.15-11.45	Multifaceted interactions of steroid hormones with seizures and epilepsy 10.15-11.45	Platform Session 11 AED Issues 2 10.15-11.45	10.15-10.30
10.30-10.45					10.30-10.45
10.45-11.00					10.45-11.00
11.00-11.15					11.00-11.15
11.15-11.30					11.15-11.30
11.30-11.45					11.30-11.45
11.45-12.00					11.45-12.00
12.00-12.15	Highlights Session 12.00-13.30				12.00-12.15
12.15-12.30					12.15-12.30
12.30-12.45					12.30-12.45
12.45-13.00					12.45-13.00
13.00-13.15					13.00-13.15
13.15-13.30					13.15-13.30
13.30-13.45					13.30-13.45
13.45-14.00					13.45-14.00
14.00-14.15					14.00-14.15
14.15-14.30					14.15-14.30
14.30-14.45					14.30-14.45
14.45-15.00					14.45-15.00
15.00-15.15					15.00-15.15
15.15-15.30					15.15-15.30
15.30-15.45					15.30-15.45
15.45-16.00					15.45-16.00
16.00-16.15					16.00-16.15
16.15-16.30					16.15-16.30
16.30-16.45					16.30-16.45
16.45-17.00					16.45-17.00
17.00-17.15					17.00-17.15
17.15-17.30					17.15-17.30
17.30-17.45					17.30-17.45
17.45-18.00					17.45-18.00
18.00-18.15					18.00-18.15
18.15-18.30					18.15-18.30
18.30-18.45					18.30-18.45



Scientific Programme

THURSDAY, 12TH JULY 2007

07:30 - 08:30

Video Session

Ballroom 1

Refer to Abstract
Book Page 26

Seizure Mimickers

Cook, M.J. (Australia), Chair

Syncope

Somerville, E (Australia)

Non-epileptic psychogenic seizures

LaFrance Jr, W.C. (USA)

Challenges in diagnosis and management

Cook, M.J. (Australia)

Please replace with sticker
saying "Refer to Abstract
Book Page 37"

08:45 - 09:45

Main Session

Ballroom 2

Refer to Abstract
Book Page 26

Difficult-To-Treat Situations In Epilepsy

Baulac, M (France) & Shih, Y.H. (Taiwan), Co-Chairs

Epileptic encephalopathies in childhood

Cross, H (UK)

Refractory idiopathic generalised epilepsies

Benbadis, S.R. (USA)

Difficult situations in surgical treatment for mesial temporal lobe epilepsy

Palmini, A (Brazil)

Please replace with sticker
saying "Refer to Abstract
Book Page 37"

10:15 - 11:45

Post Main Session

Ballroom 2

Refer to Abstract
Book Page 26

Improving Medical Evidence And Therapeutic Strategies In Difficult-To-Treat Situations

Chiron, C (France) & Ramaratnam, S (India), Co-Chairs

Clinical trials in childhood epileptic encephalopathies

Chiron, C (France)

The concept of rare epileptic diseases and orphan drug programmes

Baulac, M (France)

Clinical trials with brain stimulation

Fisher, R (USA)

What level of evidence is needed in the assessment of epilepsy surgery?

Lee, B.I. (South Korea)

Please replace with
sticker saying "Refer to
Abstract Book Page 38"

Scientific Programme

THURSDAY, 12TH JULY 2007

10:15 - 11:45

Parallel Session

Ballroom 1

Refer to Abstract
Book Page 27

Sleep, Epilepsy And Nocturnal Attacks

Puvanendran, K (Singapore) & Stefan, H (Germany), Co-Chairs

Neurobiological mechanisms of parasomnias and seizures during sleep
Mayer, G (Germany)

Arousal, antiarousal and epileptic activity during sleep
Halasz, P (Hungary)

Differential diagnosis between nocturnal epileptic seizures and parasomnias
Tinuper, P (Italy)

Overlapping of epilepsies and motoric disorders in sleep
(Video-EEG-Presentation)
Sammaritano, M (USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 39"

10:15 - 11:45

Parallel Session

Ballroom 3

Refer to Abstract
Book Page 27

Multifaceted Interactions Of Steroid Hormones With Seizures And Epilepsy

Velisek, L (USA), Chair

Oestrogens and depression
Gustafsson, J.A. (Sweden)

Oestrogen-induced neuroprotection
Veliskova, J (USA)

Synaptocrinology: Local brain synthesis of androgens and Oestrogens with
paracrine activity
Kawato, S (Japan)

Antenatal Corticosteroids - development of brain and behaviour
Harding, J (New Zealand)

Please replace with
sticker saying "Refer to
Abstract Book Page 40"



Scientific Programme

THURSDAY, 12TH JULY 2007

10:15-11:45

Platform Session 11

Room 203

Refer to Abstract
Book Page 44

AED Issues 2

Jain, S (India), Chair

*Please replace with sticker saying
"Refer to Abstract Book Page 57"*

12:00 - 13:30

Highlights Session

Ballroom 2

Refer to Abstract
Book Page 28

The 27th IEC Highlights

Lim, S.H. (Singapore) & Wolf, P (Denmark), Co-Chairs

Acevedo, C (Chile)
Baulac, M (France)
Bharucha, N.E. (India)
Falk Pedersen, J.K. (Norway)
Hauser, A (USA)
Saling, M (Australia)
Vezzani, A (Italy)

*Please replace with sticker
saying "Refer to Abstract
Book Page 41"*





Platform Sessions

MONDAY, 9TH JULY 2007

10:00 - 11:30

Platform Session 1

Room 209

Refer to Abstract
Book Page 28

Social Issues

Mehndiratta, M.M. (India) Chair

- 001 Intractable Epilepsy or Disabling Epilepsy: What should be the Criteria for Disability Certification?**
Shah U, D'Souza C, Shah P, Saxena V (India)
- 002 Comprehensive Rural Epilepsy Study: Specialist Epilepsy Care at the Doorsteps of People with Epilepsy: A Cost Saving Model**
Seshadri V, Murthy J, Ravi Raju C (India)
- 003 Cost of Epilepsy in South Morocco**
Adali N, Benkhadda S, Kissani N (Morocco)
- 004 Evaluating Effect of a TV Commercial about Epilepsy**
Martiniuk A, Secco M, (Canada)
- 005 Role of Preconception Counselling for Women with Epilepsy**
Winterbottom J, Smyth R, Jacoby A, Baker G (UK)
- 006 New Driving Regulations for PWE in Europe could have Positive Implications for other Regions of the World**
Glynn M (Ireland)

Please replace with
sticker saying "Refer
to Abstract Book Page
41

10:00 - 11:30

Platform Session 2

Room 203

Refer to Abstract
Book Page 29

AEDs and Trial Issues

Perruca, E (Italy) Chair

- 007 Evaluation of the Efficacy of Phenobarbital in Treatment of Epilepsy in Rural Areas of Sichuan Province in China**
Xue R, Zhou D (China)
- 008 Response to Valproic Acid for Photosensitive Epilepsy Possibly based on Gender**
Kasteleijn-Nolst Trenité D, Reed R (Italy)
- 009 Use of Generic Preparations of Lamotrigine: Interim Analysis of an Ongoing Prospective Study at the Epilepsy Centre, Erlangen**
Stefan H, Pawlowski M, Kerling F, Hercksen I (Germany)
- 010 Daily Fluctuations of Lamotrigine (LTG) Plasma Levels**
Nielsen K, Dahl M, Tømmerup E, Á Rogvi Hansen B, Erdal J, Wolf P (Denmark)
- 011 Appropriate Management of Women who become Pregnant while Participating in Clinical Trials of Anti-Epileptic Medications**
Beran R (Australia)
- 012 Seizure Severity Questionnaire (SSQ) as a Patient-reported Outcome in Multinational Clinical Trials**
Cramer J, Greenspan A, Rupnow M (USA)

Please replace with
sticker saying "Refer
to Abstract Book
Page 42

Platform Sessions

MONDAY, 9TH JULY 2007

15:45 – 17:15

Platform Session 3

Room 203

Refer to Abstract
Book Page 31**Neurophysiology and Imaging***Lee, B.I. (Korea) Chair***013 Localisation of Centrotemporal Spikes in Benign Focal Epilepsy of Childhood using Simultaneous EEG and Functional MRI***Harvey S, Masterton R, Flanagan D, Lillywhite L, Archer J, Abbott D, Jackson G (Australia)***014 Localisation of Language Networks in Children with Epilepsy: Comparison of Depth Electrode Intracortical Stimulation and fMRI***De Ribaupierre S, Delalande O, Bulteau C, Dorfmueller G, Jallin C, Chiron C, Hertz-Pannier L (France)***015 Cortico-cortical Network Involved in Secondary Epileptogenesis: A Combined Study of Functional and Anatomical Tractography***Matsumoto R, Sawamoto N, Taki J, Mitsueda T, Inouchi M, Hitomi T, Kinoshita M, Urayama S, Mikuni N, Behrens T, Fukuyama H, Takahashi R, Ikeda A (Japan, UK)***016 Wada Test does not predict Memory Outcome following Anterior Temporal Lobectomy***Rathore C, Alexander A, Nayak D, Sarma S, Radhakrishnan K (India)***017 Extraoperative Electrical Stimulation of the Visual Cortex***Usui N, Baba K, Terada K, Matsuda K, Tottori T, Umeoka S, Mihara T, Nakamura F, Usui K, Inoue Y (Japan)***018 Non-manipulative Unilateral Proximal Arm Automatisms Lateralise Contralaterally in Temporal Lobe Epilepsy***Kelemen A, Fogarasi A, Janszky J, Halasz P (Hungary)*Please replace with
sticker saying "Refer to
Abstract Book Page 44

Platform Sessions

TUESDAY, 10TH JULY 2007

10:00 - 11:30


Platform Session 4

Room 209

Refer to Abstract
Book Page 33

Paediatric Epileptology*Arzimanoglou, A (France) Chair***029 Diagnostic Value of Paediatric EEG-video Telemetry in Identifying Paroxysmal Non-epileptic Events in Children with Epilepsy***Hussain N, Gosalakal J (UK)***020 Clinical and EEG Features in Children with Unilateral Malformations of Cortical Development***Jovic N (Serbia)***021 Epilepsies of Perisylvian Syndromes***Neville B, Chong K, Cox T, Clark M (UK)***022 Clinical Manifestations and Risk Factors of Seizures after Haematopoietic Stem Cell Transplantation in Children***Lee I, Chung N, Lee J, Lee D, Cho B, Choi B, Kim Y, Chung S, Kim H (South Korea)***023 Outcome after Corpus Callosotomy in Children with Injurious Drop Attacks and Severe Mental Retardation***Abraham M, Rathore C, George A, Sarma S, Radhakrishnan K (India)***024 Effects of Epilepsy Surgery on Emotions, Behaviour and Psychosocial Impairment in Children and Adolescents with Drug Resistant Epilepsy: A Prospective Study***Hannan S, Cross H, Scott R, Harkness W, Heyman I (UK)*

Please replace with
sticker saying "Refer
to Abstract Book Page
46



Platform Sessions

TUESDAY, 10TH JULY 2007

10:00 – 11:30

Platform Session 5

Room 203

Refer to Abstract
Book Page 34


Please replace with
sticker saying "Refer to
Abstract Book Page 47"

Basic Science

Yamakawa K (Japan) & Jackson G (Australia) Co-Chairs

- 025 Predictive Value of MRI for Increased Seizure Susceptibility in Rat Model of Posttraumatic Epilepsy**
Kharatishvili I, Immonen R, Grohn O, Pitkanen A (Finland)
- 026 Imaging of Experimental Surgery: Deep Brain Stimulation, Callosotomy and Multiple Subpial Transections**
Tanaka T, Takebayashi S, Hashizume K, Hodozuka A (Japan)
- 027 Prospective Brain T2 Relaxometry, Diffusion Tensor Imaging and Spectroscopy in a Rat Model of Early-life Febrile Convulsions**
Jansen J, Lemmens E, Hoogland G, Schijns O, Jennerkens W, Strijkers G, Prompers J, Habets J, Kooi M, Nicolay K, Backes W (The Netherlands)
- 028 Mechanisms of Fast Activity at Seizure Onset in the Entorhinal Cortex of the Guinea Pig Isolated Brain**
De Curtis M, Gnatkowsky V, Uva L, Librizzi L (Italy)
- 029 Gene Expression Profiling in Monozygotic Twins with Absence Epilepsy**
Helbig I, Matigian N, Vadlamudi L, Lawrence K, Zielinski M, Bain S, Dibbens L, Diyagama D, Holloway A, Scheffer I, Mulley J, Berkovic S, Hayward N (Australia)
- 030 Paroxysmal Exertion-induced Dyskinesia, Haemolytic Anaemia and Epilepsy: Energy Deficit and Electrolyte Shift**
Weber Y, Storch A, Wuttke T, Brockmann K, Pekrun A, Kempfle J, Lehmann-Horn F (Germany)

Platform Sessions

TUESDAY, 10TH JULY 2007

15:45 – 17:15

Platform Session 6

Room 209

Refer to Abstract
Book Page 36

Social Issues*Hargis, E (USA) Chair*

- 031 Understanding the Real-life Effects of Epilepsy in Children: 'Future in Mind', an International Survey of Parents, Healthcare Professionals and Children**
Hargis E, Baker G, Arzimanoglou A, Glauser T, Pellock J, Hsih M, Mounfield H (USA, UK, France)
- 032 IBE Survey of Children and Young People with Epilepsy in China**
Ding D, Yu P, Zhu G, Wu X, Meng H, Hong Z (China)
- 033 Seizure Impact on the Academic Life of Children with Epilepsy**
Guerreiro M, Kouhiro B, Montenegro M (Brazil)
- 034 Global Campaign against Epilepsy: Partnership with the Government and WHO Zambia Office**
Zimba A, Nsachilwa B (Zambia)
- 035 Health Care Workers' Knowledge, Attitudes and Practices regarding Epilepsy in Burkina Faso**
Athanase M, Bakary T, Sélouké S, Braïma S, Pierre-Marie P, Dumas M (Burkina Faso, France)
- 036 'If someone is bewitching you, better he should just kill you': The Experiences of Women Living with Epilepsy in Zambia**
Birbeck G, Chomba E, Atadzhanov M, Mbewe E, Haworth A (Zambia, USA)

Please replace with sticker
saying "Refer to Abstract
Book Page 49"

15:45 – 17:15

Platform Session 7

Room 203

Refer to Abstract
Book Page 38

Treatment Issues*Kwan P (Hong Kong) Chair*

- 037 Vagus Nerve Stimulation for Refractory Status Epilepticus**
Boon P, De Herdt V, Waterschoot L, Verhelst H, De Jaeger A, Van Coster R, Van Roost D, Vonck K (Belgium)
- 038 Strategies for Tapering AED Medication in Presurgical Video/EEG Monitoring: Maximising Benefits and Reducing Risks**
Georgieva A, Velis D (Netherlands)
- 039 Longitudinal Study of Bone Mineral Density with Antiepileptic Drug Monotherapy**
Lee H, Kim S, Kim B (South Korea)
- 040 Natural History of Language Development in Children Exposed to Anti-Epileptic Drugs in Utero**
Entwistle R, Booth A, Barrie C, Baker G (UK)
- 041 Relationship between Preoperative Epilepsy Duration and Postoperative Outcome after Epilepsy Surgery**
Elsharkawy A, Pannek H, Schulz R, Hoppe M, Pahs G, Gyimesi C, Nayel M, Issa A, Ebner A (Germany, Egypt)
- 042 Outcome of Status Epilepticus in Children and Predictors for Morbidity and Mortality**
Kravljanc R, Jovic N, Djuric M, Pakmezovic T (Serbia)

Please replace with sticker
saying "Refer to Abstract
Book Page 51"



Platform Sessions

WEDNESDAY, 11TH JULY 2007

10:00 - 11:30

Platform Session 8

Room 209

Refer to Abstract
Book Page 39

Adult Epileptology

Hauser, A (USA) Chair

043 Prognosis of First Acute Symptomatic Seizure: A Prospective Study

Leung H, Kwan P, Yu E, Wong K (Hong Kong)

044 Epilepsy Specialist Nurse (ESN) Diagnosis of Epilepsy: A Direct Comparison of Consultant Neurologist and ESN Diagnosis at First Seizure Presentation

Goodwin M (UK)

045 Incidence Rate of Newly Diagnosed Epileptic Seizures in French Indian Ocean Island, La Reunion

Mignard C, De Montredon J, Herrmann F, Jallon P (France, Switzerland)

046 Symptomatic Seizures in Neurosyphilis: Experience from a University Hospital from South India

Sinha S, Harish T, Taly A, Murthy P, Chandramukhi A (India)

047 Outcome Assessment of Epilepsy Management at Primary Care Level

Li L, Fernandes P, Noronha A, Marques L, Borges M, Cendes F, Guerreiro C, Zanetta D, de Boer H, Espindola J, Miranda C, Prilipko L, Sander J (Brazil, The Netherlands, USA, Switzerland)

048 Coping Strategies used by Epilepsy Patients as Related to their Quality Of Life

Wang W (China)

Please replace with sticker
saying "Refer to Abstract
Book Page 52"

10:00-11:30

Platform Session 9

Room 203

Refer to Abstract
Book Page 41

Neuropsychology and Psychiatry

Saling, M (Australia) Chair

049 Reorganisation of Semantic Noun Processing in Left Temporal Lobe Epilepsy

Edwards J, Bass A, Goodyear B, Federico P (Canada)

050 Natural History of Cognitive Impairment in Newly Diagnosed Epilepsy: The Beginning

Taylor J, Baker G (UK)

051 Psychiatric Comorbidity in a Community Sample of Patients with Epilepsy

Lacey C, Salzberg M, Roberts H, D'Souza W (Australia)

052 Interictal Psychoses: A prospective study

Tadokoro Y, Oshima T, Shimizu H, Kanemoto K (Japan)

053 Role of the Amygdala in Mediating Anxiety after Epilepsy Surgery

Halley S, Wilson S, Wrench J, Reutens D (Australia)

054 Non Convulsive Psychic, Behavioural and Educational Disorders Related to Frontal Epileptiform Discharges

Zenkov L, Konstantinov P, Miasnikov V, Ronkin M, Shiriayeva I, Sirazitdinova E (Russia)

Please replace with
sticker saying "Refer to
Abstract Book Page 54"

Platform Sessions

WEDNESDAY, 11TH JULY 2007

15:45 - 17:30

Platform Session 10

Room 203

Refer to Abstract
Book Page 42


Basic Science

Kubova H (Czech Republic) & Galanopoulou A (USA) Co-Chairs

- 055 Possible Role of Cytokines during Epileptogenesis as Observed in the Focus Complex of EL Mice**
Murashima Y, Suzuki J, Yoshii M (Japan)
- 056 Anticonvulsant Action of Antagonists of Group I Metabotropic Receptors in Immature Rats**
Mares P, Lojkova D, Ng J (Czech Republic)
- 057 Levetiracetam Contrasts Spiking Pattern Activity in DBA2 Absence Model in a Byphasic Modality**
Marrosu F, Frau R, Orrù M, Puligheddu M, Bortolato M, Fà M, Barberini L, Mereu G (Italy)
- 058 Targeting the Interleukin (IL)-1beta System as a Novel Antiepileptic Approach**
Balosso S, Scarcelli V, Ravizza T, Randle J, Sanchez-Alavez M, Bartfai T, Vezzani A (Italy, USA)
- 059 Adenoviral-delivered Small Interfering RNA Effect on Multidrug Resistance Gene in Rat Astrocytes Model Induced by Coriaria Lactone**
Chen L, Yang T, Tian L, Zhou D (China)
- 060 Immunohistochemical Analysis and in situ Hybridisation of the KCNQ3 Potassium Channel in the Developing Mouse Brain**
Kempfle J, Weber Y, Blazevic D, H L, S M (Germany)
- 061 Benign Familial Neonatal Seizures: Molecular Basis and Evidence for a Third Locus**
Heron S, Grinton B, Pelekanos J, Zuberi S, Stanley T, Kivity S, Goldberg-Stern H, Lerman-Sagie T, Mulley J, Scheffer I, Berkovic S (Australia, UK, New Zealand, Israel)

Please replace with sticker
saying "Refer to Abstract
Book Page 55"

Platform Sessions

THURSDAY, 12TH JULY 2007

10:15-11:45

Platform Session 11

Room 203

Refer to Abstract
Book Page 44

AED Issues 2*Jain, S (India) Chair***062 Epilepsy and Infectious Diseases with Antiretroviral Treatment: Experience with Levetiracetam***Stefano Q, Marina S, Camillo F, Emilio U (Italy)***063 Effect of Levetiracetam on TMS Parameters in Healthy Volunteers***Solinas C, Reutens D (Australia)***064 Efficacy and Tolerability of Brivaracetam as Adjunctive Treatment for Adults with Refractory Partial-onset Epilepsy***Van Paesschen W, Von Rosenstiel P (Belgium)***065 Lacosamide: Efficacy and Safety as Oral Adjunctive Therapy in Adults with Partial-Onset Seizures***Chung S, Sperling M, Biton V, Krauss G, Doty P, Sullivan T, the SP754 Study Group (USA)***066 Lacosamide in Subjects with Partial-Onset Seizures: Evaluation of the Effect of Oral Lacosamide on Concomitant Antiepileptic Drug Plasma Concentrations***Kälviäinen R, Halász P, Mazurkiewicz-Beldzinska M, Rosenow F, Hoepken B, Rudd G, SP755 Study Group (Finland, Hungary, Poland, Germany, USA)*

Please replace with sticker
saying "Refer to Abstract
Book Page 57"





Poster Sessions

Please replace with sticker saying
"Refer to Abstract Book Page 59-84"


July 9th - 11th 2007

POSTER SESSION

ADULT EPILEPTOLOGY


Refer to Abstract Book Page 46-70

- p067 Lateralswing value of Ictal Dystonic Posturing of the Lower Limb in Temporal Lobe Epilepsy**
Abubakr A, Wambacq I (USA)
- p068 Corpora Amylacea in Mesial Temporal Lobe Epilepsy: Clinico-pathological Correlations**
Radhakrishnan A, Radhakrishnan K, Radhakrishnan V, Mary P, Kesavadas C, Alexander A, Sankara Sarma P (India)
- p069 Anxiety and Depression in Patients with Epilepsy**
Kulkarni O, Gallagher M, Majeed T (UK)
- p070 Public Knowledge and Attitudes towards Epilepsy in Jordan**
Daoud A, Al Saafi S, Ootom S, Wahba L, Kofahi A (Jordan)
- p071 Inhibition of Kindling Progression by Eslicarbazepine Acetate and Licarbazepine**
Potschka H, Pekcec A, Soares-Da-Silva P (Germany, Portugal)
- p072 Kozhevnikov's Epilepsy: Diagnosis Principles**
Mikhaylichenko N, Goulyayeva S, Ovchinnikova A (Russia)
- p073 High Prevalence of Treated Epilepsy in the Elderly has Implications for Future Health Prevention and Treatment**
D'Souza W, Quinn S, Fryer J, Taylor B, Ficker D, O'Brien T, Pearce N, Cook M (Australia, USA, New Zealand)
- p074 Postoperative Follow-up of Patients with Mesial Temporal Sclerosis and Facial Paresis**
Lin K, Carrete Jr H, Lin J, Alessandro Leite De Oliveira P, Sales Ferreira Caboclo L, Ceiki Sakamoto A, Márcia Targas Yacubian E (Brazil)
- p075 Comparative Mortality in People with Epilepsy in a Rural Kenyan District**
Karanja Ngugi A, Scott A, Edwards T, Chengo E, Munywoki G, Williams T, Bauni E, Mung'ala-Odera V, Sander J, Neville B, Newton C (Kenya, UK)
- p076 Comparison of Depression Occurrence in Epilepsy and Chronic Low Back Pain Syndrome**
Slonkova J, Bar M, Skoloudik D (Czech Republic)
- p077 Status Epilepticus in Singapore: Clinical Outcomes and Potential Prognostic Indicators**
Rathakrishnan R, Purnama Sidik N, Wilder-Smith E (Singapore, Scotland, UK)
- p078 Patients' Knowledge of Anti-Epileptic Medication at Time of Diagnosis**
Stow J, Dunning T, McIntosh A, Newton M (Australia)
- p079 Long-term Efficacy and Tolerability of Levetiracetam for Epilepsy: Mid-term Prospective Study Data**
Ortenzi A, Paggi A, Foschi N, Catani S (Italy)
- p080 Ictal Magnetic Source Imaging in Medically Refractory Localisation related Epilepsy**
Eliashiv D, Fried I (USA)
- p081 Seizure Outcome: A Follow-up Study**
Roy A, Achar L, Sarma G, Kamath V, Mathew T, Mahammad A (India)
- p082 Myoclonic Seizures Subside in the Fourth Decade in Juvenile Myoclonic Epilepsy: A Long-term Observational Study**
Baykan B, Altindag E, Bebek N, Ozturk A, Aslantas B, Gurses C, Barak-Kulaksizoglu I, Gokyigit A (Turkey)
- p083 Treatment of Epilepsy in Patients with Alzheimer Disease**
Alfieri P (Italy)
- p084 Public Perception and Attitude towards Epilepsy in North-Eastern Nigeria**
Ibrahim A, Nyandaiti Y, Bwala S, Tahir A, Vasumu J, Alaebo J (Nigeria)
- p085 Clinical and SEEG Analysis of Ictal Locomotor Behaviour**
Gardella E, Tassi L, Castana L, Nobili L, Rubboli G, Tassinari C, Lo Russo G, Francione S (Italy)
- p086 High Incidence of Oxygen Desaturations Associated with Partial Seizures**
Bateman L, Seyal M (USA)
- p087 Effect of Valproic Acid Therapy on the Metabolic Profile (Fatty Acids) of Patients with Epilepsy**
Plonka-Poltorak E, Westermarck T, Kaipainen P, Kaski M, Atroshi F (Poland, Finland)
- p088 Long-term Efficacy of Zonisamide for Patients with Refractory Partial-onset Epilepsy**
Wroe S, Yeates A (UK)
- p089 Magnetic Resonance Imaging of Cerebellum Volumetric Analysis in Epilepsy**
Chen T (Taiwan)
- p090 Levetiracetam for Epilepsy Patients**
Goulding P, Geldard J, Basu R (UK)
- p091 Neuronal Death in Autonomic Cortical Brain Centres and Granular Cell Dispersion in the Stratum Granulosum of the Dentate Gyrus are found in Patients with Epilepsy and Sudden Death**
Manosalva H, Lorenzana P, Colegial C (Colombia)




Poster Sessions

- p092 International Bureau for Epilepsy (IBE) Epilepsy and Cognitive Function Survey in Taiwan**
Hsieh M, Chuang Y (Taiwan)
- p093 Long-term Retention of Levetiracetam in Patients with Epilepsy in Taiwan**
Chuang Y, Tsai J, Hsieh M, Yen D (Taiwan)
- p094 Levetiracetam as Monotherapy in Alzheimer Disease Patients with Late-onset Seizures: A Prospective Observational Study**
Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L (Italy)
- p095 Levetiracetam thorough QT Study: Lack of Pro-arrhythmic Effect**
Hulhoven R, Rosillon D, Bridson W, Salas E, Chen D, Watanabe S, Meesus M, Stockis A (Belgium, USA)
- p096 Open-label Study Evaluating Seizure Control and Quality of Life in Patients with Brain Tumour-related Epilepsy Treated with Levetiracetam Monotherapy**
Maschio M, Dinapoli L, Zarabla A, Pace A, Fabi A, Carapella C, Pompili A, Jandolo B (Italy)
- p097 Efficacy and Tolerability of Levetiracetam as Monotherapy in Juvenile Myoclonic Epilepsy (JME)**
Candelieri G (Italy)
- p098 Neurodynamic Molecular-Genetic Conception of Epileptogenesis**
Levyatov I (USA)
- p099 Nocturnal Paroxysmal Events Reported as possible Seizure to a Sleep Clinic for Differential Diagnosis and Therapeutic Management**
Silvestri R, Arico I, Mento G, Conduurso R, Gervasi G, Laura Rosa P (Italy)
- p100 Association between Cysticercosis and Epilepsy in Sub-Saharan Africa: A Systematic Review**
Guerchet M, Quet F, Pion S, Druet Cabanac M, Ngoungou E, Preux P, Dumas M (France)
- p101 Clinical Characteristics of Epilepsy and Migraine in Adult Patients with Epilepsy**
Vyskocilova D, Grunermelova M (Czech Republic)
- p102 Levetiracetam Monotherapy: Tolerability in the Elderly**
Caruso A, Palumbo P, Campostrini R, Forleo P, Cantini A (Italy)
- p103 Effect of Levetiracetam on EEGs: An Inspective and Quantitative Study on Patients with Epilepsy**
Li Voti P, Falla M, Pro S, Zarabla A, Randi F, Pulitano P, Mecarelli O (Italy)
- p104 Levetiracetam in Adult Taiwanese Patients with Refractory Partial Epilepsy: Interim Results of the Skate-II Study in Taiwan**
Lo Y, Hsieh P, Hsieh M, Liou C, Chen Y, Wu H, Hsin Y, Yiu C, Lai S, Chen T, Hiu Ngar L, Mei S, Liu C, Tai C, Tsai J (Taiwan)
- p105 Epileptic Syndrome in Patients with Brain Gliomas**
Urakov S, Loshakov V, Kobiakov G, Solokha A (Russia)
- p106 Medication Persistence and Compliance by Epilepsy Patients**
Grossman P, Cramer J, Beyer A, Van Holle L (USA, UK, Belgium)
- p107 Gender and Racial Disparities in AED Use for Epilepsy in Nursing Homes**
Leppik I, Garrard J, Eberly L, Harms S, Zhu Y (USA)
- p108 Magnetoencephalography and Quantitative FDG-PET Co-localisation**
Shamim S, Lim Y, Liew C, Theodore W, Ostuni J, Sato S (USA)
- p109 Bone Density in Climacteric Women with Epilepsy**
Vlasov P, Antonyuk M, Gasparian N (Russia)
- p110 Long Term Observation of Patients with Electric Screen Game Induced Seizures (ESGS)**
Okajima H, Aikawa H, Yamashita H, Maruki T, Toyoshima R, Yamauchi T (Japan)
- p111 Solitary Cysticercus Granuloma: Status Epilepticus**
Jawatkar J, J S, Murthy J (India)
- p112 Burden of Potentially Preventable Epilepsy: A Community-based Prevalence Study in Rural India (Comprehensive Rural Epilepsy Study South India, CRESSI)**
UR Rahman A, Murthy J, Seshadri V, Raju R (India)
- p113 Treatment Gap and Possible Reasons: A Community-based Study in Rural India (Comprehensive Rural Epilepsy Study, South India)**
Murthy J, Seshadri V, Raviraju C (India)
- p114 Levetiracetam Monotherapy in Epilepsy and Migraine Prevention: A New Open-label Study**
Allocca S, Alfieri P, Barbato G, Sanges G (Italy)
- p115 Open Label, Randomised, Cross-over Trial in Epilepsy Patients with Cryptogenic Focal, Refractory Epilepsy, Comparing Levetiracetam and Pregabalin as Add-on Therapy**
Tata M, Guizzaro A, Daniele O, Natalè E (Italy)
- p116 Cognitive and Quality of Life Effects of Levetiracetam as an Add-on Therapy for Partial Seizures**
Zhou B, Zhou D, Tian L, Xiao J (China)




Poster Sessions

- p117 Clinical Factors Predicting Responsiveness to Initial 1st Monotherapy in Newly Diagnosed Epilepsy: 2 Years Follow Up Study**
Kim S (Korea)
- p118 Different Effects of Antiepileptic Drug Monotherapy on Sexual Function in Men Suffering from Epilepsy**
Kuba R, Pohanka M, Novotná I, Zákopčan J, Rektor I (Czech Republic)
- p119 Levetiracetam in Eyelid Myoclonia with Absences Syndrome (Jeavons Syndrome): An Italian Experience**
Striano P, Coppola A, Pezzella M, Ciampa C, Errichiello L, Nicoletta E, Ruosi P, Striano S (Italy)
- p120 Development of a Compact, Wireless, Multi-channel, Video-EEG Monitoring System for Seizure Detection in the Paediatric Intensive Care Unit**
Shahwan A, Bailey C, Charles C, Edmonds M, Mackay M, Freeman J, Harvey S (Australia)
- p121 Aetiology in Periodic Lateralised Epileptiform Discharges**
Aslan K, Bozdemir H, Balal M, Sarýca Y (Turkey)
- p122 Quality of Life in Patients with Carbamazepine or Oxcarbazepine Monotherapy**
Bozdemir H, Aslan K, Uguz P, Seydaoolu G, Sarýca Y (Turkey)
- p123 Predictors of Drug Resistance in Juvenile Myoclonic Epilepsy**
Sattaluri S, Ashok Kumar B, Shanmukhi S, Meena A (India)
- p124 Biodegradable Polymer Sheets Implanted Subdurally may be useful for Intracranial Drug Delivery**
Halliday A, Nelson T, Cook M, Paolini A, Campbell T, Wallace G (Australia)
- p125 Running Towards Epilepsy?**
Wang Y, Murphy M, Cook M (Australia)
- p126 Using the Internet to Recruit Patients for Epilepsy Trials**
Bergin P, Ip T, Sheehan R, Ye X (New Zealand)
- p127 Over-expression of NCAM in the Temporal Lobes of Intractable Epilepsy Patients**
Tao L, Xuefeng W (China)
- p128 Epilepsy as a Major Clinical Manifestation of Neurocysticercosis in Sanglah Hospital Denpasar-Bali**
Sudewi A (Indonesia)
- p129 Hashimoto's Encephalopathy and Status Epilepticus**
Akdağ G, Yaka E, Yener G, Men S, Baklan B (Turkey)
- p130 Sleepiness and Sleep Quality in Epilepsy Patients: An Outpatient Clinic-based Study**
Bentes C, Mestre T, Henriques I, Peralta R, Paiva T (Portugal)
- p131 A Multi-centre, Outpatient, Open-label Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX® as Monotherapy in the Treatment of Epilepsy in Clinical Practice**
Sankar R, Ramsay E, McKay A, Zhu Y, Hulihan J, Wiegand F (USA)
- p132 Value of Febrile Seizures in Patients with Idiopathic Generalised Epilepsies**
Rega I, Camejo C, Braga P, Bogacz A, Scaramelli A, Avellanal A, Martinez C, Arciere B, Salinas D, Yorio D (Uruguay)
- p133 Febrile Seizures in Partial Epilepsies: Are they Specifically Associated to Mesial Temporal Sclerosis?**
Scaramelli A, Braga P, Rega I, Bogacz A, Camejo C, Avellanal A, Martinez C, Salinas D, Arciere B, eYorio D (Uruguay)
- p134 Characteristics of Generalised Convulsion or Complex Partial Seizure Patients with Hospitalisation**
Asano S, Miyawaki S, Hasegawa I, Nakaguchi H, Murakami M, Matsuno A (Japan)
- p135 Epilepsy and Sexual Dysfunction**
Beghi E, Bellini A, Bogliun G, Fiordelli E (Italy)
- p136 Albendazole Use could Precipitate a First Seizure in some Patients with Solitary Neurocysticercosis**
Agarwal A (India)
- p137 Importance of Interictal EEG Recording and Neurological Symptoms in Epilepsy Outpatient Database in Eastern Hungary**
Horváth L, Fekete K, Csótó E, Vámosi B, Fekete I (Hungary)
- p138 Unilateral Gynaecomastia and Epilepsy in Male Members of a Family: A New Clinical Syndrome?**
Soon D, Chaudhuri A (UK)
- p139 Yield of 'Combined Bilateral Depth and Subdural Electrode' and 'Subdural Electrodes Alone' for Ictal Lateralisation in Temporal Lobe Epilepsy**
Kang B, Lee E, No Y, Hong S, Lee J, Lee S, Kang J (Korea)
- p140 Video-EEG Monitoring of Patients with Juvenile Myoclonic Epilepsy: A Feasible Tool for Diagnosis?**
Park K, Lee S, Chu K, Kim D, Jung K, Lee J, Kim H (Korea)



Poster Sessions

- p141 Application of Vagal Nerve Stimulator in Patient with Cardiac Pace Maker after Post Ictal Cardiac Arrest**
Cáceres R, Richter J, Säfström K, Landtblom A (Sweden)
- p142 Teaching Nurses to Diagnose and Manage Epilepsy in a Developing Country**
Somerville E, Black A, Pelekanos J, Todd L, Fonseca C Amaral Z, Pinto Gonzaga P (Australia, East Timor)
- p143 Rasmussen's Encephalitis: An Indian Experience**
Bhagavatheeswaran R, Radhakrishnan A, Radhakrishnan K, Abraham M, Chandrasekhar K, Thomas B (India)
- p144 Prevalence of Malformations of Cortical Development in Refractory Focal Epilepsy in Singapore**
Tan N, Pan A, Sitoh Y, Chng S, Lim T, Ng D, Goh A, Lim S (Singapore)
- p145 Profile of Myoclonic Epilepsies in South Morocco**
Ait Oussous S, Jaafari H, Louhab N, Kissani N (Morocco)
- p146 Predictive Factors of Early Seizures and Further Seizure Recurrence in Patients with an Acute Ischemic Cerebrovascular Event**
Gallmetzer P, Glawar B, Ferrari J, Lalouschek W, Wehinger C, Mamoli B (Austria)
- p147 Cerebral Venous Thrombosis in Stroke patients who present with Seizures**
Chua H (Singapore)
- p148 Central Pattern Generators and Locomotor Behaviours during Frontal-hyperkinetic Seizures and Parasomnias**
Tassinari C, Cantalupo G, Gardella E, Rondelli F, Rios L, Pinardi F, Ferando I, Nobili L, Rubboli G (Chile, Italy)
- p149 Efficacy and Tolerability of Brivaracetam as Adjunctive Treatment for Adults with Refractory Partial-onset Seizures**
French J, von Rosenstiel P (USA, Belgium)
- p150 Correlation of Metabolic activity using [11C] Methionine PET and Initial Symptoms in Primary Insular Glioma**
Kato T (Japan)
- p151 Seizures in Patients with Cerebral Venous Thrombosis: Frequency, Pattern and Outcome**
Wasay M, Khealani B, Dai A, Roach S (Pakistan, USA, Turkey)
- p152 Epileptic Status at the Neurology Clinic, Clinical Centre, Sarajevo**
Alajbegovic A, Alajbegovic S, Mehmedika Suljic E, Resic H (Bosnia)
- p153 Cerebral Cysticercosis: Most Common Cause of Epilepsy in Central India**
Meshram C, Khandel wal R, Kamble S, Kanphade S, Baheti M, Ramteke S, Shembalkar P (India)
- p154 Exposure to Anti-epileptic Drugs (AEDs) in Cancer Patients Increases the Risk for AED Related Hypersensitivity Reactions**
Dergalust S, Licht E, Ferrer M, Lee W, Lee M, Wallis R, Pannizon K, Sayers J, Galssman P, Melkonian S, Sankar R (USA)
- p155 Sexual Dysfunction and Epilepsy**
Marak R, Pohanka M, Kanovsky P (Czech Republic)
- p156 Epileptic and non-epileptic seizures with dropped head syndrome in one patient: entity or organic and psychogenic co-morbidity?**
Marak R, Pohanka M, Kanovsky P (Czech Republic)
- p157 Two Variants of Sturge-Weber Syndrome: Clinical, Radiological and Electroencephalographic Correlates**
Fogarasi A, Tuxhorn I, Halasz P, Barsi P, Rasonyi G, Gyimesi C, Siegler Z, Janszky J, Jakus R, Woermann F (Germany, Hungary)
- p158 Extensive Expression of HSPBAP1 in the Anterior Temporal Neocortex of Patients with Intractable Epilepsy**
Liu F, Xi Z, Sun J, Wang X, Li M (China. USA)
- p159 Albendazole in Solitary Cysticercus Granuloma**
Garg R (India)
- p160 Prospective Evaluation of Epileptic Vertigo in Specialised Consultation in Marrakech**
Nissrine L, Khadija A, Najib K (Morocco)
- p161 Obstructive Sleep Apnea in Epilepsy Patients and its Impact on Quality of Life**
Piperidou H, Mauraki E, Terzoudi A, Triantafillou N, Vadikolias K, Grigorios T, Heliopoulos I (Greece)
- p162 Predictive factors for Post Stroke Seizures**
Dhamija R, Kaintura A, Kumar M (India)
- p163 Prevalence of Epilepsy among Students in Uludag University, Turkey**
Calybyr N, Bora Y, Bican A, Seferoalu M, Yrgil E (Turkey)
- p164 Age Related Gender Difference of Ictal Fear Expression: A Video-EEG Study**
Chiesa V, Gardella E, Tassi L, Piazzini A, Canger R, Turner K, Lo Russo G, Canevini M (Italy)



Poster Sessions

Please replace with sticker saying
"Refer to Abstract Book Page 84-85"

July 9th - 11th 2007

POSTER SESSION

ALTERNATIVE THERAPIES

Refer to Abstract Book Page 71-72

- p165 Indirect Vagus Nerve Stimulation and Reflexology for Management of Epilepsy**
Singh A, Dalal K, Tripathi M (India)
- p166 Low-frequency Repetitive Transcranial Magnetic Stimulation for Seizure Suppression in Patients with Extratemporal Lobe Epilepsy: A Pilot Study**
Kinoshita M, Ikeda A, Begum T, Yamamoto J, Hitomi T, Shibasaki H (Japan)
- p167 Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Children with Drug Resistant Epilepsy**
Neal E, Chaffe H, Edwards N, Lawson M, Schwartz R, Cross H (UK)
- p168 Interstitial Radiosurgery as a Treatment Option in Pharmacoresistant Gelastic Epilepsy due to Hypothalamic Hamartomas**
Schulze-Bonhage A, Trippel M, Bast T, Ebner A, Eiger C, Ernst J, Hamer H, Keimer R, Mayer T, Schoendienst M, Steinhoff B, Tuxhorn I, Deimling F, Wagner K, Ostertag C (Germany)
- p169 Stigma and Misconceptions about Seizure/Epilepsy and the Resulting Treatment Gap among South India Rural Population**
Aleem M (India)

Please replace with sticker saying
"Refer to Abstract Book Page 85 -"

July 9th - 11th 2007

POSTER SESSION

BASIC SCIENCES

Refer to Abstract Book Page 73-83


- p170 Analysis of Dynamic Properties on the Effect of Electro-acupuncture Therapy in Rat Epilepsy**
Kim Y, Kim Y, Yoo S, Li Z, Hahn S (China, Korea)
- p171 Effect of Eslicarbazepine Acetate (BIA 2-093) on the Increase in Extracellular Amino Acids Induced by Microperfusion of Latrunculin A in the Rat Hippocampus**
Sierra-Paredes G, Oreiro-García T, Vázquez-Illanes D, Sierra-Macujo G (Spain)
- p172 Juvenile Myoclonic Epilepsy: Novel Mutations in Myoclonin1/EFHC1 in Families, Singletons and Sporadics**
Medina M, Suzuki T, Duron R, Alonso M, Martinez-Juárez I, Bailey J, Inoue Y, Yoshimura I, Kaneko S, Ochoa A, Jara Prado A, Fujimoto S, Ito M, Hamano S, Sugita K, Ueda Y, Osawa M, Oguni H, Yamakawa K, Delgado-Escueta A (USA, Japan, Mexico)

- p173 Mutations in the Voltage-gated KV7.2 Potassium Channel associated with Neonatal Convulsions or Myokymia**
Wuttke T, Penzien J, Lehmann-Horn F, Paulus W, Jurkat-Rott K, Lerche H (Germany)
- p174 Activity of Thiocolchicoside on various Subtypes of Recombinant GABAA Receptors expressed in *Xenopus Laevis* Oocytes**
Mascia M, Bachis E, Obili N, Maciocco E, Cocco G, Sechi G, Biggio G (Italy)
- p175 Isobolographic and Behavioural Characteristics of Interaction between Vigabatrin and Gabapentin in two Experimental Models of Epilepsy**
Luszczki J, Czuczwar S (Poland)
- p176 Novel Mutation of SCN1A in a Chinese Family with Febrile Seizures: Transmitted or De novo?**
Shi Y, Deng W, Chen L, Gao M, Yu M, Liao W (China)
- p177 Effect of Acute and Chronic Mianserin on the Protective Action of Conventional Antiepileptic Drugs in Mice**
Borowicz K, Banach M, Zarczuk R, Lukasik D, Luszczki J, Czuczwar S (Poland)
- p178 Anticonvulsant and Neuroprotective Effect of (2R,4R)-4-Aminopyrrolidine-2,4-Dicarboxylate is Diminished when given after the Onset of Seizures Induced by Homocysteic Acid in Immature Rats**
Folbergrova J, Druga R, Otahal J, Tsenov G, Haugvicova R, Kubova H (Czech Republic)
- p179 Neurogenesis in Human Hippocampus from Temporal Lobe Epilepsy Patients**
Sugano H, Nakajima M, Kondo A, Ogino I, Arai H, Seki T (Japan)
- p180 Differentially Expressed Genes in the Epileptic Mouse Hippocampus**
Wang Y, Sang Q, Sweerts K, Smith P, Murphy M, Cook M, Tan S (Australia)
- p181 Barriers to Utilisation of Anti-epileptic Drugs in Kilifi District, Kenya**
Kathomi C, Carter J, Murira G, Gona J, Molyneux S, Hartley S, Newton C (Kenya, UK)
- p182 Changes of Synapsin I Expression in Hippocampus and Dentate Gyrus and Mossy Fibre Sprouting after Pilocarpine-induced Status Epilepticus**
Yi Y, Wang B, Wei Z, Su T, Sun W, Liao W (China)
- p183 Influences of Interleukin-1beta on the Propensity of Hyperthermia-induced Seizures in Developing Rats**
Fukuda M, Shinonaga C, Morimoto T, Suzuki Y, Ishida Y (Japan, USA)

Poster Sessions



- p184 Effects of Levetiracetam on Hippocampal Kindling in Noda Epileptic Rats**
Ishimaru Y, Chiba S, Serikawa T, Sasa M, Inaba H, Tamura Y, Ishimoto T, Takasaki H, Sakamoto K, Yamaguchi K (Japan)
- p185 Interictal Discharges Induced by High Extracellular Potassium in Seizure-resistant *Proechimys caeyannensis* is Age-dependent**
Ueda E, da Silva A, Cavalheiro E (Brazil)
- p186 Effects of Three Calcium Channel Blockers (Amlodipine, Diltiazem and Verapamil) on the Anticonvulsant Activity of Oxcarbazepine in the Mouse Maximal Electroshock Seizure Model**
Czucwar S, Trojnar M, Trojnar M, Luszczycki J (Poland)
- p187 Hippocampal Electrophysiology in Two Animal Species of the Cavia Family: One Resistant to Epileptogenesis and another Seizure-prone**
Cavalheiro E, Silva A, Nascimento A, Oliveira E (Brazil)
- p188 LIS 1 Heterozygous Mutant Mice Show Epileptic EEG Pattern and Lethal Seizure Induced by Increasing-current Electroshock Test**
Yamashita H, Yoda H, Okajima H, Kitana Y, Takazawa A, Toyo-oka K, Hirotsune S, Maruki T, Toyoshima R, Yamauchi T (Japan)
- p189 Effects of Cyclin Dependent Protein Kinase Inhibitor Olomoucine on Neuronal Apoptosis after Pilocarpine Induced Status Epilepticus**
Sun M, Du X, Xie M, Wang W, Chen H, Tian D (China)
- p190 NPY Over-expression Focally in the Ventrobasal Thalamus Suppresses Absence-like Seizures in a Genetic Rat Model**
Morris M, Jovanovska V, Krishnasamy N, Bland R, During M, O'Brien T (Australia, USA)
- p191 Effects of Levetiracetam on Kindled Epileptogenesis and Blood-brain Barrier Integrity in Rats with Cortical Dysplasia**
Gurses C, Kaya M, Kalayci R, Arican N, Ahishali B, Ekizoglu O, Elmas I, Kucuk M, Ustek D, Orhan N, Kemikler G (Turkey)
- p192 Early Postnatal Separation Stress Enhances Vulnerability to Later Limbic Epileptogenesis in Young Adult Female but not Male Rats**
Kumar G, Jones N, Morris M, O'Brien T, Salzberg M (Australia)
- p193 Measurement of Local Cerebral Blood Flow during Amygdala Kindling Process in Rats with Genetic Absence Epilepsy (GAERS)**
Carcak N, Ferrandon A, Koning E, Aker R, Ozdemir O, Onat F, Nehlig A (Turkey, France)
- p194 Differences in Nitrergic and Proteolytic Indices in Cerebrospinal Fluid (CSF) of Stroke Patients with and without early Poststroke Seizures (EPS)**
Guekht A, Gulyaeva N, Khaimovsky I, Lebedeva A, Onufriev M, Brylev L (Russia)
- p195 Firing Patterns of Somatosensory Higher Order Thalamocortical Neurons in a Genetic Rat Model of Absence Epilepsy**
O'Brien T, Pinault D (Australia, France)
- p196 Oxidative Stress in the Amygdala Kindling Model of Temporal Lobe Epilepsy**
Sashindranath M, Trounce I, Wang Y, Cotton R, Cook M (Australia)
- p197 High Resolution Recordings of Activation and Deactivation of the Transient Sodium Current (INa(t)) in Rat CA1 Neurons with Inactivation Removal Provide a Detailed Kinetic Description Incompatible with the Hodgkin-Huxley Model**
French C (Australia)
- p198 Simulating Concomitant Ionic Currents during Nonsynaptic Epileptiform Activity in the Hippocampus**
Almeida A, Rodrigues A, Teixeira H, Duarte M, Arruda E, Silveira G (Brazil)
- p199 NPY alters Synaptic Transmission onto Hippocampal GABAergic Interneurons**
Ledri M, Sorensen A, Szabo G, Kokaia M (Sweden, Hungary)
- p200 Pilocarpine-induced Epilepsy is accompanied by Changes in Purinoceptors and ATP Metabolism in the Rat Brain.**
Fernandes M, Dona F, Conceição I, Freitas T, Cavalheiro E (Brazil)
- p201 Activation by Zonisamide, a Newer Anti-Epileptic Drug, of Large-Conductance Calcium-Activated Potassium Channel in Differentiated Hippocampal Neuron-Derived H19-7 Cells**
Huang C, Huang C, Tsai J, Wu S (Taiwan)
- p202 Effects of Beta-hydroxybutyrate on Pilocarpine-induced Seizures in Young Mice**
Kim D (Korea)
- p203 Absence Seizures are Reduced by the Enhancement of GABA-ergic Inhibition in the Hippocampus in WAG/Rij Rats**
Tolmacheva E, van Luijckelaar G (Russia, The Netherlands)
- p204 Evaluation of Propofol Effect in Altering Pentylentetrazol Induced Seizure Threshold in Peripheral Inflammatory Models in Rats**
Medhi B (India)



Poster Sessions

- p205 Patterns of Firing in Human Hippocampal Neurons**
Da Costa J, Tavares A, Azambuja N, Paglioli-Neto E, Salamoni S, Breda R, de Abreu D, Carlesso F (Brazil)
- p206 In vivo Quantification of Benzodiazepine Receptor Density and Affinity in Rat Brain using Small Animal PET with a Multi-injection Protocol**
Gregoire M, Dedeurwaerdere S, Vivash L, Binns D, Roselt P, Franklin M, Taylor P, Pham T, Katsifis A, Hicks R, O'Brien T, Myers D (Australia)
- p207 Epilepsy Comprehensive Shared Care Management through Information Technology**
Kenkre R, Gad R, Naik G (India)
- p208 Anticonvulsive Role of Specific 5-HT₃ Receptor Agonist in Pentylenetetrazole-induced Seizure Model in Mice**
Gholipour T, Rasouli A, Ghaffarpour M, Dehpour A (Iran)
- p209 Quantitation of P-glycoprotein in the Human Brain Microvascular unit: Possible Focal Impairment of a Blood-brain Barrier Agent in Epilepsy**
Jensen S, Free S, Martinian L, Yogarajah M, Sen A, Thom M, Sisodiya S (UK, Italy)
- Please replace with sticker saying "Refer to Abstract Book Page 96-101"*
- July 9th - 11th 2007 POSTER SESSION**
CLINICAL NEUROPHYSIOLOGY
Refer to Abstract Book Page 84-88
- p210 Electrocorticography of Periodic Lateralised Epileptiform Discharges**
Kalamangalam G, Tandon N, Slater J (USA)
- p211 Clinical Usefulness of EEGs**
Chan K, Beran R (Australia)
- p212 Responsiveness to Antiepileptic Medication Correlates with Changes in Cortical Excitability**
Badawy R, Berkovic S, Newton M, Macdonell R (Australia)
- p213 Serum Neuron Specific Enolase Level In Single Generalised Tonic-Clonic Seizure Patients**
Song T, Lee S, Seo K, Kim S, Kim D (South Korea)
- p214 Comparison of Sphenoidal, Cheek and Anterior Temporal Electrodes in Mesial Temporal Lobe Epilepsy**
Nayak D, P S, Radhakrishnan K (India)
- p215 Continuous Focal Electrical Status during Wakefulness and Sleep Associated with Polymicrogyria**
Guerreiro C, Teixeira K, Cardoso T, Cendes F,
- p216 Seizures as Initial Symptoms in Patients with Acute Stroke**
Naka H, Kono T, Kaseda Y, Mimori Y, Wakabayashi S, Kajikawa H, Nomura E, Matsumoto M (Japan)
- p217 Electrocorticographic Discharge Patterns in Primary Brain Tumours: A Perspective Series of Patients with Recurrent Seizures**
Pauletto G, Pineschi E, Skrap M, Gigli H, Bergonzi P (Italy)
- p218 Epidemiological, Clinical and Electrophysiological Features in Epilepsy Patients with Myoclonic Seizures induced by Antiepileptic Drugs**
Kuester G, del Río P, Mesa T, Santin J, Godoy J (Chile)
- p219 Sensitivity of Sleep EEG in New Onset Epilepsy**
Yeni N, Tutuncu M, Karadağ N (Turkey)
- p220 Continuous EEG Monitoring (EEGc) in the Intensive Care Unit Setting**
Mesa T, Solari F, Santin J, Godoy J, Kuester G, Andrade L (Chile)
- p221 Seizure Detection using Scalp EEG: Comparison of Measures Leading to Seizure Probability Estimates**
Kuhlmann L, Mareels I (Australia)
- p222 Interictal Hypometabolism in Relation to Ictal EEG Patterns for Unilateral Hippocampal Sclerosis: A PET Study using SPM**
Lee E, Im K, Kim J, No Y, Kim J, Lee S, Hong S, Lee J, Kang J (Korea)
- p223 Importance of EEG Evaluation in First Epileptic Seizures in Children from Community Hospitals**
Guilhoto L, Ballester D, Gilio A (Brazil)
- p224 Electroencephalography with Sleep Deprivation in Generalised and Focal Seizures**
Harirchian H, Hashemi A (Iran)
- p225 Possibility of a Focal Cortical Origin in Childhood Absence Epilepsy**
Van Luijcklaar G, Westmijse I, Gunning B, Ossenblok P (The Netherlands)
- p226 Value of Overnight Sleep Recording for Diagnosis of Continuous Spike Waves of Slow Wave Sleep (CSWS) in Children and Adolescents**
Das K, Chivers F, Boyd S, Aylett S, Patil S (UK)
- p227 Teratogenic Potential of Generic Antiepileptic drugs : A New Concept and a Case Report**
Yardi N, Acharya D, Sethi A, Unni J (India)
- p228 Singular Value Decomposition (SVD) for Localisation of Induced Focal Changes in Brain Wave Rhythms**
Claus S, Leijten F, Velis D, Kalitzin S (The Netherlands)



Poster Sessions

Please replace with sticker saying "Refer to Abstract Book Page 101-114"


July 9th - 11th 2007

POSTER SESSION

DRUG THERAPY

Refer to Abstract Book Page 89-101

- p229 Comparative Efficacy of New Antiepileptic Drugs in Partial Epilepsy associated with Epileptic Drop Attacks**
Nikanorova M, Søndergaard M, Alving J (Denmark)
- p230 Levetiracetam in the Treatment of Creutzfeldt-Jacob Disease**
Daniele O, Urso L, Fierro B, D'Amelio M, Savettieri G, La Bella V, Piccoli F, Natale E (Italy)
- p231 Measurement of the Level of Cerebrospinal Orexin in Adults with Hypersomnia**
Westermarck T, Partinen M, Kaipainen P, Laakso M, Kaski M, Atroshi F (Finland)
- p232 Effective Dose of Carbamazepine in Mongolian People with Partial Epilepsy**
Uuriintuya M, Olziibayar D, Bathuyag P, Naran G, Bayarmaa D (Mongolia)
- p233 Disappearance of Continuous Spikes and Waves during Sleep using Levetiracetam**
D'Alessandro P, Piccirilli M, Maccone S, Gianfranco P, Arcuri F (Italy)
- p234 Synergism of Lacosamide and First-generation and Novel Antiepileptic Drugs in the 6 Hz Seizure Model in Mice**
Shandra A, Shandra P, Kaschenko O, Stöhr T (Ukraine, Germany)
- p235 Low Potential for Drug-Drug-Interaction of Lacosamide**
Thomas D, Scharfenecker U, Nickel B, Doty P, Cawello W, Horstmann R (Germany, USA)
- p236 Novel Dual Mechanism of Action of the Antiepileptic Lacosamide**
Heers C, Beyreuther B, Freitag J, Lees G, Errington A, Stoehr T (New Zealand)
- p 237 Expression of P-glycoprotein Induced by Phenobarbital and Levetiracetam in Immortalised Brain Endothelial GPNT Cells**
Cardile V, Pavone A, Lombardo L (Italy)
- p238 Efficacy and Tolerability of Levetiracetam as Second Line Monotherapy**
Rovera A, Coletti Moja M, Malan L, Ferrero B, Durelli L (Italy)
- p239 Curcumin Protects Aging Rats from Electrophysiological Progression of Seizures in Iron-induced Experimental Model of Epileptogenesis**
Jyoti A, Sethi P, Sharma D (India)
- p240 Change of Serum Sodium Level after Oxcarbazepine Monotherapy in Children with Epilepsy**
Nam S, Lee Y (Korea)
- p241 Effect of Levetiracetam on Epileptic Generalised Discharges Monitored with Ambulatory EEG**
Pro S, Li Voti P, Falla M, Zarabla A, Randi F, Pulitano P, Mecarelli O (Italy)
- p242 Levetiracetam in Stiff-Person Syndrome**
Sechi G, Barrocu M, Piluzza M, Cocco G, Sau G (Italy)
- p243 Utilisation of Antiepileptic Drugs: A Comparison between Croatia and Slovenia**
Vitezic D, Matana Z, Cebular B, Mrcic- Pelcic J, Zupan G, Sepic- Grahovac D, Simoncic A (Croatia, Slovenia)
- p244 Event-related Potentials in the Evaluation of the Effect of Levetiracetam and Carbamazepine on Cognitive Functions in Newly Diagnosed Epilepsy Patients: Preliminary Results of a Randomised Trial**
Guido M, de Tommaso M, La Neve A, Boero G, de Stefano G, Sardaro M, de Palo A, Di Claudio T, Specchio L (Italy)
- p245 Lacosamide Demonstrates no Potential for QTC-Prolongation**
Horstmann R, Zisowsky J, Thomas D (Germany)
- p246 Retention Rate of Zonisamide in Patients with Refractory Epilepsy**
Brandt C, Theodor M, Esther N, Bernd H, Volker B, Karin W, Bernd P (Germany)
- p247 Epileptogenic Kluver-Bucy Syndrome (EKBS) Treated by Nasogastric Levetiracetam as Adjunctive Therapy: A Case of Good Neurological Recovery**
Felleppa M, Fucci S, Addonizio M, Apice G, Ciannella L, D'Alessio A, D'Argenio M, Di Muccio L, Ricci M, Sparaco M (Italy)
- p248 Unilateral Electrical Stimulation of Mediodorsal Thalamic Nucleus Ineffective in Reducing Seizure Duration and Severity in Amygdala Kindled Rats**
Nelson T, Paolini A, Halliday A, Cook M (Australia)
- p 249 Pathophysiology of Attenuation of Myoclonus in a Case of Progressive Myoclonus Epilepsy**
Hino K, Miyashita M, Tanaka S, Hara K, Okazaki M, Watanabe M, Watanabe Y (Japan)
- p250 Croatian Pregnant Women with Epilepsy: Neurodevelopmental and Teratogenic Effects of Antiepileptic Drugs**
Miskov S, Gjergja R, Mikula I, Cvitanovic Sojat L, Bosnjak J, Demarin V (Croatia)



Poster Sessions

- p251 Influence of AEDs on the Auditory System in Children with Epilepsy**
Steinborn B, Sek A, Wicher A (Poland)
- p252 Retention Rate of Pregabalin in Patients with Refractory Epilepsy**
May T, Brandt C, Nieder E, Elsner H, Witte-Boelt K, Schuermann I, Pohlmann-Eden B (Germany)
- p253 Effects of Newer and Older Anti-Epileptic Drugs (AEDs) on Warfarin Therapy: An Open Comparative Retrospective Study**
Habetzwallner F, Fels A, Moccia L, Rossi V (Italy)
- p254 Efficacy of Different Combinations of Antiepileptic Drugs for Patients with Drug-resistant Epilepsy**
Blaszczyk B? (Poland)
- p255 Biopharmaceutics of Divalproex Sodium Extended-release Tablets vs other Formulations: Top Ten Pharmacokinetic Essentials for the Clinician**
Reed R, Dutta S (USA)
- p256 Mild Cognitive Impairment, Focal Epilepsy and Levetiracetam**
Minervini M, d'Orsi G, Demaio V, Ricchiuti L, Petruzzellis M, Pinto K (Italy)
- p257 Role of Therapeutic Drug Monitoring (TDM) in Epilepsy**
Nadkarni V, Khare S, Dalvi S (India)
- p258 Initial and Long-term Effects of Cloxazolam in Patients with Intractable Epilepsy**
Kimura N, Fujii T, Mikuni T, Miyajima T, Itou M (Japan)
- p259 Choice of Second-line AED for Patients with Localisation Related Epilepsy: The SLICE Trial**
Deckers C (The Netherlands)
- p260 Levetiracetam as an Add-on Therapy for Adult Epilepsy Patients: An open-label, Prospective, Observational Study**
Aktekin B, Ekmekci Usta B, Apaydin Dogan E, Senol Y (Turkey)
- p261 Outcomes of a Community Protocol for Managing Prolonged Seizures using Intranasal Midazolam**
Kyrkou M, Harbord M, Kyrkou N, Kay D, Coulthard K, Bailey K (Australia)
- p262 Add-on Effect of Low Dose Acetazolamide (AZM) in Adult Patients with Intractable Epilepsy**
Murahara T, Kinoshita M, Hitomi T, Kanda M, Takahashi R, Ikeda A (Japan)
- p263 Evaluation of a QMS® Lamotrigine Immunoassay**
Clarke L, Berry D, Wall M, Ouyang A, Arabshahi L, (USA, UK)
- p264 Stigma Leads to more Social Breakup and Suicide among People with Epilepsy and their Families in Indian Rural Settings.**
Edwin Raja Kumar D, Sundarraj P, Raja Christian C (India)
- p265 A 6-month Prospective Study of Valproate with Slow Release Formulation in Patients with Epilepsy**
Zhu G, Yu P, Wu X, Li T, Ding D, Hong Z (China)
- p266 Pregabalin 300 mg/d is Efficacious and Well Tolerated as Adjunctive Therapy for Partial-Onset Seizures: Data Analysis of 2 Randomised Clinical Trials**
Perucca E, Baldinetti F, Leon T, Huang S, Emir B (Italy, USA)
- p267 Influence of the Number of Concomitant AEDs on Pregabalin Efficacy as Add-on Treatment for Partial Seizures: An Exploratory Analysis**
Tomson T, French J, Whalen E, Benabou R, Griesing T, Baldinetti F, Leon T (Sweden, USA)
- p268 Seizure Freedom is Associated with Baseline Seizure Frequency in Pregabalin Studies**
Benabou R, French J, Whalen E, Griesing T, Baldinetti F, Leon T (USA)
- p269 Frequency of Irreversible Ataxia after Chronic Exposure to Phenytoin for the Treatment of Epilepsy**
Sokic D, Vojvodic N, Ristic A, Jankovic S, Sindjelic A (Serbia)
- p270 Oxcarbazepine (OXC) in Epilepsy: Efficacy of a generic drug**
Czapinski P, Czapinska E (Poland)
- p271 Can Therapeutic Thresholds be Defined for Levetiracetam?**
Spanila L, Nielsen K, Wolf P (Denmark)
- p272 Levetiracetam Efficacy on Epileptic Encephalopathies with Continuous Spike-waves during Sleep (CSWS) Pattern**
Zamponi N, Cesaroni E (Switzerland)
- p273 Efficacy and Safety of Levetiracetam in Patients with Refractory Partial-Onset Seizures: Interim Analysis of a Multicentre, Open-Label Single-Arm Study in Singapore**
Lim S, Wilder-Smith E, Loh N, Tan N, Pan A, Puvanendran K (Singapore)
- p274 Neuroprotective Effect of Topiramate on Global Cerebral Ischemia in Adolescent Rat**
Eun B, Choi H, Lee H, Eun S, Kang H, Sun W, Kim H (Korea)



Poster Sessions

p275 Clinical Effect of Topiramate as Adjunctive Therapy for Age-dependent Epileptic Encephalopathy
Liu Z, Wu G, Sun D, Xiong X, Tu W, Hu J, Wang F (China)

p276 Significance of Facial Dysmorphism in Children of Mothers with Epilepsy
John J, Haroon N, K E E, Thomas S (India)

p277 Effects of Pregabalin on Sleep-wake Cycle in Epilepsy Patients: A Polysomnographic Study
Marciani M, Izzi F, Fabio F, Sperli F, Grossi K, Zannino S, Corte F, Uasone E, Romigi A? (Italy)

p278 Oral Levetiracetam for the Treatment of Refractory Status Epilepticus
Rosati E, Muscas G, Di Bonaventura C, Giallonardo A (Italy)

Please replace with sticker saying "Refer to Abstract Book Page 114-120"

July 9th - 11th 2007

POSTER SESSION

EPILEPSY SURGERY

Refer to Abstract Book Page 102-106

p279 Comparison between Statistical Parametric Mapping (SPM) and Qualitative Analysis of Provoked Ictal SPECT
Barba C, Di Giuda D, Totaro M, Fuggetta F, Colicchio G (Italy)

p280 Deep Brain Stimulation for Treatment of Refractory Epilepsy: Preliminary Report of the first Brazilian Patients
Cukiert A, Burattini J, Seda L, Mariani P, Baldauf C, Argenton-Baldochi M, Baise-Zung C, Mello V, Forster C (Brazil)

p281 Oligoastrocytoma Presenting with Intractable Epilepsy
Hiremath G, Prayson R, Bingaman W (USA)

p282 Efficacy Results of Spontaneous and Magnet-activated Adjunctive Vagus Nerve Stimulation (VNS) Therapy in Children 12 Years with Pharmacoresistant Epilepsy
Zwoliński P, Roszkowski M (Poland)

p283 Less Invasive Selective Amygdalohippocampectomy using Navigation System via Inferior Temporal Gyrus
Kishima H, Kato A, Hirata M, Oshino S, Tani N, Saitoh Y, Yoshimine T (Japan)

p284 Cost of Epilepsy Surgery in Australia
Bulluss K, Murphy M, Beran R, Cook M (Australia)

p285 Surgical Outcome and Prognostic Factors of Temporal Lobe Epilepsy
Luan G, Dong X, Li Y (China)

p286 Surgical Treatment of Intractable Frontal Lobe Epilepsy in Children: The Sick Kids Experience
Vachhrajani S, de Ribaupierre S, Ochi A, Otsubo H, Snead O, Rutka J (Canada)

p287 Predictors of Intractable Epilepsy: A Review of 254 Intractable Epilepsy Patients Operated at a Tertiary Care Centre in Northern India.
Tripathi M, Singh M, Madakasira P, Gaikwad S, Srivastava A, Bal C, Sarkar C, Chandra S (India)

p288 Modern Surgical Strategy for Drug-Resistant Epilepsy In Relation to Neurophysiologic Mechanisms of Epileptogenesis
Bersnev V, Stepanova T, Kasumov R, Kasumov V (Russia)

p289 Quality of Life of Asian Indian Women with Epilepsy following Epilepsy Surgery
Chary P, Chendilnathan B (India)

p290 Estimates of Seizure Freedom after Epilepsy Surgery Vary: An Investigation of One Potential Contributing Factor
McIntosh A, Berkovic S (Australia)

p291 Magnetic Resonance Images and Pathology in Focal Cortical Dysplasia
Kameyama S, Kakita A, Masuda H, Murakami H, Sugiyama I, Takahashi H (Japan)

p292 Stereotactic Radiofrequency Ablation for Hypothalamic Hamartoma
Tani N, Kato A, Kishima H, Hirata M, Oshino S, Saitoh Y, Okinaga T, Shimono K, Yoshimine T (Japan)

p293 Clinical Significance of Ictal DC Shifts (iDCSs) Recorded by Invasive Electrodes in Surgical Candidates with Bilateral Temporal Lobe Epilepsy (TLE)
Mitsueda-Ono T, Kinoshita M, Terada K, Usui K, Inoue Y, Takahashi R, Ikeda A (Japan)

p294 Outcomes of a Community Protocol for Managing Prolonged Seizures using Intranasal Midazolam
Tyrlíkova I, Fanfrdlova Z, Brazdil M, Kuba R, Novak Z, Chrástina J, Rektor I (Czech Republic)

p295 Outcome of Epilepsy Surgery for Intractable Childhood Epilepsy
Seo J, Kang H, Lee J, Kim H (Korea)

p296 Streamlining Evaluation of Children for Epilepsy Surgery
Patil S, Boyd S, White S, Das K, Saunders D, Chong K, Harkness W, Neville B, Cross H, Scott R (UK)



Poster Sessions

- p297 Epilepsy Surgery in Infancy and Early Childhood**
Otsuki T, Nakama H, Kaido T, Kaneko Y, Nakagawa E, Sugai K (Japan)
- p298 Interictal EEG as a Predictor of Outcome after Surgery in Patients with Refractory Temporal Lobe Epilepsy and Hippocampal Sclerosis**
Medchlam Dana K R, Sailaja S, Sita Jaya;akshmi S, Meena AK (India)
- p299 Temporal Lobe Disconnection for Refractory Mesial Temporal Lobe Epilepsy**
Legros B, Levivier M, Smida K, Van Bogaert P, Depondt C, Tugendhaft P, Massager N (Belgium)
- p300 MTLE's Surgical Outcome and Patterns of Gray Matter Atrophy Revealed by Voxel-based Morphometry (VBM)**
Yasuda C, Betting L, Coan A, Morita M, Tedeschi H, Oliveira E, Li L, Cendes F (Brazil)
- p301 Seizure Outcome in Operated and Non-operated MRI-negative Epilepsy Patients**
Bien C, Szinay M, Urbach H, Becker A, Schramm J, Elger C (Germany)
- p302 Pathological Results in Paediatric Temporal Lobe Epilepsy Surgery Cases**
Wilfong A, Bhattacharjee M, Yoshor D, Malphrus A (USA)
- p303 Surgical Treatment for Intractable Paediatric Epilepsy with Widespread or Multilobar Cortical Dysplasia**
Kato A, Kishima H, Okinaga T, Hirata M, Oshino S, Shimono K, Tani N, Kagawa N, Ninomiya H, Saitoh Y, Yoshimine T (Japan)
- p304 Hungarian VNS Program: Unexpected Reduction of Seizure Severity not Frequency**
Fabó D, Eröss L, Halász P (Hungary)
- p307 Benign Familial Neonatal-infantile Seizures: The Mutational and Phenotypic Spectrum**
Heron S, Grinton B, Herlenius E, Keay D, Kron K, Mulley J, Scheffer I, Berkovic S (Australia)
- p308 Whole Genome Array CGH (Comparative Genome Hybridisation) of Epilepsy Patients with Congenital Brain Malformations**
Møller R, Tümer Z, Pilebæk Hansen C, Tommerup N, Ullmann R (Denmark, Germany)
- p309 A Genetic Screening of Steven-Johnson Syndrome from Carbamazepine and Phenytoin among People with Epilepsy in Thailand**
Lopplumlert J, Locharernkul C, Shotelersuk V, Limotai C (Thailand)
- p310 Balanced Translocation Disrupts the Na⁺ - Channel Gene SCN1A in a Patient with Severe Epilepsy and Mental Retardation**
Hansen C, Poulsen L, Møller R, Bugge M, Tümer Z, Tommerup N (Denmark)
- p311 Sub-Phenotypes of Common Idiopathic Generalised Epilepsies**
Braga P, Scaramelli A, Rodriguez M (Montevideo, Uruguay)
- p312 Association between Multidrug Resistance in Epilepsy and Haplotypes in the Drug Transporter Gene ABCB1 in Han Chinese**
Kwan P, Wong V, Ng P, Lui C, Sin N, Hui A, Yip P, Yu E, Baum L (Hong Kong)
- p313 Association between Response to Antiepileptic Drugs with Sodium Channel Blocking Properties and Polymorphisms in the SCN2A Gene in Epilepsy Patients**
Baum L, Huang P, Wang D, Kang D, Ng H, Wong V, Ng P, Lui C, Sin N, Hui A, Yip P, Cheung B, Yu E, Kwan P (Hong Kong)
- p314 Epilepsy as Part of the Phenotype Associated with ATP1A2 Mutations**
Weckhuysen S, Peeters K, Deprez L, Deconinck T, Claeys K, Claes L, Suls A, Van Dyck T, Palmieri A, De Jonghe P, Van Paesschen W (Belgium)
- p315 Microdeletional Mutations of SCN1A in Individuals with Severe Myoclonic Epilepsy in Infancy (SMEI) and Borderline SMEI**
Wang J, Kurahashi H, Hamachi A, Yonetani M, Inoue T, Ogawa A, Yasumoto S, Hirose S, Kaneko S (Japan)
- p316 Candidate Gene Analysis of GRM8, CHRM2, SSTR5 and CACNA1H in Epilepsy-related Photosensitivity**
Pinto D, Kasteleijn-Nolst-Trenité D, de Kovel C, Westland B, Lindhout D, Koeleman B, Stephani U, Martins da Silva B, Covanis T, Capovilla G, Brinciotti M, Verrotti A, Butinnelli C, Rudolf G, de Haan G (The Netherlands, Germany, Portugal, Italy, France)

Please replace with sticker saying

"Refer to Abstract Book Page 120 - 125"

July 9th - 11th 2007


POSTER SESSION

GENETICS

Refer to Abstract Book Page 109-112

- p305 Adeno-associated Virus-mediated Expression and Intracellular Peptide Delivery of Apurinic/aprimidinic Endonuclease Ameliorate Kainate-induced Hippocampal Cell Death in Mice**
Cho Y, Cho K, Jung Y, Koh H, Kim G, Heo K, Lee B (Korea)
- p306 To Identify the Genetic Susceptibility Locus in a large South Indian Family with Juvenile Myoclonic Epilepsy**
Ratnapriya R, Satishchandra P, Srinivas H, Kapoor A, Anand A (India)

Poster Sessions



p317 Association of Variants in SCN1A and CYP3A with Carbamazepine Doses: Racial Differences
Kijisanayotin P, Cloyd J, Oetting W, Birnbaum A, Ramsay R, Rarick J, Prasittisopin B, White J, Pennell P, Leppik I (USA)

p318 Altered DNA Copy Number in Patients with Different Seizure Disorders: By Array-CGH
Kim Y, Chung S, Lee I, Kim H, Lee K, Yim S (Korea)

p319 Partial Epilepsy with Febrile Seizure Plus (PEFS+) and Novel SCN1A Mutations
Liao Wei Ping, Shi Yi-Wu, Chen Li, Deng Wi-Yi, Fu Lun-Jiao, Yu Mei-Juan, Liu Xiao-Rong, Deng Yu-Hong, Yi Yong-Hong, Qin Bing, Li Tian, Li Bing-Mei, Su Tao, Long Yu-Sheng (China)

p320 A de Novo LG11 Mutation causing Telephone-induced Epilepsy
Michelucci R, Mecarelli O, Testoni S, Bovo G, Bisulli F, Striano P, Striano S, Tinuper P, Nobile C (Italy)

Please replace with sticker saying "Refer to Abstract Book Page 125-131"

July 9th - 11th 2007

POSTER SESSION

NEUROIMAGING

Refer to Abstract Book Page 113-118

p321 Voxel-based Analysis of Diffusion Tensor Imaging in Refractory Partial Epilepsy at 3.0T
Chen Q, Ou-Yang L, Yang T, Lui S, Gong Q, Shang H, Zou L, Zhou D (China, UK)

p322 Added Value of EEG-fMRI in the Pre-operative Workup for Epilepsy Surgery
Zijlmans M, Huiskamp G, Hersevoort M, Seppenwoolde J, van Huffelen A, Leijten F (The Netherlands)

p323 fMRI in Lateralisation of Memory in Patients with Mesial Temporal Sclerosis
Shiva Shankar J, Ravishankar S, Jayakumar P, Sinha S (India)

p324 Proposed Systematic Assessment of Vagal Nerve Stimulation Therapy
Limotai C, Locharernkul C, Loplumlert J, Srikiyvilaiikul T (Thailand)

p325 Neuroimaging in Epilepsy: MRI Evaluation in Refractory Complex Partial Seizures
Muttaqin Z (Indonesia)

p326 Language Determination by fMRI with Korean Paradigms
Cho Y, Yi S, Sohn C, Jang Y, Berl M, Theodore W, Gaillard E (Republic of Korea, USA)

p327 EEG-fMRI in Children with Pharmacoresistant Focal Epilepsy
Cross J, Laufs H, Boyd S, Harkness W, Allen P, Clark C, Connolly A, De Tiège X (UK)

p328 Utilities of MRI Scoring and Pathological Grading Systems for Hippocampal Sclerosis in Mesial Temporal Lobe Epilepsy
Murakami H, Fujimoto A, Sugiyama I, Masuda H, Kameyama S, Kakita A, Takahashi H (Korea, Japan)

p329 Hippocampal Malformation in Familial Mesial Temporal Lobe Epilepsy Linked to Chromosome 18p11.3-11.2
Morita M, Maurer-Morelli C, Secolin R, Kobayashi E, Conz L, Yasuda C, Lopes-Cendes I, Cendes F (Brazil, Canada)

p330 ISSP4 Analysis of 123I-Iomazenil SPECT in Patients with Temporal Lobe Epilepsy
Nikaido K, Nakamura F, Matsuda K, Yamaguchi T (Japan)

p331 Localisation of the Irritative Zone in Epilepsy using Simultaneous EEG/fMRI and Independent Component Analysis (ICA)
Jann K, Hauf M, Mathis J, Meyer K, Dierks T, König T, Wiest R (Switzerland)

p332 Noninvasive Evaluation of Language Dominance and Localisation using Synthetic Aperture Magnetometry: Comparison with the Wada Test and Stimulation Mapping
Hirata M, Kato A, Kishima H, Oshino S, Tani N, Goto T, Saitoh Y, Hashimoto N, Shiro Y, Yorifuji T (Japan)

p333 Usefulness of Interictal 123I-iomazenil-SPECT for Localising Epileptogenic Focus compared with 18F-FDG-PET and 99mTc-ECD-SPECT as Presurgical Evaluation for Intractable Epilepsy
Akamatsu N, Yamano M, Tsuji S, Tomoda Y (Japan)

p334 Preoperative Amygdala fMRI in Mesial TLE (mTLE): A possible Predictor for Mood Disturbances after Temporal Lobe Surgery
Bonelli S, Powell R, Yogarajah M, Thompson P, Symms M, Koepp M, Duncan J (UK)

p335 Tractography of the Parahippocampal Gyrus and Material Specific Memory Impairment in Unilateral Temporal Lobe Epilepsy
Yogarajah M, Powell R, Parker G, Alexander D, Symms M, Boulby P, Wheeler-Kingshott C, Barker G, Thompson P, Koepp M, Duncan J (UK)

p336 Paediatric Cortical Dysplasia and Microdysgenesis: Correlations between Clinical Features, Neuroimaging, and Electrophysiology
Lee J, Jung D, Lee E, Hur Y, Kim H, Lee S, Kim S (Korea)

p337 1H MR Spectroscopic Changes in Histopathological Subgroups of Mesial Temporal Lobe Epilepsy: Correlation with MRI and Seizure Outcome
Krsek P, Hajek M, Dezortova M, Marusic P, Zamecnik J, Kynci M, Tomasek M, Komarek V (Czech Republic)



Poster Sessions

p338 Brief Seizures do not Cause MRI Abnormalities in Rats

Munashinge J, Acosta M, Guerron A, Theodore W (USA)

p339 Correlation Study of Optimised Voxel-based Morphometry and 1H MRS in Patients with Mesial Temporal Lobe Epilepsy and Hippocampal Sclerosis (MTLE/HS)

Brazdil M, Marecek R, Mikl M, Fojtikova D, Kuba R, Krupa P, Rektor I (Czech Republic)

p340 The Role of FDG-PET in Identification of Seizure Focus

Gökdemir S (Turkey)

p341 Slow Wave within Epileptiform Discharges is associated with Negative BOLD Response: An EEG-fMRI Study

Siniatchkin M, Moeller F, Boor R, Wolff S, Jansen O, Stephani U (Germany)

Please replace with sticker saying "Refer to Abstract Book Page 131-134"

July 9th - 11th 2007

POSTER SESSION

NEUROPSYCHOLOGY

Refer to Abstract Book Page 119-122

p342 Psychological Impact of a Newly-diagnosed Seizure: Relationship to Cognitive Complaints and Attentional Processing

Velissaris (Nee Willetts) S, Saling M, Wilson S, Newton M, Berkovic S (Australia)

p343 Cognitive, Behavioural and Social Communication Comorbidities In Childhood Absence Epilepsy

Gurbani S, Siddarth P, Lanphier E, Caplan R (USA)

p344 Hippocampal and Rhinal Contributions to Verbal Memory: A T2 Relaxometry Study in Epilepsy

Lillywhite L, Saling M, Briellmann R, Weintrob D, Pell G, Jackson (Australia)

p345 Cognitive Variability in Children with Epilepsy

Thomason K, Wright I, Nicolson R, Rittey C, Kandler R, Chattopadhyay A (UK)

p346 Cognitive Effects of Newer Antiepileptic Drugs: A Comparative Study with Valproate in Epilepsy Patients

Park S, Kang K, Suh J (Korea)

p347 Neuropsychological Impairments in Individuals with Mutations of the $\alpha 4$ Nicotinic Acetylcholine Receptor Subunit associated with Autosomal Nocturnal Frontal Lobe Epilepsy

Wood A, Fedi M, Saling M, Scheffer I, Berkovic S, Reutens D (Australia)

p348 Modality Specific Memory Deficits and fMRI in Mesial Temporal Sclerosis: Relevance for the Functional Organisation of Memory Networks and Plasticity

Santana I, Cunha C, Lemos R, Machado E (Portugal)

p349 Developmental and Cognitive Profile of Children with Early Onset Epilepsy

Merrett A, Eltze C, De Haan M, Scott R, Neville B, Cross J (UK)

p350 Assessment of Visual Function and Skill Before and After Surgical or Drug Treatments for Paediatric Intractable Epilepsy

Eiji N, Iwao K, Tsukasa O, Hirokata O, Hirofumi K, Kenji S, Masayuki S, Taisuke O (Japan)

p351 Coimbra Neuropsychological Battery: Results of Validation in Children with Epilepsy

Duarte Lopes A, Simões M, Robalo C, Fineza I, Gonçalves O (Portugal)

p352 Speech Problems in Children with Focal Epilepsy

Jocic-Jakubi B (Serbia)

p353 Unilateral Mesial Temporal Lobe Spatial Memory Impairment: Structural and Functional Correlates in a Virtual Environment

Glikmann-Johnston Y, Saling M, Reutens D (Australia)

p354 Pregabalin: Cognitive and Behavioural Aspects

Piazzini A, Turner K, El Kiky E, Vignoli A, Goracci A, Chiesa V, La Briola F, Canger R, Canevini M (Italy)

p355 Frontal Lobe Function in Juvenile Myoclonic Epilepsy

Vucinic D, Jovic N, Ignjatovic P, Borkovic M, Jelic S (Serbia)

Please replace with sticker saying "Refer to Abstract Book Page 134-155"

July 9th - 11th 2007

POSTER SESSION

PAEDIATRIC EPILEPTOLOGY

Refer to Abstract Book Page 123-143

p356 Somatosensory Reflex Seizures with Side-shifting Triggering Area: Presentation of a Unique Clinical Case with Ictal Video-EEGs and Functional MRI


Sanmarti F, Málaga I, Donaire A, Falcón C, Bargalló N, Galceran L (Spain)

p357 Levetiracetam Monotherapy in Newly Diagnosed Children and Adolescents with Idiopathic Generalised Epilepsies: Efficacy and Tolerability in Long-term Clinical Study

Cerminara C, Battuello M, Pinci M, Coppola G, Vigevano F, Curatolo P (Italy)


p358 Characteristics of Clinical Evolution, EEG and Neuroimaging in Rasmussen's Syndrome

Liang J (China)




Poster Sessions

- p359 Acute Seizure-related Hospitalisation for Children with Newly Diagnosed Epilepsy**
Kwong K, Ting Y, Wong S, So K, (Hong Kong)
- p360 Electroclinical Characteristics and Treatment of Rasmussen Syndrome**
Zhang Y, Liu X, Xiong H, Li Y, Liu X, Luan G, Qin J, Wu X (China)
- p361 Pharmacokinetics of Eslicarbazepine Acetate in Children and Adolescents with Epilepsy**
Nunes T, Minciu I, Almeida L, Magureanu S, Falcão A, Butoianu N, Burloiu C, Soares-da-Silva P (Portugal, Romania)
- p362 Treatment of Epilepsy in Children with Cerebral Palsy**
Trabacca A, Losito L, De Rinaldis M (Italy)
- p363 Actigraphic and Parental Reports of Sleep Disturbances in Children with Epilepsy**
Huyton C, Wright I, Nicolson R (UK)
- p364 Seizure Related Accidents in Childhood**
Montenegro M, Buffo T, Guerreiro M (Brazil)
- p365 Use of Risperidone in Children with Epilepsy**
Holzhausen S, Guerreiro M, Baccin C, Montenegro M (Brazil)
- p366 Systematic Add-on Therapy with Levetiracetam in Childhood Refractory Epilepsies**
Pelliccia A, Luchetti A, Miano S, Costa A, Parisi P (Italy)
- p367 Childhood Epilepsy: A study from a Tertiary Care Centre in South India**
Menon B, Bhuma V (India)
- p368 ICCA Syndrome in Malaysia**
Wong S, Ong L, Szepekowski P (Malaysia, France)
- p369 Prediction of Seizure Outcome following Resective Surgery in Children with Epileptic Spasms**
Asano E, Chugani H, Juhasz C, Haseeb A, Mihaylova T, Sood S (USA)
- p370 Levetiracetam: Efficacy for Partial Epilepsy of Infancy with Continuous Spikes and Waves during Slow Sleep (CSWS)**
La Selva L (Italy)
- p371 Intravenous Midazolam in the Treatment of Convulsive Symptomatic and Cryptogenic Status Epilepticus in Children**
Papavasiliou A, Kotsalis C, Paraskevoulakos E, Karagounis P, Rizou C, Bazigou H (Greece)
- p372 Normalisation of Regional Cerebral Glucose Metabolism Abnormalities in the Recovery Phase of CSWS**
De Tiege X, Ligot N, Poznanski N, de Saint Martin A, Goldman S, Van Bogaert P (Belgium, France)
- p373 Delay in Diagnosis of Tumours in Children with Cerebral Tumours and Epilepsy**
Diaconu G, Grigore I, Burlea M, Frasin M (Romania)
- p374 Incidence of Epilepsies in Child Populations of Canton Sarajevo, Bosnia and Herzegovina**
Zubcevic S, Gavranovic M (Bosnia And Herzegovina)
- p375 Capillary Glucose Monitoring During Initiation of the Ketogenic Diet in Children**
Dong L, Ong H, Ku Y (Singapore)
- p376 Clinical Study of Seizures Associated with a Heavy Meal**
Woo Y, Kim Y (South Korea)
- p377 Symptomatic epilepsy in the course of polymicrogyria in one of the set of monozygous twins**
Szczepanik E, Antczak-Marach D, Terczynska I, Tryfon J, Hoffman-Zacharska D, Płoski R (Poland)
- p378 Solitary Generalised Seizure in Children with Accidental Ingestion of Camphor**
Jadhav V, Nigade R, Vasagadekar D, Jadhav P (India)
- p379 Levetiracetam in Children and Adolescents with Refractory Epilepsy: Preliminary Data**
Pieri I, Vittorini R, Capizzi G (Italy)
- p380 Supracondylar Femur Fracture Complicating Epileptic Insult: A Specific and Under-diagnosed Complication?**
Ceulemans B, Vanheer P, Boel M, Lagae L, Molenaers G, Adam A, van Rhijn J (Belgium)
- p381 Long-term Safety and Anticonvulsant Activity of Add-on Ganaxolone in Treatment-refractory Paediatric Epilepsy**
Tsai J, Pieribone V, Shaw K, Soufflet C, Dulac O, Giller E (USA, France)
- p382 Epileptic Encephalopathy of Infancy: A Case Report**
Conti P, Sciricchio V, Gagliardi D, Bitetto S, Galeone D (Italy)
- p383 Efficacy of Levetiracetam in the Treatment of Panayiotopoulos Syndrome**
Garcia C, Rubio G (Spain)
- p384 Carers' Perception of the Impact and Burden of Epilepsy and its Treatment for Children and Adolescents**
Chang M (Taiwan)



Poster Sessions

- p385 Preliminary Efficacy and Tolerability of Levetiracetam in Children and Young Adults with Refractory Epilepsy in Taiwan**
Tsu T, Chang K (Taiwan)
- p386 Levetiracetam in West Syndrome**
Arcas J Martínez-Bermejo A, Roche C, Velazquez R, Merino M (Spain)
- p387 Efficacy of Levetiracetam in Children and Adolescents with Focal Symptomatic Refractory Epilepsy**
Vittorini R, Pieri I, Capizzi G (Italy)
- p388 Epilepsy Surgery for Paediatric Patients: A Review from a large Tertiary Centre (AIIMS, New Delhi)**
Chandra S, Padma V, Singh M, Srivastava A, Gaikwad S, Gupta A, Sarkar C, Bal C, Tripathi M (India)
- p389 Lacosamide, an Investigational Antiepileptic, has a Favourable Profile in Preclinical Reproductive, Developmental and Juvenile Toxicity Studies**
Krebsfaenger N, Stoehr T (Germany)
- p390 Efficacy and Safety of Levetiracetam Monotherapy for Children with Epilepsy**
García-Peñas J, González Gutiérrez-Solana L, Ruiz-Falcó Rojas M, Lara Hergueras J, Duat Rodríguez A (Spain)
- p391 Comparison of Health-related Quality of Life (HRQL) in Children with Epilepsy in Hong Kong and Canada**
Cherk S, Ronen G, Chan K, Rosenbaum P, Yam W, Streiner D, Cheng S, Fung C, Ho J, Kwong K, Ma L, Ma D, Tsui K, Wong V, Wong T (Hong Kong)
- p392 Beyond 1 Year Retention Rate of Levetiracetam Add-on Therapy in Taiwanese Children with Refractory Epilepsies of Epileptic Syndromes**
Chang J, Chi C, Lee H, Chen C (Taiwan)
- p393 Clinical Profiles and Outcome of Children with Status Epilepticus in Northern Thailand: Current Status and Future Direction with Limited Resources**
Katanyuwong K, Chavachart I, Mahatape S (Thailand)
- p394 Prednisone Therapy in Refractory Childhood Epilepsy**
Mahvelati F, Amin zadeh V, Ghofrani M (Iran)
- p395 Variable Ictal Discharges of Complex Partial Seizures in an Infant with Glucose Transporter 1 Deficiency Syndrome**
Yasuhisa T, Yukiko M, Keiko Y, Yasuhiro S (Japan)
- p396 EEG Characteristics of Lennox-Gastaut Syndrome for Localising Primary Epileptogenic Region by Digital Analysis**
Park J, Jung Da Eun, Kim H (Korea)
- p397 Heart Rate Variability in Children with Refractory Generalised Epilepsy**
Harnod T, Hsin Y, Kuo T, Yang C, Chen (Taiwan)
- p398 Language Deficits in Paediatric Epilepsy**
Siddarth P, Gurbani S, Lanphier E, Bailey C, Stahl L, Vona P, Caplan R (USA)
- p399 Cognitive Outcome in Paediatric Epilepsy Patients in Mexico**
Barragán E, Hernández M, Alejandro C, Huerta A (Mexico)
- p400 Epileptiform activity on overnight sleep EEG and psychological profile in developmental dysphasia**
Neuschlová L, Stírbová K, Záhková J, Komárek V (Czech Republic)
- p401 Ictal EEG Findings of Infantile Spasms**
Kim K, Lee J, Moon J, Park J, Lim B, Hwang H, Chae J, Hwang Y (Korea)
- p402 Midazolam for the Treatment of Neonatal EEG-confirmed Seizures**
Ogawa A, Shirotani G, Hashimoto J, Ohta E, Mori T, Yukitake K, Hirose S (Japan)
- p403 Acute Symptomatic Seizures as an Initial Presentation from Reversible Posterior Leukoencephalopathy Syndrome in Children**
Kwon S, Kim J (Korea)
- p404 Levetiracetam as Monotherapy or Add-on Drug in a Large Cohort of Paediatric and Young Adult Epilepsy Patients**
Coppola G, Operto F, Sarnataro E, Cascella R, Salzano A, Fortunato D, Pascotto A (Italy)
- p405 Referral Patterns of Epilepsy Patients to the Epilepsy Centre in Ilsan**
Lee J, Kim Gyu Sik (Korea)
- p406 High Dose Lidocaine in the Treatment of Acute Encephalitis with Refractory, Repetitive Partial Seizures in Children**
Lin J, Lin K, Wang H (Taiwan)
- p407 fMRI Activation of the Thalamus during Generalised Epileptiform Discharges in Children with Idiopathic Generalised Epilepsy using Different Haemodynamic Response Functions**
Moeller F, Muhle H, Wolff S, Boor R, Granert O, Siebner H, Jansen O, Siniatchkin M, Stephani U (Germany)
- p408 Co-existing Disabilities in Children with Epilepsy**
Akhter S, Mannan M, Rahman M (Bangladesh)
- p409 Febrile Seizures and Epilepsy: Retrospective Analysis of Paediatric Patients**
Cvitanovic-Sojat L, Gjergja R, Malenica M, Sabol Z, Sojat T (Croatia)



Poster Sessions

- p410 Immunological Biomarkers in CSF for the Early and Accurate Diagnosis of Rasmussen Syndrome**
Takahashi Y, Kubota Y, Yamazaki E, Nikaidou H, Ootani H, Egawa K, Ikeda H, Nishimura S, Tsunogae H, Fujiwara T (Japan)
- p411 Quality of Life in Children with Epilepsy**
Ko T, Kim S, Yum M, Yoo H (Korea)
- p412 Epilepsy in Infancy: First Results of a Collaborative Population based Study in North London**
Eltze C, Scott R, Chin R, de Haan M, Cox T, Chong W, Boyd S, Neville B, Cross J (UK)
- p413 Safety of Thiopental for the Treatment of Status Epilepticus in Dravet Syndrome**
Chiron C, Nabbout R, Chipaux M, Desguerre I, Dulac O (France)
- p414 Differential Diagnosis of Temporal Lobe Epilepsy in Children: Findings from a Community-based Study**
Whitney A, Spooner C, Berkovic S, Harvey S (Australia, UK, New Zealand)
- p415 Effects of Rufinamide on the Frequency of Different Seizure Types in Patients with Lennox-Gastaut Syndrome: A Long-term Study**
Glauser T, Kluger G, Krauss G, Arroyo S (USA)
- p416 Electroencephalographic Characteristics in Paediatric Lupus Patients**
Espinoza R, Huerta A, Barragán E, Hernández M, Capistro F, GUerra D, Garza S, Hernández J (Mexico)
- p417 Topiramate Kinetics during Lactation**
Öhman I, Leuf G, tomson T (Austria, Sweden)
- p418 Mitochondrial Respiratory Chain Defect: Newly Postulated Aetiology in Various Epileptic Conditions**
Kim H, Lee Y, Kang H, Lee J, Slama A (Korea, France)
- p419 Demographic Features of Infantile Spasms in a Tertiary Paediatric Hospital in Singapore: A Two Year Retrospective Study**
Tang S, Chan D, Liew W (Singapore)
- p420 Paediatric Refractory Status Epilepticus at a Tertiary Paediatric Hospital**
Chan D, Phuah H, Wong J, Choong C, Lim K (Singapore)
- p421 Migrating Partial Seizures in Infancy: An Age-specific Symptomatic Epilepsy or True Epileptic Encephalopathy?**
Hadac J, Brozova K, Siskova D (Czech Republic)
- p422 Rasmussen's Syndrome: Characterising the Course of Paediatric Patients**
Malphrus A, Shultz R, Wilfong A (USA)
- p423 Efficacy, Safety and Tolerability of Levetiracetam for the Treatment of Epilepsy in Neonates (under 28 days old)**
Ritter F, Wical B, Norberg S (USA)
- p424 Epidemiological Study of Epilepsy in Severe Motor and Intellectual Disabilities Syndrome in Okayama Prefecture**
Yamatogi Y (Japan)
- p425 Treatment of Epilepsy in Paediatric Patients with Mental Retardation**
Mazurkiewicz-Beldzinska M, Matheisel A (Poland)
- p426 Potentially Serious Lamotrigine-Related Skin Rash**
Jan M (Saudi Arabia)
- p427 Study of Clinical, EEG and Radiological Predictors of Intractable Epilepsy in Children**
Aithala G, Sztriha L (Malaysia, Hungary)
- p428 Topiramate Monotherapy in Catastrophic Epilepsies**
Kwon Y, Kim D, Son B (Korea)
- p429 Effect of Levetiracetam in Children with Electric Status Epilepticus during Slow-wave Sleep**
Lee W, Wang S, Weng W (Taiwan)
- p430 Atkin's Diet In Childhood Refractory Seizure: An Iranian Experience**
Tonekaboni S, Mostaghimi P (Iran)
- p431 Eyelid Myoclonia and Absences (EMA): One or Two Syndromes?**
Beccaria F, Montagnini A, Capovilla G (Italy)
- p432 Predictors for Outcome of Childhood Epilepsy: Early Onset versus Late Onset Epilepsy**
Rahman M, Moinuddin A, Akther S, Kawser C (Bangladesh)
- p433 Clinical Features of Epileptic Negative Myoclonus: Personal Data and Review of the Literature**
Rubboli G, Stanzani-Maserati M, Cantalupo G, Rondelli F, Gardella E, Meletti S, Pinardi F, Volpi L, Riguzzi P, Michelucci R, Tassinari C (Italy)
- p434 Severe Partial Epilepsy due to Immunomediated Encephalopathy**
Specchio N, Balestri M, Claps D, Valeriani M, Fusco L, Vigeveno F (Italy)
- p435 Neurological and Neuropsychological Prognosis of Children with Cryptogenic Localisation related Epilepsy in a Tertiary Outpatient Clinic**
Reijs R, van Mil S, Debeij-Van Hall M, Arends J, Weber J, Renier W, Aldenkamp A (The Netherlands)



Poster Sessions

- p436 Modelling Experimental Status Epilepticus of Bioelectric Secondly Generalised Seizures in an Animal Model of Penicillin Epilepsy**
Sobieszek A, Zmysłowski W (Poland)

Please replace with sticker saying "Refer to Abstract Book Page 155-158"

July 9th - 11th 2007

POSTER SESSION

PSYCHIATRY

Refer to Abstract Book Page 144-146

- p437 Prediction of Health-related Quality of Life, Anxiety and Depression among Young Adults with Epilepsy in Short-term Residential Care: The Effects of Neuroticism and Age at Disability Onset**
Endermann M, Zimmermann F, Knoop M (Germany)
- p438 Screening for Symptoms of Anxiety and Depression in Epilepsy Associated with Migraine**
Martinovic Z, Buder N, Djokic R, Jovanovic M, Milovanovic M, Simonovic P (Serbia)
- p439 Themes in Cultural Competence: III. Pseudoseizures, Anticipatory Grief and Limited Access to Medical Care**
Kaufman K, Zuber N, Pellino L, Grimaldi L, Mahalingam R, Wollack J (USA)
- p440 Prevalence of Psychiatric Disorders in a Series of Patients with Mesial Temporal Sclerosis Compared to a Group with Juvenile Myoclonic Epilepsy**
Araujo Filho G, Rosa V, Lin K, Caboclo L, Sakamoto A, Yacubian E (Brazil)
- p441 Case Report of Verbal Auditory Hallucinations in a Young Female Patient with Epilepsy**
Hara K, Watanabe Y, Tanaka S, Suzuki M, Hino K, Okazaki M, Watanabe M (Japan)
- p442 Spike-wave Stupor during Treatment with Paroxetine: A Case Report**
Miyajima M, Kimura M, Okazaki M, Hara K, Hino K, Watanabe M, Ohnuma T (Japan)
- p443 Evidence for Co-morbid Psychotic-Like Behaviour in a Genetic Rat Model of Absence Epilepsy**
Jones N, van den Buuse M, Salzberg M, Morris M, O'Brien T (Australia)
- p444 Comparative Study of Obsessive-Compulsive Disorder and other Psychiatric Comorbidities in Patients with Temporal Lobe Epilepsy and Idiopathic Generalised Epilepsy**
Aslantas Ertekin B, Baral Kulaksizoglu I, Ertekin E, Baykan B, Gurses C, Gokyigit A (Turkey)
- p445 Attention Deficit/Hyperactivity Disorder and Subclinical Epileptiform Discharges: Comorbidity Findings and ADHD Symptoms**
Socanski D, Aarsland D, Herigstad A (Norway)

- p446 Rolandic Spikes in Children with or without Epilepsy with ADHD/LD: Cognitive and Behavioural Aspects**
Turkdogan D, Zaimoğlu S (Turkey)

- p447 Epilepsy in Mental Retardation**
Darghal M (Morocco)

- p448 High Prevalence of Alexithymia among Epilepsy Patients: A Controlled Study**
Baral Kulaksizoglu I, Aslantas Ertekin B, Ertekin E, Gurses C, Baykan B, Gokyigit A (Turkey)

Please replace with sticker saying "Refer to Abstract Book Page 158-164"


July 9th - 11th 2007

POSTER SESSION

SOCIAL ISSUES / NURSING

Refer to Abstract Book Page 147-151

- p449 Nine Years of the International Emergency Epilepsy Card (IEEC) Evaluated, Accepted and Established: A Comparative Analysis**
Porschen T, Stefan H (Germany)
- p450 Personality, Self-concept and Self-management of Women with Epilepsy in the Northern Philippines**
Estrada P, Espinosa R (The Philippines)
- p451 Influence of Traditional Yoga, Pranayama and Nyasa Therapy in the Management of Patients with Epilepsy**
Karandikar M (India)
- p452 Epilepsy - Out of the Shadows - Into the Spotlight Comedy Program**
Fyfe K (Canada)
- p453 Detection and Management of Catastrophic Childhood Epilepsies in the Community by Integrating a Specific Non-governmental Initiative with an Existing Governmental Program: A Model from a Rural District of Kerala State, South India.**
Puthenveetil V, P.D S, C.P A (India)
- p454 Audit of Parents' Use of and Satisfaction with the Neurology Advice Line**
Sawal M, Hall A, Philips S, Wassmer E, Peak D, Gupta R (UK)
- p455 Prediction Factors of Seizure-Related Injury in People with Epilepsy**
Tiamkao S, Shorvon S (Thailand, UK)
- p456 Behaviour Problems in Children and Adolescents with Seizure Disorder: Associations and Risk Factors in a Developing Country**
Joshi S, BK S, Bhandari R, Raman V (Nepal, India)
- p457 Problems that Mothers with Epilepsy Experience when Caring for their Children**
Crawford P, Bagshaw J, Chappell B (UK)



Poster Sessions

Please replace with sticker saying "Refer to Abstract Book Page 164-166"

- p458 Risk Factors for Epilepsy: A Population Based Case Control Study in Kolkata, India**
Roy T, Chaudhuri A, Banerjee T, Raut D, Biswas A, Ray B, Hazra A, Das S (India)
- p459 Development and Evaluation of an Epilepsy Curriculum Unit for Grade 11 and 12 Biology Students**
Secco M, Martiniuk A (Canada, Australia)
- p460 Confident Living, Despite Seizures**
Ireland C, Todd L (Australia)
- p461 Knowledge of Epilepsy among Nurses in an Acute Care Hospital in Singapore**
Wang S, Loh S, Pan A, De-Silva D, Ratnagopal P, Lim S (Singapore)
- p462 Psychosocial Status Of Patients With Epilepsy**
Bozdemir N, Utkan B, Saatci E, Bozdemir H (Turkey)
- p463 Experience of Moroccan Society against Epilepsy in Managing Epilepsy in Morocco**
Kissani N (Morocco)
- p464 Community Epilepsy Education in East Timor**
Todd L, Amoroso C, Graves J, Fonseca Amaral Z, Pinto Gonzaga P, Somerville E (Australia, East Timor)
- p465 Developing and Validating a Singapore Version of the Quality of Life in Epilepsy Inventory (QOLIE-31)**
Yeo L.L.S., Thumboo J, Wang S, Lim S.H., Cramer J (Singapore, USA)
- p466 Media Campaigning for Openness and Good Care**
Lindström K, Kälviäinen R, Tervonen S (Finland)
- p467 Factors Affecting the Quality of Life of Chinese Patients with Epilepsy**
Yu E, Lau J, Wong C, Kwan P (Hong Kong)
- p468 Epilepsy Education through Public Service Announcements**
Yake L, Traverse L, Secco M (Canada)
- p469 Epilepsy, Epidemiology and Society**
Schumacher N (USA)
- p470 Parents want more Information about their Children's Epilepsy: Interviews with a group of Xhosa-speaking Parents in Cape Town, South Africa**
Keikelame M (South Africa)

July 9th - 11th 2007

POSTER SESSION

MISCELLANEOUS

Refer to Abstract Book Page 152-154

- p471 Melatonin in Refractory Epilepsy**
Paprocka J, Dec R, Jamroz E, Marszaa E (Poland)
- p472 Implementation of Dynamic Brain Perfusion CT into the Diagnostic Workup of Non-convulsive Status Epilepticus**
Hauf M, Schindler K, Mathis J, Donati F, Ozdoba C, Wiest R (Switzerland)
- p473 Seizures of Extratemporal Origin as a Prominent Feature in a Tamilian Male with Chorea-acanthocytosis**
Dorn T, Bader B, Danek A, Jung H, Achermann Y, Frey B, Kramer G (Switzerland, Germany)
- p474 Investigating the Epileptic Network with Resting State fMRI and Arterial Spin Labelling: A Case Study**
Wiest R, Hauf M, Jann K, Fedespiel A (Switzerland)
- p475 Stereotypy of Frontal Lobe Seizures**
Roethlisberger N, Kollar M, Pihan H, Mathis J, Donati F (Switzerland)
- p476 Pregabalin in Partial Seizures: A Pragmatic 21 Week, Open-label Study (PREPS)**
Ryvlin P, Chatamra K, Von Raison F, Mallison R (France, Germany)
- p477 Role of ERK1/2 Signalling Pathway in the Formation of Mossy Fibre Sprouting in the Pilocarpine Model of Epilepsy**
Chen Yang-mei, Zheng Li-hua XU, Jing (China)
- p478 Topiramate as add-on therapy in children with refractory partial seizure**
Wang Z (China)
- p479 Clinical and Molecular Genetic Analysis of one Pedigree with Benign Familial Neonatal Convulsion**
Zhou Shui-Zhen, Song Yi-Qing, Sun D (China)

Speakers List



Surname		Date	Time	Room
Acevedo, C (Chile)	Chair	Wed July 11th	08:30	Hall 603
Acevedo, C (Chile)	Chair / Speaker	Wed July 11th	10:00	Hall 603
Acevedo, C (Chile)	Speaker	Thur July 12th	12:00	Ballroom 2
Akiyama, T (Japan)	Speaker	Tues July 10th	15:45	Theatre
Alarcon, G (UK)	Speaker	Sun July 8th	10:45	Room 203
Ali, A (Jamaica)	Speaker	Mon July 9th	10:00	Hall 603
Ali, R.A. (Malaysia)	Chair	Mon July 9th	15:45	Ballroom 2
Andermann, F (Canada)	Chair	Mon July 9th	10:00	Hall 603
Arzimanoglou, A (France)	Discussant	Wed July 11th	07:30	Ballroom 1
Avanzini, G (Italy)	Speaker	Mon July 9th	08:30	Hall 603
Avanzini, G (Italy)	Chair	Mon July 9th	15:45	Ballroom 3
Avanzini, G (Italy)	Discussant	Tues July 10th	07:30	Theatre
Baker, G (UK)	Speaker	Wed July 11th	15:45	Ballroom 2
Battaglia, G (Italy)	Speaker	Tues July 10th	15:45	Ballroom 2
Baulac, M (France)	Chair	Thur July 12th	08:45	Ballroom 2
Baulac, M (France)	Speaker	Thur July 12th	10:15	Ballroom 2
Baulac, M (France)	Speaker	Thur July 12th	12:00	Ballroom 2
Baumgartner, C (Austria)	Speaker	Mon July 9th	07:30	Room 209
Baxendale, S (UK)	Speaker	Wed July 11th	15:45	Ballroom 2
Bazil, C.W. (USA)	Chair / Speaker	Mon July 9th	17:30	Hall 603
Beck, H (Germany)	Chair	Sun July 8th	12:45	Room 203
Beghi, E (Italy)	Speaker	Mon July 9th	15:45	Ballroom 2
Ben Menachem, E (Sweden)	Speaker	Tues July 10th	12:00	Hall 603
Ben Menachem, E (Sweden)	Speaker	Wed July 11th	10:00	Ballroom 2
Benbadis, S.R. (USA)	Speaker	Mon July 9th	12:00	Hall 603
Benbadis, S.R. (USA)	Speaker	Thur July 12th	08:45	Ballroom 2
Berg, A (USA)	Speaker	Mon July 9th	14:15	Ballroom 2
Berg, A (USA)	Speaker	Tues July 10th	15:45	Theatre
Berkovic, S.F. (Australia)	Chair	Mon July 9th	12:00	Hall 603
Berkovic, S.F. (Australia)	Chair / Speaker	Tues July 10th	14:15	Ballroom 2
Berkovic, S.F. (Australia)	Chair	Tues July 10th	15:45	Ballroom 2
Bernard, C (France)	Chair	Mon July 9th	10:00	Theatre
Bernard, C (France)	Chair	Mon July 9th	15:45	Theatre
Bernard, C (France)	Speaker	Tues July 10th	17:30	Theatre

Speakers List



Surname		Date	Time	Room
Bertram, E.H. (USA)	Chair / Speaker	Sat July 7th	08:30	Room 203
Bharucha, N.E. (India)	Chair	Mon July 9th	08:30	Hall 603
Bharucha, N.E. (India)	Speaker	Thur July 12th	12:00	Ballroom 2
Bien, C (Germany)	Speaker	Mon July 9th	15:45	Room 209
Birbeck, G (USA)	Speaker	Mon July 9th	10:00	Hall 603
Bleasel, A (Australia)	Speaker	Tues July 10th	10:00	Ballroom 2
Bogacz, A (Uruguay)	Speaker	Tues July 10th	15:45	Ballroom 3
Brodie, M.J. (UK)	Speaker	Mon July 9th	14:15	Ballroom 2
Brooks-Kayal, A (USA)	Speaker	Tues July 10th	10:00	Ballroom 3
Brooks-Kayal, A (USA)	Speaker	Wed July 11th	10:00	Theatre
Brooks-Kayal, A (USA)	Speaker	Wed July 11th	15:45	Theatre
Cabral Lim, L (Philippines)	Chair / Speaker	Wed July 11th	10:00	Ballroom 3
Canevini, M.P. (Italy)	Discussant	Mon July 9th	07:30	Room 209
Caplan, R (USA)	Speaker	Mon July 9th	15:45	Ballroom 1
Capovilla, G (Italy)	Discussant	Mon July 9th	07:30	Ballroom 1
Capovilla, G (Italy)	Discussant	Tues July 10th	07:30	Ballroom 1
Capovilla, G (Italy)	Speaker	Wed July 11th	15:45	Ballroom 1
Carmant, L (Canada)	Speaker	Tues July 10th	15:45	Ballroom 2
Carpio, A (Ecuador)	Speaker	Mon July 9th	15:45	Ballroom 2
Cavalheiro, E (Brazil)	Speaker	Mon July 9th	15:45	Ballroom 3
Chambliss, J (Australia)	Speaker	Tues July 10th	10:00	Hall 603
Chavez Sell, F.C. (Costa Rica)	Speaker	Tues July 10th	15:45	Ballroom 3
Chiron, C (France)	Speaker	Mon July 9th	10:00	Ballroom 1
Chiron, C (France)	Chair / Speaker	Thur July 12th	10:15	Ballroom 2
Chugani, D (USA)	Speaker	Sun July 8th	09:00	Room 203
Chugani, H.T. (USA)	Chair / Speaker	Wed July 11th	10:00	Ballroom 1
Chugani, H.T. (USA)	Chair	Wed July 11th	15:45	Ballroom 1
Clignet, M (France)	Speaker	Mon July 9th	12:00	Hall 603
Clignet, M (France)	Speaker	Tues July 10th	10:00	Hall 603
Combi, R (Italy)	Speaker	Wed July 11th	15:45	Room 209
Cook, M.J. (Australia)	Chair / Speaker	Thur July 12th	07:30	Ballroom 1
Covanis, A (Greece)	Discussant	Mon July 9th	07:30	Ballroom 1
Covanis, A (Greece)	Discussant	Tues July 10th	07:30	Ballroom 1
Covanis, A (Greece)	Chair	Tues July 10th	15:45	Ballroom 1

Speakers List



Surname		Date	Time	Room
Cramer, J (USA)	Chair / Speaker	Tues July 10th	10:00	Ballroom 1
Cross, H (UK)	Discussant	Wed July 11th	07:30	Ballroom 1
Cross, H (UK)	Speaker	Thur July 12th	08:45	Ballroom 2
Dahlqvist, P (Sweden)	Speaker	Tues July 10th	15:45	Ballroom 1
D'Alessio, L (Argentina)	Speaker	Tues July 10th	10:00	Ballroom 1
Ding, D (China)	Speaker	Tues July 10th	10:00	Theatre
D'Souza, C (India)	Speaker	Wed July 11th	10:00	Hall 603
Dua, T (Switzerland)	Speaker	Sun July 8th	17:00	Hall 603
Dulac, O (France)	Speaker	Wed July 11th	10:00	Ballroom 1
Dumas, M (France)	Speaker	Mon July 9th	10:00	Hall 603
Dunn, D (USA)	Speaker	Mon July 9th	15:45	Ballroom 1
During, M.J. (USA)	Speaker	Tues July 10th	10:00	Ballroom 3
Ebner, A (Germany)	Speaker	Tues July 10th	10:00	Ballroom 2
Ebner, A (Germany)	Chair	Tues July 10th	15:45	Theatre
Elger, C.E. (Germany)	Speaker	Mon July 9th	10:00	Ballroom 2
Escayg, A (USA)	Speaker	Mon July 9th	10:00	Theatre
Falk Pedersen, J.K. (Norway)	Chair	Tues July 10th	08:30	Hall 603
Falk Pedersen, J.K. (Norway)	Speaker	Thur July 12th	12:00	Ballroom 2
Fejerman, N (Argentina)	Speaker	Wed July 11th	15:45	Ballroom 1
Fernandez, P.T. (Brazil)	Speaker	Wed July 11th	08:30	Hall 603
Fisher, R.S. (USA)	Speaker	Thur July 12th	10:15	Ballroom 2
Francione, S (Italy)	Speaker	Tues July 10th	07:30	Room 209
French, J (USA)	Speaker	Mon July 9th	14:15	Ballroom 2
French, J (USA)	Discussant	Wed July 11th	07:30	Ballroom 1
French, J (USA)	Chair	Wed July 11th	10:00	Ballroom 2
French, J (USA)	Speaker	Wed July 11th	12:00	Hall 603
Friedman, A (Israel)	Speaker	Mon July 9th	10:00	Ballroom 3
Friedman, A (Israel)	Speaker	Tues July 10th	17:30	Theatre
Gaillard, W.D. (USA)	Chair	Mon July 9th	10:00	Ballroom 1
Gaillard, W.D. (USA)	Speaker	Mon July 9th	15:45	Room 209
Gajda, Z (Hungary)	Speaker	Tues July 10th	17:30	Theatre
Galanopoulou, A (USA)	Speaker	Sat July 7th	08:30	Room 203
Garcia, H.H. (Peru)	Speaker	Wed July 11th	15:45	Ballroom 3
Gardella, E (Italy)	Speaker	Tues July 10th	07:30	Room 209

Speakers List



Surname		Date	Time	Room
Gedlie Damtie, Z (Ethiopia)	Chair	Mon July 9th	10:00	Hall 603
Gedlie Damtie, Z (Ethiopia)	Chair	Mon July 9th	15:45	Ballroom 3
Gidal, B.E. (USA)	Speaker	Sun July 8th	17:00	Hall 603
Glynn, M (Ireland)	Speaker	Tues July 10th	15:45	Ballroom 1
Gotman, J (Canada)	Speaker	Sun July 8th	10:45	Room 203
Gray, W (UK)	Speaker	Wed July 11th	15:45	Room 209
Guekht, A (Russia)	Speaker	Wed July 11th	07:30	Theatre
Gueye, L (Senegal)	Chair	Wed July 11th	15:45	Ballroom 3
Gunawan, D (Indonesia)	Chair	Wed July 11th	15:45	Ballroom 3
Gurses, C (Turkey)	Speaker	Wed July 11th	15:45	Ballroom 3
Gustafsson, J.A. (Sweden)	Speaker	Thur July 12th	10:15	Ballroom 3
Halasz, P (Hungary)	Speaker	Thur July 12th	10:15	Ballroom 1
Harden, C.L. (USA)	Speaker	Wed July 11th	10:00	Ballroom 3
Harding, J (New Zealand)	Speaker	Thur July 12th	10:15	Ballroom 3
Hargis, E (USA)	Chair	Tues July 10th	10:00	Hall 603
Harvey, A (Australia)	Speaker	Mon July 9th	10:00	Ballroom 1
Hauser, A (USA)	Speaker	Sun July 8th	14:30	Hall 603
Hauser, A (USA)	Chair	Mon July 9th	14:15	Ballroom 2
Hauser, A (USA)	Chair / Speaker	Mon July 9th	15:45	Ballroom 2
Hauser, A (USA)	Chair	Tues July 10th	10:00	Theatre
Hauser, A (USA)	Speaker	Thur July 12th	12:00	Ballroom 2
Hermann, B (USA)	Chair	Mon July 9th	15:45	Ballroom 1
Hermann, B (USA)	Chair	Wed July 11th	15:45	Ballroom 2
Hesdorffer, D.C. (USA)	Speaker	Mon July 9th	15:45	Ballroom 1
Hesdorffer, D.C. (USA)	Speaker	Tues July 10th	10:00	Theatre
Heyman, I (UK)	Speaker	Mon July 9th	15:45	Ballroom 1
Hills, M (New Zealand)	Speaker	Tues July 10th	08:30	Hall 603
Hopwood, M (Australia)	Speaker	Wed July 11th	14:15	Ballroom 2
Hung, A (Hong Kong)	Chair	Tues July 10th	08:30	Hall 603
Ikeda, A (Japan)	Chair / Speaker	Tues July 10th	10:00	Ballroom 2
Inoue, Y (Japan)	Chair	Wed July 11th	14:15	Ballroom 2
Jackson, G (Australia)	Speaker	Sat July 7th	08:30	Room 203
Jacobson, S (USA)	Speaker	Mon July 9th	15:45	Room 209
Jacoby, A (UK)	Speaker	Wed July 11th	08:30	Hall 603

Speakers List



Surname		Date	Time	Room
Jain, S (India)	Chair	Mon July 9th	10:00	Theatre
Jain, S (India)	Chair	Mon July 9th	15:45	Theatre
Juhasz, C (USA)	Speaker	Mon July 9th	10:00	Ballroom 1
Kahane, P (France)	Speaker	Mon July 9th	10:00	Ballroom 2
Kahane, P (France)	Speaker	Tues July 10th	07:30	Room 209
Kahane, P (France)	Discussant	Wed July 11th	07:30	Room 209
Kanner, A.M. (USA)	Speaker	Wed July 11th	07:30	Theatre
Kanner, A.M. (USA)	Speaker	Wed July 11th	14:15	Ballroom 2
Kawato, S (Japan)	Speaker	Thur July 12th	10:15	Ballroom 3
Kazuichi, Y (Japan)	Chair	Tues July 10th	10:00	Ballroom 1
Köehling, R (Germany)	Speaker	Sun July 8th	14:30	Hall 603
Kokaia, M (Sweden)	Chair / Speaker	Tues July 10th	10:00	Ballroom 3
Kotagal, P (USA)	Chair / Speaker	Tues July 10th	10:00	Ballroom 2
Koutroumanidis, M (UK)	Discussant	Mon July 9th	07:30	Ballroom 1
Koutroumanidis, M (UK)	Discussant	Tues July 10th	07:30	Ballroom 1
Koutroumanidis, M (UK)	Speaker	Wed July 11th	10:00	Ballroom 1
Krauss, G.L. (USA)	Speaker	Tues July 10th	12:00	Hall 603
Kubova, H (Czech Republic)	Chair	Tues July 10th	15:45	Ballroom 1
Kubova, H (Czech Republic)	Speaker	Wed July 11th	10:00	Theatre
Kwan, P (Hong Kong)	Speaker	Mon July 9th	10:00	Hall 603
Kwan, P (Hong Kong)	Speaker	Mon July 9th	12:00	Hall 603
Kwan, P (Hong Kong)	Speaker	Mon July 9th	17:30	Hall 603
LaFrance Jr, W.C. (USA)	Speaker	Thur July 12th	07:30	Ballroom 1
Lai, C.W. (Taiwan)	Chair	Wed July 11th	10:00	Hall 603
Lee, B.I. (South Korea)	Speaker	Thur July 12th	10:15	Ballroom 2
Lee, P (UK)	Chair	Mon July 9th	08:30	Hall 603
Lee, S (South Korea)	Speaker	Tues July 10th	10:00	Ballroom 1
Lee, W.L. (Singapore)	Speaker	Wed July 11th	15:45	Ballroom 1
Lerche, H (Germany)	Speaker	Sun July 8th	12:45	Room 203
Li, S (China)	Chair / Speaker	Wed July 11th	08:30	Hall 603
Lim, S.H. (Singapore)	Chair	Sun July 8th	14:30	Hall 603
Lim, S.H. (Singapore)	Speaker	Mon July 9th	08:30	Hall 603
Lim, S.H. (Singapore)	Chair	Thur July 12th	12:00	Ballroom 2
Liou, H (Taiwan)	Speaker	Wed July 11th	10:00	Hall 603

Speakers List



Surname		Date	Time	Room
Locharernkul, C (Thailand)	Chair	Mon July 9th	10:00	Ballroom 2
Luders, H.O. (USA)	Discussant	Mon July 9th	07:30	Room 209
Luders, H.O. (USA)	Chair	Mon July 9th	10:00	Ballroom 2
Luders, H.O. (USA)	Discussant	Tues July 10th	07:30	Ballroom 1
Luders, H.O. (USA)	Speaker	Tues July 10th	15:45	Theatre
Lund, S (Sweden)	Chair / Speaker	Sun July 8th	17:00	Hall 603
Mathern, G.W. (USA)	Chair / Speaker	Sat July 7th	08:30	Room 203
Mathern, G.W. (USA)	Speaker	Wed July 11th	10:00	Ballroom 2
Mayer, G (Germany)	Speaker	Thur July 12th	10:15	Ballroom 1
Medina, M.T. (Honduras)	Chair / Speaker	Tues July 10th	15:45	Ballroom 3
Mehndiratta, M.M. (India)	Speaker	Mon July 9th	15:45	Ballroom 3
Mikati, M (Lebanon)	Speaker	Wed July 11th	10:00	Ballroom 1
Morris-Coole, C (UK)	Speaker	Tues July 10th	10:00	Hall 603
Moshe, S.L. (USA)	Chair / Speaker	Sat July 7th	08:30	Room 203
Moshe, S.L. (USA)	Chair	Wed July 11th	10:00	Ballroom 1
Moshe, S.L. (USA)	Chair / Speaker	Wed July 11th	15:45	Ballroom 1
Najm, I (USA)	Speaker	Mon July 9th	07:30	Theatre
Najm, I (USA)	Speaker	Mon July 9th	10:00	Ballroom 2
Najm, I (USA)	Speaker	Tues July 10th	07:30	Theatre
Nehlig, A (France)	Chair / Speaker	Wed July 11th	10:00	Theatre
Newton, C (Kenya)	Speaker	Wed July 11th	15:45	Ballroom 3
Noachtar, S (Germany)	Speaker	Mon July 9th	17:30	Hall 603
Noe', F (Italy)	Speaker	Tues July 10th	10:00	Ballroom 3
Noebels, J.L. (USA)	Speaker	Tues July 10th	14:15	Ballroom 2
Nunez, L (Mexico)	Chair / Speaker	Tues July 10th	15:45	Ballroom 3
O'Brien, T (Australia)	Speaker	Sat July 7th	08:30	Room 203
O'Shea, M (Australia)	Speaker	Wed July 11th	15:45	Ballroom 2
Ottman, R (USA)	Speaker	Mon July 9th	15:45	Theatre
Ozkara, C (Turkey)	Speaker	Mon July 9th	07:30	Theatre
Ozkara, C (Turkey)	Discussant	Wed July 11th	07:30	Theatre
Ozkara, C (Turkey)	Chair	Wed July 11th	10:00	Ballroom 3
Palmini, A (Brazil)	Speaker	Thur July 12th	08:45	Ballroom 2
Pan, A (Singapore)	Speaker	Tues July 10th	15:45	Ballroom 1
Perucca, E (Italy)	Speaker	Sun July 8th	17:00	Hall 603

Speakers List



Surname		Date	Time	Room
Perucca, E (Italy)	Chair	Wed July 11th	12:00	Hall 603
Petrou, S (Australia)	Speaker	Sat July 7th	08:30	Room 203
Pitkanen, A (Finland)	Speaker	Tues July 10th	15:45	Ballroom 2
Plouin, P (France)	Discussant	Mon July 9th	07:30	Ballroom 1
Plouin, P (France)	Discussant	Tues July 10th	07:30	Ballroom 1
Plouin, P (France)	Chair	Tues July 10th	15:45	Theatre
Polack,O (France)	Speaker	Mon July 9th	10:00	Theatre
Potschka, H (Germany)	Speaker	Mon July 9th	10:00	Ballroom 3
Puvanendran, K (Singapore)	Chair	Thur July 12th	10:15	Ballroom 1
Ramaratnam, S (India)	Chair	Thur July 12th	10:15	Ballroom 2
Ravizza, T (Italy)	Speaker	Mon July 9th	10:00	Ballroom 3
Reutens, D (Australia)	Speaker	Wed July 11th	10:00	Ballroom 3
Rogawski, M.A. (USA)	Chair / Speaker	Mon July 9th	10:00	Ballroom 3
Rogawski, M.A. (USA)	Speaker	Tues July 10th	12:00	Hall 603
Ryvlin, P (France)	Speaker	Sun July 8th	09:00	Room 203
Ryvlin, P (France)	Speaker	Sun July 8th	14:30	Hall 603
Ryvlin, P (France)	Speaker	Mon July 9th	12:00	Hall 603
Sabers, A (Denmark)	Speaker	Wed July 11th	10:00	Ballroom 3
Sakamoto, A (Brazil)	Speaker	Mon July 9th	10:00	Ballroom 2
Saling, M (Australia)	Chair	Wed July 11th	14:15	Ballroom 2
Saling, M (Australia)	Speaker	Thur July 12th	12:00	Ballroom 2
Salzberg, M (Australia)	Speaker	Tues July 10th	10:00	Ballroom 1
Sammaritano, M (USA)	Speaker	Thur July 12th	10:15	Ballroom 1
Scheffer, I (Australia)	Speaker	Mon July 9th	10:00	Theatre
Scheffer, I (Australia)	Speaker	Wed July 11th	15:45	Theatre
Serratos, J (Spain)	Speaker	Mon July 9th	15:45	Theatre
Sethi, P (India)	Speaker	Tues July 10th	15:45	Ballroom 1
Shih, Y.H. (Taiwan)	Chair	Thur July 12th	08:45	Ballroom 2
Shinnar, S (USA)	Speaker	Mon July 9th	15:45	Room 209
Silberberg, D (USA)	Speaker	Mon July 9th	08:30	Hall 603
Singhi, P (India)	Speaker	Wed July 11th	15:45	Ballroom 3
Solbrig, M (USA)	Speaker	Wed July 11th	15:45	Room 209
Somerville, E (Australia)	Chair	Tues July 10th	12:00	Hall 603
Somerville, E (Australia)	Speaker	Thur July 12th	07:30	Ballroom 1

Speakers List



Surname		Date	Time	Room
Spencer, D (USA)	Chair / Speaker	Wed July 11th	15:45	Theatre
Sperk, G (Austria)	Chair	Wed July 11th	15:45	Room 209
Staba, R (USA)	Chair / Speaker	Sun July 8th	10:45	Room 203
Stefan, H (Germany)	Speaker	Tues July 10th	07:30	Theatre
Stefan, H (Germany)	Chair	Thur July 12th	10:15	Ballroom 1
Suzuki, K (Japan)	Speaker	Wed July 11th	15:45	Ballroom 2
Swann, J.W. (USA)	Chair / Speaker	Wed July 11th	15:45	Theatre
Taglialatela, M (Italy)	Speaker	Sun July 8th	12:45	Room 203
Tan, C.T. (Malaysia)	Speaker	Mon July 9th	15:45	Ballroom 3
Tan, N (Singapore)	Speaker	Mon July 9th	15:45	Theatre
Tassinari, C.A. (Italy)	Discussant	Mon July 9th	07:30	Room 209
Tassinari, C.A. (Italy)	Discussant	Wed July 11th	07:30	Room 209
Tauboll, E (Norway)	Speaker	Tues July 10th	08:30	Hall 603
Theodore, W (USA)	Chair / Speaker	Sun July 8th	09:00	Room 203
Theodore, W (USA)	Chair	Mon July 9th	15:45	Room 209
Tinuper, P (Italy)	Speaker	Thur July 12th	10:15	Ballroom 1
Tomson, T (Sweden)	Speaker	Tues July 10th	10:00	Theatre
Tomson, T (Sweden)	Speaker	Wed July 11th	07:30	Theatre
Tsai, J.J. (Taiwan)	Chair / Speaker	Tues July 10th	10:00	Theatre
Van Emde Boas, W (The Netherlands)	Discussant	Mon July 9th	07:30	Theatre
Van Emde Boas, W (The Netherlands)	Speaker	Tues July 10th	07:30	Theatre
Vecht, C.J. (The Netherlands)	Speaker	Sun July 8th	14:30	Hall 603
Velis, D (The Netherlands)	Speaker	Mon July 9th	07:30	Theatre
Velisek, L (USA)	Chair	Thur July 12th	10:15	Ballroom 3
Veliskova, J (USA)	Speaker	Thur July 12th	10:15	Ballroom 3
Vezzani, A (Italy)	Chair	Tues July 10th	14:15	Ballroom 2
Vezzani, A (Italy)	Speaker	Wed July 11th	10:00	Theatre
Vezzani, A (Italy)	Speaker	Thur July 12th	12:00	Ballroom 2
White, H.S. (USA)	Speaker	Wed July 11th	12:00	Hall 603
Wiebe, S (Canada)	Speaker	Wed July 11th	10:00	Hall 603
Willoughby, J (Australia)	Speaker	Sat July 7th	08:30	Room 203
Wilson, S.J. (Australia)	Speaker	Wed July 11th	14:15	Ballroom 2
Wilson, S.J. (Australia)	Chair	Wed July 11th	15:45	Ballroom 2
Wolf, P (Denmark)	Chair / Speaker	Sun July 8th	17:00	Hall 603

Speakers List



Surname		Date	Time	Room
Wolf, P (Denmark)	Speaker	Tues July 10th	15:45	Theatre
Wolf, P (Denmark)	Chair	Thur July 12th	12:00	Ballroom 2
Yaari, Y (Israel)	Speaker	Sun July 8th	12:45	Room 203
Yacubian, E.M. (Brazil)	Speaker	Tues July 10th	08:30	Hall 603
Yamakawa, K (Japan)	Speaker	Sat July 7th	08:30	Room 203
Yardi, N (India)	Speaker	Wed July 11th	10:00	Ballroom 2
Yeo, S (Singapore)	Chair / Speaker	Tues July 10th	10:00	Hall 603



8th EUROPEAN CONGRESS ON EPILEPTOLOGY

Under the auspices of
the German and Israeli ILAE Chapters

Berlin, September 21 - 25, 2008



ILAE-CEA

www.epilepsyberlin2008.org

8th ECE BERLIN 2008

Exhibitors List



EXHIBITION OPENING HOURS


Monday, 9 July 2007	08.00 - 17.00
Tuesday, 10 July 2007	09.00 - 17.00
Wednesday, 11 July 2007	09.00 - 17.00
Thursday, 12 July 2007	09.00 - 12.00

Exhibitor	Stand no.
Ad-Tech Medical Instrument Corp.	1
Bio-logic Systems Corp., a Natus company	5
Blackwell Publishing	24
Cyberonics	11/12
DIXI Medical	8
EB Neuro SpA	6
Eisai Europe Ltd.	B
Electrical Geodesics, Inc.	16
Elekta	9/10
Elsevier	22
Future Meetings	17/18
GlaxoSmithKline	F
International Bureau for Epilepsy	C1
International League Against Epilepsy	C2
Janssen-Cilag	A
John Libbey Eurotext Ltd.	21
Lifelines Ltd.	20
Live Beyond Epilepsy - UCB Pharma SA	G
Micromed	7
Nihon Kohden	25
Pharmigene Inc.	2
Pfizer Inc.	E
Schwarz Pharma AG	H
Singapore Tourism Board	C3
Stellate	19
UCB Pharma SA	D
Valeant Pharmaceuticals International	26/27
Viasys Healthcare	28

Exhibition Floor Plan



SUNTEC SINGAPORE INTERNATIONAL CONVENTION & EXHIBITION CENTRE



Notes



[illegible]

Notes



This image shows a single page of white paper with horizontal blue lines. The lines are evenly spaced and run across the width of the page, typical of notebook paper or a document template. There are no margins, text, or other markings on the page.



ABBREVIATED PRODUCT INFORMATION

NAME OF THE MEDICINAL PRODUCT: Keppra® (levetiracetam) film-coated tablets, oral solution and 100 mg/ml concentrate for solution for infusion. **QUALITATIVE AND QUANTITATIVE COMPOSITION:** Each film-coated tablet contains 250 mg, 500 mg, 750 mg or 1000 mg levetiracetam. Each ml of oral solution contains 100 mg levetiracetam. Each ml of concentrate contains 100 mg of levetiracetam. The 5 ml vial of concentrate contains 500 mg of levetiracetam. **PHARMACEUTICAL FORM:** Film-coated tablet, oral solution and concentrate for solution for infusion. Keppra concentrate is a clear, colorless, sterile solution. **CLINICAL PARTICULARS:** **Therapeutic indications:** Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Keppra is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. Keppra is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. Keppra is indicated as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy. Keppra concentrate is an alternative for patients when oral administration is temporarily not feasible. **Posology and method of administration:** Keppra therapy can be initiated with either intravenous or oral administration. Conversion to or from oral to intravenous administration can be done directly without titration. The daily dose is administered in two equally divided doses. The total daily dose and frequency of administration should be maintained. The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. The oral solution may be diluted in a glass of water and may be taken with or without food. A graduated oral syringe and instructions for use in the package leaflet are provided with Keppra. Keppra concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion. There is no experience with administration of intravenous levetiracetam for longer period than 4 days.

Monotherapy: Adults and adolescents from 16 years of age: The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily. **Add-on therapy:** Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks. **Elderly (65 years and older):** Adjustment of the dose is recommended in elderly patients with compromised renal function (see "Patients with renal impairment" below). **Children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg:** The initial therapeutic dose is 10 mg/kg twice daily. Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used. Dosage in children 50 kg or greater is the same as in adults. The physician should prescribe the most appropriate pharmaceutical form and strength according to weight and dose.

Dosage recommendations for children and adolescents:

Weight	Starting dose: 10 mg/kg twice daily	Maximum dose: 30 mg/kg twice daily
15 kg (1)	150 mg twice daily	450 mg twice daily
20 kg (1)	200 mg twice daily	600 mg twice daily
25 kg	250 mg twice daily	750 mg twice daily
From 50 kg (2)	500 mg twice daily	1500 mg twice daily

(1) Children 20 kg or less should preferably start the treatment with Keppra 100 mg/ml oral solution.

(2) Dosage in children and adolescents 50 kg or more is the same as in adults. The graduated oral syringe contains up to 1,000 mg levetiracetam (corresponding to 10 ml) with a graduation every 25 mg (corresponding to 0.25 ml). A Keppra concentrate vial contains 500 mg levetiracetam in 5 ml (corresponding to 100 mg/ml).

Infants and children less than 4 years: Keppra is not recommended for use in children below 4 years of age due to insufficient data on safety and efficacy.

Patients with renal impairment: The daily dose must be individualised according to renal function. For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLCr) in ml/min is needed. The CLCr in ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula:

$$CLCr = \frac{[140 - \text{age (years)}] \times \text{weight (kg)}}{72 \times \text{serum creatinine (mg/dl)}} \quad (\times 0.85 \text{ for women})$$

Dosing adjustment for adult patients with impaired renal function:

Group	Creatinine clearance (ml/min)	Dosage and frequency
Normal	>80	500 to 1,500 mg twice daily
Mild	50-79	500 to 1,000 mg twice daily
Moderate	30-49	250 to 750 mg twice daily
Severe	<30	250 to 500 mg twice daily
End-stage renal disease patients Undergoing dialysis (1)	-	500 to 1,000 mg once daily (2)

(1) A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.

(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended.

For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients. **Patients with hepatic impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is <70 ml/min. **Contraindications:** Hypersensitivity to levetiracetam or other pyrrolidone derivatives or any of the excipients. **Special warnings and special precautions for use:** In accordance with current clinical practice, if Keppra has to be discontinued it is recommended to withdraw it gradually (e.g. in adults: 500 mg decreases twice daily every two to four weeks; in children: dose decrease should not exceed 10 mg/kg twice daily every two weeks). Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown. An increase in seizure frequency of more than 25% was reported in 14% of levetiracetam treated adult and paediatric patients with partial onset seizures, whereas it was reported in 26% and 21% of placebo treated adult and paediatric patients, respectively. When Keppra was used to treat primary generalised tonic-clonic seizures in adults and adolescents with idiopathic generalised epilepsy, there was no effect on the frequency of absences. The administration of Keppra to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see "Posology" above). Keppra 100 mg/ml oral solution includes methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed). It also includes maltitol; patients with rare hereditary problems of fructose intolerance should not take this medicine. Keppra concentrate contains 0.313 mmol (or 7.196 mg) of sodium per vial. To be taken into consideration by patients on a controlled sodium diet. **Interaction with other medicinal products and other forms of interaction:** Pre-marketing data from clinical studies conducted in adults indicate that Keppra did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Keppra. As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam. A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 22% higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dosage adjustment is not required. Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low. It is expected that other medicinal products excreted by active tubular secretion could also reduce the renal clearance of the metabolite. The effect of

levetiracetam on probenecid was not studied and the effect of levetiracetam on other actively secreted medicinal products, e.g. NSAIDs, sulfonamides and methotrexate, is unknown. Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam. No data on the influence of antacids on the absorption of levetiracetam are available. The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available. **Pregnancy and lactation:** There are no adequate data from the use of Keppra in pregnant women. Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Keppra should not be used during pregnancy unless clearly necessary. Discontinuation of antiepileptic treatments may result in exacerbation of the disease which could be harmful to the mother and the foetus. Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. **Effects on ability to drive and use machines:** No studies on the effects on the ability to drive and use machines have been performed. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected. **Undesirable effects:** Pooled safety data from clinical studies conducted with Keppra oral formulations in adult patients with partial onset seizures showed that 46.4% of the patients in the Keppra group and 42.2% of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 2.4% of the patients in the Keppra and 2.0% of the patients in the placebo groups. The most commonly reported undesirable effects were somnolence, asthenia and dizziness. In the pooled safety analysis, there was no clear dose-response relationship but incidence and severity of the central nervous system related undesirable effects decreased over time. In monotherapy 49.8% of the subjects experienced at least one drug related undesirable effect. The most frequently reported undesirable effects were fatigue and somnolence. A study conducted in paediatric patients (4 to 16 years) with partial onset seizures showed that 55.4% of the patients in the Keppra group and 40.2% of the patients in the placebo group experienced undesirable effects. Serious undesirable effects were experienced in 0.0% of the patients in the Keppra group and 1.0% of the patients in the placebo group. The most commonly reported undesirable effects were somnolence, hostility, nervousness, emotional lability, agitation, anorexia, asthenia and headache in the paediatric population. Safety results in paediatric patients were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse events which were more common in children than in adults (38.6% versus 18.6%). However, the relative risk was similar in children as compared to adults.

Undesirable effects that resulted from Keppra intravenous use are similar to those associated with Keppra oral use. The most frequently reported adverse reactions were dizziness, somnolence, headache and postural dizziness. A study conducted in adults and adolescents with myoclonic seizures (12 to 65 years) showed that 33.3% of the patients in the Keppra group and 30.0% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effects were headache and somnolence. The incidence of undesirable effects in patients with myoclonic seizures was lower than that in adult patients with partial onset seizures (33.3% versus 46.4%). A study conducted in adults and children (4 to 65 years) with idiopathic generalised epilepsy with primary generalised tonic-clonic seizures showed that 39.2% of the patients in the Keppra group and 29.8% of the patients in the placebo group experienced undesirable effects that were judged to be related to treatment. The most commonly reported undesirable effect was fatigue. Since there was limited exposure for Keppra intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of Keppra intravenous will rely on Keppra oral use. Undesirable effects reported in clinical studies (adults and children) or from post-marketing experience are listed below per System Organ Class and per frequency. For clinical trials, the frequency is defined as follows: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), including isolated reports. Data from post-marketing experience are insufficient to support an estimate of their incidence in the population to be treated. **Very common undesirable effects (≥1/10):** General disorders and administration site conditions: asthenia/fatigue; Nervous system disorders: somnolence. **Common undesirable effects (≥1/100, <1/10):** Nervous system disorders: amnesia, ataxia, convulsion, dizziness, headache, hyperkinesia, tremor, balance disorder, disturbance in attention, memory impairment; Post-marketing experience: paraesthesia; Psychiatric disorders: agitation, depression, emotional lability/mood swings, hostility/aggression, insomnia, nervousness/irritability, personality disorders, thinking abnormal; Post-marketing experience: abnormal behaviour, anger, anxiety, confusion, hallucination, psychotic disorder, suicide, suicide attempt and suicidal ideation; Gastrointestinal disorders: abdominal pain, diarrhoea, dyspepsia, nausea, vomiting; Post-marketing experience: pancreatitis; Hepatobiliary disorders: Post-marketing experience: hepatic failure, hepatitis, liver function test abnormal; Metabolism and nutrition disorders: anorexia, weight increase. The risk of anorexia is higher when topiramate is coadministered with levetiracetam; Post-marketing experience: weight loss; Ear and labyrinth disorders: vertigo; Eye disorders: diplopia, vision blurred; Musculoskeletal and connective tissue disorders: myalgia; Injury, poisoning and procedural complications: accidental injury; Infections and infestations: infection, nasopharyngitis; Respiratory, thoracic and mediastinal disorders: cough increased; Skin and subcutaneous tissue disorders: rash, eczema, pruritus; Post-marketing experience: alopecia; in several cases, recovery was observed when Keppra was discontinued; Blood and lymphatic system disorders: thrombocytopenia; Post-marketing experience: leukopenia, neutropenia, pancytopenia (with bone marrow suppression identified in some of the cases). **Overdose:** Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Keppra overdoses. There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite. **PHARMACEUTICAL PARTICULARS: Nature and contents of container:** Keppra film-coated tablets are packaged in aluminium/PVC blisters placed into cardboard boxes containing film-coated tablets of 250, 500, 750 or 1000 mg. Keppra oral solution is packaged in 300 ml amber glass bottles (type III) with a white child resistant closure (polypropylene) in a cardboard box also containing a graduated oral syringe (polyethylene, polystyrene) and a patient information leaflet. Not all pack sizes may be marketed in each EU country. Keppra concentrate is packed in glass vials (type I) with Teflon-faced stoppers and sealed with an aluminium/polypropylene flip-off cap. The vials are placed into cartons of 10 vials. Each vial contains 5 ml of concentrate. Keppra concentrate was found to be physically compatible and chemically stable when mixed with the following diluents for at least 24 hours and stored in PVC bags at controlled room temperature 15-25° C. Diluents: Sodium chloride (0.9%) injection; Lactated Ringer's injection; Dextrose 5% injection. Product with particulate matter or discoloration should not be used.

MARKETING AUTHORISATION HOLDER: UCB PHARMA, S.A. Allée de la Recherche 60 B-1070 Bruxelles Belgium.

MARKETING AUTHORISATION NUMBER(S): EU/1/00/146/001-030

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 29 September 2000

Date of last renewal: 08 July 2005

FULL PRESCRIBING INFORMATION including Summary of Product Characteristics is available from UCB PHARMA, S.A.


DATE OF REVISION OF THE TEXT: January 2007



© 2007, UCB PHARMA, S.A., Belgium
Printed in U.S.A.

All rights reserved.
GSPRC CNS 004 TA 0107

TO SEE HOW KEPPRA® HELPS PEOPLE WITH EPILEPSY VISIT UCB AT **BOOTH D**



Bryan, Dana, and John are patients on Keppra® living life on their terms.

Many lives... One AED

Help patients reach seizure freedom with
the broad-spectrum efficacy of Keppra®*

In Europe: Keppra® (levetiracetam) is indicated for¹...

- Monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy†
- Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy
- Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy†
- Adjunctive therapy in the treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy†

Approved indications may vary from country to country; please check local Prescribing Information.

In Singapore, Keppra® is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.

†These indications have not been approved for use in Singapore.

*Keppra® achieved high seizure-freedom rates during the following Phase III trials: Monotherapy for partial onset seizures in newly diagnosed adults (≥16 years of age): 73% (173/237) ≥6 months²; Adjunctive therapy for PGTC seizures in patients ≥4 years of age with IGE: 34% (27/79) during 20-week evaluation period³; Adjunctive therapy for myoclonic seizures in adults and adolescents (≥12 years of age) with JME: 25% (15/60) during 12-week evaluation period⁴; Adjunctive therapy for partial onset seizures in adults: 9% (23/269) during 16- to 18-week treatment period⁵; Adjunctive therapy for partial onset seizures in children (4-16 years of age): 7% (7/101) during 14-week treatment period.⁶


References: 1. Keppra® (levetiracetam) Summary of Product Characteristics (SmPC), UCB PHARMA, S.A., January 2007. 2. Brodie MJ, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. *Neurology*. 2007;68:402-408. 3. Morrow J, L.E.V. N01057 Study Group. Efficacy and safety of levetiracetam as adjunctive treatment in adult and paediatric patients suffering from idiopathic generalised epilepsy with primary generalised tonic-clonic seizures. Abstract presented at: 10th Congress of the European Federation of Neurological Societies; September 2-5, 2006; Glasgow, UK. 4. Andermann E, et al. Efficacy and tolerability of levetiracetam add-on therapy in patients with refractory idiopathic generalised epilepsy. Poster presented at: 6th Asian & Oceanian Epilepsy Congress; November 16-19, 2006; Kuala Lumpur, Malaysia. 5. Meencke H-J, et al. Assessment of a dose-response relationship of levetiracetam. *Eur J Neurol*. 2006;13:942-946. 6. Glauser TA, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. *Neurology*. 2006;66:1654-1660.



Keppra®

Destination: Freedom™*


B U D A P E S T



28th INTERNATIONAL EPILEPSY CONGRESS

June 28th - July 2nd, 2009

INTERNATIONAL
LEAGUE
AGAINST
EPILEPSY



www.epilepsybudapest2009.org

